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Abstract: An investigation into the application of Raman Spectroscopy for cervical cancer 
screening 
 
 
Raman spectroscopy is a powerful tool that has the potential to be, used for cervical cancer 
screening. It is a label-free, low-cost method providing a biochemical fingerprint of a given 
sample. The objective of this thesis was to address issues associated with the application of 
Raman spectroscopy for cervical cancer screening and to demonstrate the potential for triage 
of HPV positive cases. 
The first study investigated hormonal effects due to the menstrual cycle, the use of hormone- 
based contraceptives (HC) and the onset of menopause on Raman spectra of cervical cells and 
determined if these changes would affect the ability to successfully identify dyskaryotic cells. 
Spectral changes were observed depending on the day of the menstrual cycle and on the use 
of HC. Despite this, high grade (HG) dyskaryotic cells could be discriminated from normal cells 
regardless of the day on which the sample was taken or the use of HC. 
The second study aimed to extend previous work on blood contamination of cervical smear 
samples and to investigate if excessively bloody samples could be rendered suitable for 
Raman spectroscopy. ThinPrep liquid based cytology (LBC) specimens were treated by adding 
hydrogen peroxide directly to the vial before slide preparation. Good discrimination between 
negative and HG cytology could be achieved for samples with no blood contamination 
(sensitivity 92%, specificity 93%) and heavy blood contamination (sensitivity 89%, specificity 
88%) with poorer classification when samples were combined (sensitivity 82%, specificity 
87%). The improved potential of Raman spectroscopy for analysis of ThinPrep specimens 
regardless of blood contamination was shown. 
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The third study investigated Raman spectroscopy for screening for histologically confirmed 
cases of CIN using long term biobanked LBC samples. Classification of CIN was compared using 
Raman spectra from fresh LBC samples and biobanked LBC samples. Raman spectroscopy was 
found to effectively discriminate negative from CIN 3 fresh and biobanked  LBC  samples. In 
addition, it was found that biobanked LBC samples could be combined with fresh LBC samples 
and still achieve a similar sensitivity and specificity. 
The fourth study investigated the ability of Raman spectroscopy as a triage of HPV positive 
cases to discriminate between latent HPV infections and persistent HPV infections which are 
clinically more important. The results showed that Raman spectroscopy could distinguish 
between patients with latent and persistent HPV infections and a sensitivity and specificity of 
90% and 100% respectively was achieved for an unknown test set. 
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1 Introduction 
 
1.1 What is Cervical Cancer? 
 
Cellular maturation is a normal part of a cell’s life cycle which involves the growth, ageing 
and death of cells. This process of maturation is controlled by the cell’s own genetic makeup. 
If a mutation occurs within this genetic makeup, control over the cell’s maturation can be lost 
resulting in abnormal growth and a mass of cells known as a tumour (Fouad and Aanei, 
2017). 
Cervical Cancer is a cancer of the cells of the cervix. It is a slow progressive form of cancer 
that has three precancerous stages which are currently screened for via the national cervical 
cancer screening programme (CervicalCheck, 2013). The aim of CervicalCheck is to screen 
for and prevent the progression of cervical cancer. It does this through a series of molecular 
and objective based tests. 
1.2 The Female Reproductive System 
The female reproductive system is made up of the ovaries, fallopian tubes, uterus and vagina 
(Figure 1.1). The ovaries and fallopian tubes control the production and release of eggs 
during a women’s menstrual cycle. The vagina allows the passage of a baby and receives the 
penis and sperm during intercourse. The uterus provides mechanical support for a developing 
foetus and will expel the foetus by forceful contractions of its smooth muscles. Located at the 
inferior portion of the uterus is the cervix. The cervix is a 2-4 cm long cylinder shaped tissue 
that connects the vagina and uterus. The cervix itself is made up of the ectocervix and 
endocerix, where they meet is called the squamous columnar junction. The ectocervix is the 
outer portion of the cervix and is lined with stratified non-keratinising squamous epithelium 
and is in continuation with the endocervix at the external os. The external os is the opening in 
the centre of the ectocervix which connects the vagina to the uterus. The endocervical canal is 
located within the cervix between the internal os and the external os which contains glandular 
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epithelium. The squamous columnar junction is where the squamous and glandular 
epithelium meet between the endocervix and ectocervix (Koss, 2005). 
The site of the squamous columnar junction will change during puberty. This junction is a 
known site of metaplasia. Metaplasia is the transformation of vulnerable glandular epithelium 
into protective stratified squamous epithelium. Metaplasia occurs due to the glandular 
epithelium’s exposure to the acidic environment of the vagina. The area of metaplasia close 
to the original position of the squamous columnar junction is known as the transformation 
zone. More than 90% of premalignant lesions develop in the transformation zone (Koss, 
2005) 
 
 
 
 
 
Figure 1.1 Diagram of female reproductive system (Medlineplus, 2018)(Canadian Cancer society, 2019) 
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1.2.1 Stratified squamous epithelium 
The stratified squamous epithelium is made up of four cell types, Basal, Parabasal, 
Intermediate and Superficial cells. Basal cells are immature cells which are parent cells to all 
cells which make up the epithelium. They are firmly attached to the basement membrane. 
They are small round cells with oval nuclei, fine chromatin and a high nuclear to cytoplasmic 
ratio (Figure 1.2 (A)). Parabasal cells lay above the basal cells. Their nuclei occupy about 
half of the cell’s cytoplasm and have a fine chromatin pattern (Figure 1.2 (B)). Intermediate 
cells are large polygonal cells (Figure 1.2 (C)). They have round to oval vesicular nuclei and 
have a diameter 2-3 times the size of a Parabasal cell. Superficial cells are large polygonal 
cells. They have small condensed nuclei, angular cytoplasm and keratohyaline granules 
(Figure 1.2 (D)) (Koss, 2005). 
 
 
 
Figure 1.2:Pap stained (A) Basal cell small round cells with oval nuclei, fine chromatin and a high nuclear to 
cytoplasmic ratio. (B) Small round cells with fine chromatin pattern. (C) Intermediate cells, large polygonal cells 
which have round to oval vesicular nuclei. (D) Superficial cells, large polygonal cells with a small condensed 
nuclei, angular cytoplasm and keratohyaline granules (Basicmedicalkey.com, 2016). 
 B 
C  
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1.2.2 The Menstrual cycle 
 
The menstrual cycle (Figure 1.3) is a change that occurs within the female reproductive cycle 
that makes pregnancy possible (Silverthorn, 2013). It is controlled by the rise and fall of 
hormones. Each cycle is divided between the ovarian and uterine cycle. The ovarian cycle is 
made up of the follicular phase, ovulation and luteal phase. The uterine cycle is made up of 
menstruation, proliferative and secretory phase. The uterine cycle is the most clinically 
relevant for this study. The proliferative phase averages over 14 days for most women and 
begins with the start of menstruation. It involves the rapid production of follicle stimulating 
hormone and luteinizing hormone which stimulate the growth of follicles which in turn 
produce oestrogen which stimulates the rapid growth of the endometrium. The secretory 
phase involves the production of progesterone and small amounts of oestrogen which 
stimulates the shedding of the endometrium if implantation doesn’t occur (Boron, 2005). 
 
 
Figure 1.3 Schemmatic illustration of the menstrual cycle over 28 days (Gettyimages, 2018) 
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1.2.3 Hormonal Contraceptive 
 
Hormonal contraceptive is the most commonly used method of birth control. In the United 
States over 30% of sexually active women use a form of hormone based contraceptive (HC). 
There are different forms of contraceptive that are widely available including oestrogen and 
progesterone based forms and a combination of the two. The contraceptives work by 
lowering the level of follicle stimulating hormone and luteinizing hormone produced, thereby 
preventing the growth of the endometrium thus preventing implantation. Progesterone only 
pills work by causing cervical mucus to thicken thus preventing the sperm penetrating the 
uterus (Boron, 2005). There is no direct link between the amount of hormone present in the 
contraceptive and the response of the cervical epithelium. This relationship varies 
significantly from patient to patient (Koss, 2005) 
1.3 Cervical Cancer 
There were an estimated 570,000 new cervical cancer cases and 311,000 deaths from cervical 
cancer worldwide in 2018 (Bray et al., 2018). There are three main types of cervical cancer. 
Cervical cancer which develops from the squamous epithelium is known as squamous cell 
carcinoma and accounts for 80-85% of all detected cervical cancers and will be the main 
topic of this research. Cervical cancer which develops from endocervical cells is known as 
adenocarcinoma and accounts to approximately 10% to 15% of all invasive cervical cancers 
(Koss, 2005). Cervical cancer which develops from the ecto or endocervical cells is known as 
adenosquamous carcinoma and accounts for approx. 3% of all detected cervical cancers 
(Sahdev, 2010). 
6  
1.3.1 Human Papillomavirus 
 
The Human Papillomavirus, is present in 99% of all cervical cancers worldwide and is the 
main aetiological agent associated with the disease. It is sexually transmitted and affects up to 
80% of women at some point in their life (Sahdev, 2010). There are over 100 known HPV 
types which are classified according to their potential to induce malignant transformations. 
HPV 16, 18, 31, 35, 39, 45, 50, 51, 53, 55, 56, 58, 59, 64 and 68 are classified as high risk 
types (Sahdev, 2010). HPV 16 and 18 are found in 70% of all cases of cervical cancer 
(Sanjosé et al., 2007). 
1.3.1.1 HPV Infection 
The HPV genome (Figure 1.4) is made up of 8,000 base pairs. It has five early genes E1, E2, 
E5, E6, E7 and two late genes, L1 and L2 (Fouad and Aanei., 2017). HPV infection is 
thought to start in the basal layer of cells in the epithelium which it gains access via micro 
abrasions in the epithelium. The virus first attacks the host cell’s DNA where it uses the host 
cell machinery to transcribe its early genes. Following genome amplification, the virus is 
maintained in a stable condition via an episome. Viral replication can then begin via the 
transcription of E1 and E2 (Zheng and Baker, 2006). E1 is responsible for the helicase which 
allows the E2 viral DNA to bind which results in the helicase binding to the replication 
associated proteins including DNA polymerase alpha primase. E2 also has a role in the 
binding of the viral episome to the chromosome undergoing mitosis which allows for 
segregation of the HPV episome into each progenitor cell (Zheng and Baker, 2006). 
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Figure 1.4 Graphical representation of the HPV genome (Semantic Scholar, 2019) 
 
1.3.1.2 Cell Proliferation and Genome Amplification 
The increased proliferation of HPV infected cells is a result of the HPV oncogenes E6 and E7 
working with E1 and E2. Together these proteins stimulate the progression of the infected 
cells into the S-phase of its life cycle (Zheng and Baker, 2006). This method of progression is 
first controlled by E7 which involves the binding and degradation of the retinoblastoma 
protein (pRb). Under normal conditions the role of pRb is to control the expression of 
proteins that are required for cell cycle progression. The degradation of pRb results in the 
release of E2F. E2F is then free to recruit proteins for viral replication and cellular proteins 
cyclin A and E which control S-phase progression. The role of E6 is to degrade the tumour 
suppressor protein P53 which is overly produced due to the function of E7. Under normal 
conditions P53 acts as a regulator of the cell cycle that triggers growth arrest or apoptosis to 
prevent the replication of damaged DNA. The lack of P53 due to E6 results in the replication 
of damaged DNA. The complete HPV life cycle involves the expression of both minor and 
major coat proteins which allow genome packaging. This involves a change in splice site 
usage which results in a switch from the production from E1^E4, E5 mRNA to E1^E4, L1 
transcript which facilities the end of genome amplification and gives way to genome 
packaging (Johansson , et al.,2012, Doorbar .,2005, Milligan et al.,2007). Encapsidation of 
the genome requires the accumulation of E2 and the collection of infectious virions in the 
nucleus. Virus maturation is then free to occur in superficial cells, which is triggered by a 
8  
change from a reducing to an oxidizing environment within the cell (Doorbar .,2005). This 
change enables the accumulation of disulphide bonds between L1 proteins resulting in the 
production of infectious HPV virions (Holmgren , et al,2005). 
1.3.1.3 Possible Outcomes of a HPV infection 
HPV DNA can be detected in the epithelial tissues due to its presence as virus particles on the 
surface of the epithelium. This detection can be misinterpreted as HPV latency. To cause a 
lesion or to initiate a latent infection, the virus particles have to gain access to the epithelial 
basal cells at a sufficiently high level. Each type of virus has a specific epithelial site where it 
can initiate a productive life cycle, as well as sites where the virus entry occurs in the absence 
of lesion formation. At low titres or at non permissive epithelial sites an asymptomatic 
infection can occur, in which viral genomes may exist in the basal layer without gene 
expression or lesion formation. This is a form of latency as it does not trigger an immune 
response. Certain high risk HPV types at a particular epithelial site can deregulate viral gene 
expression which has the potential to lead to neoplasia. Persistent high risk HPV infections 
can lead to the accumulation of genetic errors and the progression to cancer (Zheng and 
Baker, 2006, Youssef et al., 2016) 
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1.3.1.4 Persistence 
If a HPV infection is not cleared by the host immune system, it can persist over many years 
resulting in intermittent or constant disease. In order for a persistent infection to occur, HPV 
must maintain the viral genome in the epithelial stem cell and the host immune system must 
fail to recognise it and clear the infection (Doorbar et al., 2012). 
1.3.1.5 Regression 
Persistent infection with high risk HPV is necessary but not sufficient for the development of 
squamous carcinoma of the cervix or its precursor lesions CIN 1, 2, 3. A CIN 1 lesion 
represents a chronic HPV infection, in which HPV DNA is episomal and intact viron 
production and shedding is occurring. In women who are immune competent, many CIN 1 
lesions (up to 58% over 24 months) will eventually regress without treatment (Burd, 2003). 
Only 2% will progress to high grade lesions. High grade lesions are less likely to regress. The 
risk for progression to invasive cancer at 24 months in women with high–grade lesions is 1- 
2%. However CIN 1 and CIN 2 regression rates vary due to the subjectivity involved in their 
diagnosis (Rodriguez et al., 2012  ). The main reason for over treatment of patients remains 
the lack of a diagnostic test to directly identify lesions that are likely to progress or regress. 
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1.4 Cervical Screening 
CervicalCheck is the national cervical screening programme for Ireland. It provides a free 
cervical smear for all eligible women (1.1 million) between the ages of 25 and 60. The 
purpose of screening is to reduce the incidence and mortality of cervical cancer 
(CervicalCheck, 2013). 
There are four current screening/diagnostic tests currently in use by CervicalCheck for 
cervical cancer: 
1) Papanicolaou test 
 
2) HPV test 
 
3) Colposcopy 
 
4) Histopathology 
 
1.4.1 The Papanicolaou Test 
The Papanicolaou test (Pap test) is named after its inventor George Papanicolaou. 
Papanicolaou’s work in cytology involving the female genital tract helped cytology diagnosis 
gain credibility ( Koss, 2005). Since it was introduced in hospitals in the 1940’s the Pap test 
has become the most commonly used method for identifying cervical cancer and its 
associated pre-cancerous lesions. 
Within the last 10 to 15 years conventional cytology has been replaced by liquid based 
cytology (LBC) such as ThinPrep or SurePath. Conventional cytology and LBC both share 
them same method of sampling cells from the transformation zone of the cervix with a 
cervical brush or spatula. In the case of conventional smears, the cells are directly spread onto 
a glass slide, fixed and stained. In the case of LBC, the cervical brush in rinsed in a vial of 
preservative fluid and transferred to the lab where a uniform layer of cells on a glass slide is 
prepared and then fixed and stained (Rozemeijer et al., 2016). The LBC method improves 
sample quality by producing a more even layer of cells and helps remove unwanted cellular 
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material such as red blood cells and inflammatory cells (leukocytes). Specimen vials can also 
be stored allowing an additional smear to be made if necessary and ancillary techniques to be 
performed on the same sample. The Pap smear generally has a specificity of 96.5% but its 
sensitivity can vary from 30-85% depending on the prevalence of the disease within the 
population (Nanda et al., 2000). Thinprep (Figure 1.5) is the preferred method of sample 
processing employed throughout Ireland, hence all samples used in this study will only be 
processed using the ThinPrep method. 
 
Figure 1.5 Illustration of Thinprep process of sample collection and processing (HeakthDxs,2017) 
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1.4.1.1 Cytology 
Cytology is the study of the microscopic appearance of cells. Cytologists are trained to 
identify the type of cells that are normally present in different areas of the body. The cells are 
then screened to detect either changes in the morphology of the cells or the presence of 
inappropriate cells that are associated with particular conditions. 
1.4.1.2 Bethesda Classification for Cytology 
CervicalCheck employs the Bethesda Classification system for its terminology of squamous 
intraepithelial lesions (SIL). This is divided into three categories: 
1) Low grade SIL (LSIL) which includes HPV- associated cellular changes and mild 
dyskaryosis. 
2) High grade SIL (HSIL) which includes moderate dyskaryosis and severe dyskaryosis  
3) Query squamous cell carcinoma 
 
Cytological changes in squamous cells which are not normal and do not fit the criteria for SIL 
are classed as atypical squamous cells (ASC). ASC is divided into two subcategories: 
1) ASC-US Atypical Squamous cells of undetermined significance. 
 
2) ASC-H Atypical Squamous cells of undetermined significance but high grade changes 
cannot be ruled out (CervicalCheck 2013). 
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1.4.1.3 Low grade (LSIL) 
The cytological features of LSIL (Figure 1.6) are: 
 
 Abnormal/irregular chromatin pattern
 
 Irregular nuclear membrane
 
 Irregular nuclear contours
 
 Nuclear enlargement
 
 Hyperchromasia
 
 Hypochromasia
 
 Multi-nucleation
 
 Seen in Intermediate and Superficial cells
 
 Often seen with Koilocytic changes
 
 Features correspond to changes in CIN 1
 
 Nuclear to cytoplasmic ration
 
 
Figure 1.6 Cytological representation of LSIL on Pap smear (CPLmag.com, 2019) 
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1.4.1.4 High grade (HSIL) 
The cytological features of HSIL (Figure 1.7) are: 
 
 Nuclear enlargement
 
 An increase in the nuclear to cytoplasmic ratio
 
 Abnormal nuclear morphology
 
 Nuclear contours
 
 Seen in immature cells – parabasal and metaplastic
 
 
 
Figure 1.7 Cytological features of HSIL on Pap smear (CPLmag.com, 2019) 
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1.4.1.5 Squamous Cell Carcinoma 
The cytological features of Squamous Cell Carcinoma (Figure 1.8) are: 
 
 Windowing- irregular chromatin distributed causing holes
 
 Fibre/tadpole/ bizarre cells
 
 Keratinisation
 
 Diathesis
 
 Blood
 
Invasive squamous cell carcinoma can’t be diagnosed on cervical cytology, but these features 
can suggest invasion. 
 
 
Figure 1.8 Cytological features of Squamous Cell Carcinoma on Pap smear (eurocytology.eu, 2019) 
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1.4.1.6 Inflammation Vs Dyskaryosis 
Cells are susceptible to injury. The response of tissues or cells to injury is known as 
inflammation. When inflammation occurs in the cervix the condition is called cervicitis 
(Figure 1.9). Inflammatory smears usually contain abundant polymorphs and histiocytes. If 
the inflammation persists lymphocytes, plasma cells and multinucleated histiocytes may be 
seen. A dirty background may be seen. Epithelial cells are not involved in the process of 
inflammation but they do react to it via a process of degeneration and regeneration 
(Shambayati.,2011) 
Nuclear changes associated with inflammation are: 
 
 Wrinkling of nuclear membrane
 
 Condensation of chromatin
 
 Nuclear death
 
 Nuclear enlargement
 
 Course but regular granulation of chromatin
 
 Prominent nucleoli
 
 Multi-nucleation
 
Cytoplasmic changes associated with inflammation are: 
 
 Vacuolisation
 
 Perinuclear halo
 
 Altered staining pattern
 
 Dense cytoplasm
 
 Cytoplasmic projections
17  
There are many cytological similarities between inflammation and dyskaryosis. However, 
dyskaryosis will usually show coarse chromatin granularity with uneven distribution and 
irregular nuclear membranes with contours. The causes of inflammation can vary but could 
be related to the use of intrauterine devices, radiation, cytotoxic drugs, hormones or infection 
(Shambayati., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 The cytological presentation of cervicitis on Pap smear. Note the high level of polymorphs (General 
cytopathology, 2016) 
 
 
1.4.2 HPV Testing 
 
HPV testing has been incorporated in most cervical cancer screening programmes and can be 
applied in three ways 
1. Primary screening 
 
2. Management and triage 
 
3. Test of cure 
 
At present HPV testing is currently only being used by Cervical Check as a triage test for Pap 
smears graded as LSIL on cytology and as a test of cure following treatment at colposcopy. 
HPV testing will be discussed in more detail in the section on current screening practice 
 
(section 1.1.31). 
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1.4.3 Colposcopy 
As of 2013 there are currently 15 colposcopy services available as part of CervicalCheck. 
Women can be referred to colposcopy for a number of reasons: 
 Abnormal vaginal bleeding
 
 Suspicious cervix
 
 Abnormal cytology referral
 
 HPV result
 
The CervicalCheck guidelines (CervicalCheck, 2013) state that 90% of women with a high 
grade cytological abnormality should be offered an appointment for colposcopy within four 
weeks of the result being issued. All women with low grade cytological abnormalities should 
be offered an appointment within eight weeks. 
1.4.3.5 Diagnosis at Colposcopy 
Colposcopy plays an important role in the evaluation of women with suspected cervical 
abnormalities. It allows the identification of the site of the abnormality as well as an 
estimation of the grade of abnormality including the presence or absence of features which 
are suggestive of invasive cancer. As a procedure used alone however, it has diagnostic 
limitations with a lack of correlation between the colposcopic and histological diagnosis, lack 
of reproducibility and difficulties in assuring the optimum site (transformation zone) and the 
quality of any biopsies taken (Powers, 2011). 
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1.4.3.6 Colposcopy Process 
A speculum is used to spread apart the walls of the vagina before dilute acetic acid is applied 
to the cervix under direct vision (Figure 1.10). The diagnosis is made using visual 
recognition. The acetic acid interacts with the cell’s protein structure. Abnormal tissue will 
show up as a white area (Figure 1.11). The intensity of the colour change as well as the 
sharpness of the margins helps discriminate between grades of abnormality. (low or high 
grade). New blood vessel formation often accompanies high grade on the cervix. Invasive 
cancer often presents with abnormal blood vessel formation (CervicalCheck, 2013) A review 
of colposcopy services demonstrated sensitivity and specificity levels for discrimination 
between high and low grades of disease to be 96% and 48% respectively (CervicalCheck, 
2013). The performance of colposcopy increases with the severity of the lesion. However a 
study showed that colposcopy had a detection accuracy of only 52% for high grade lesions 
(Zuchna et al., 2010) which confirms that some lesions may be difficult to detect and 
highlights the risk of a false-negative biopsy result. When compared to the identification of 
glandular lesions at colposcopy the sensitivity of colposcopy for glandular lesions drops to 
9.8% (Ullal.A et al., 2009) which again highlights the difficulty in identifying areas of 
abnormality. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 A graphical representation of the Colposcopy process ( manhattancenterforgynecology, 2019) 
20  
  
 
Figure 1.11 (A) Visual appearance of a normal cervix. (B) visual appearance of CIN 1 after the application of 
acetic acid to the cervix (Shekinah Medical Centre, 2017) 
 
 
 
1.4.3.7 Biopsy Methods 
A histological diagnosis can be obtained by taking one or more diagnostic punch biopsies 
using a tissue sampling forceps, small loop biopsy or by complete removal of the atypical 
area using an excisional biopsy via a large loop excision of the transformation zone (LLETZ) 
(Figure 1.12). The aim when taking a biopsy is to sample an area which is indicative of the 
most abnormal area of cervical tissue to provide confirmation of the colposcopic impression. 
The accuracy of the biopsy is dependent on the target site chosen by the colposcopist. There 
are two types of biopsy that can be taken during colposcopy - punch or cone biopsy. Punch 
biopsies are small pieces of tissue a few millimetres in diameter that are removed from the 
cervical mucosa. Cone biopsies/excision biopsies are made up of cone shaped portions if 
cervical tissue and taken with the aim of removing all the pathological tissue on the cervix. 
This is both diagnostic and therapeutic (Bulten et al., 2011). 
 B 
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There are certain situations where a diagnostic biopsy must be performed: 
 
 If the cytology shows HSIL. 
 
 If there is evidence of significant atypia (irregularity) on the transformation zone. 
 
 If there is a completely visible normal TZ and confirmed low grade cytological 
abnormality. 
 
 
Figure 1.12 Graphical representation of Large loop excision of the transformation zone (LLETZ) process of 
biopsy collection(Clinic, 2014) 
 
 
1.4.4 Histopathology Examination 
Histopathology refers to the examination of stained tissue sections under a microscope for the 
presence of abnormality. It is referred to as the gold standard in cancer diagnosis. Once a 
biopsy is taken it is immediately placed into a fixative and processed into a paraffin wax 
block. Sections from this block are then cut, placed on to a glass slide, stained and reviewed 
under a light microscope by a pathologist. The terminology for reporting disease in 
histopatholology is cervical intraepithelial neoplasia (CIN) rather than SIL which is used for 
cytology. 
A judgement of whether or not a cervical tissue specimen reveals CIN, and to what degree, is 
dependent on the histological features concerned with differentiation, maturation and 
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stratification of cells and nuclear abnormalities. The proportion of the thickness of the 
epithelium showing mature and differentiated cells is used for grading CIN. More severe 
degrees of CIN are likely to have a greater proportion of the thickness of epithelium 
composed of undifferentiated cells, with only a narrow layer of mature, differentiated cells on 
the surface. 
Nuclear abnormalities such as enlarged nuclei, increased nuclear-cytoplasmic ratio, and 
increased intensity of nuclear staining (hyperchromasia), nuclear polymorphism and variation 
in nuclear size (anisokaryosis) are assessed when a diagnosis is being made. There is often a 
strong correlation between the proportion of epithelium revealing maturation and the degree 
of nuclear abnormality. As the severity of CIN increases, the number of mitotic figures also 
increases; these may be seen in the superficial layers of the epithelium. The less 
differentiation in an epithelium, the higher the level at which mitotic figures are likely to be 
seen (Bulten et al., 2011). 
1.4.4.5 CIN histological features 
In CIN 1 there is good maturation with minimal nuclear abnormalities and few mitotic 
figures, undifferentiated cells are confined to the deeper layers (lower third) of the 
epithelium. Cytopathic changes due to HPV infection may be observed in the full thickness 
of the epithelium (Figure 1.13(A)). CIN 2 is characterized by dysplastic cellular changes 
mostly restricted to the lower half or the lower two-thirds of the epithelium, with more 
marked nuclear abnormalities than in CIN1. Mitotic figures may be seen throughout the 
lower half of the epithelium (Figure 1.13(B)). In CIN 3 differentiation and stratification may 
be totally absent or present only in the superficial quarter of the epithelium with numerous 
abnormal mitotic figures. Nuclear abnormalities extend throughout the thickness of the 
epithelium. 
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Figure 1.13 Histological representation of normal (A),CIN I (B), CIN II (C), and CIN III (D) of H&E stained cervical 
tissue (Medicoapps.org ,2019) 
 
 
1.4.4.6 Principles of treatment 
Not all women who attend colposcopy will require treatment. If the colposcopist is able to 
identify a high grade lesion and can clearly identify its limits, then immediate treatment is 
possible. This is known as a see and treat approach (CervicalCheck, 2013). If the 
colposcopist assessment or biopsy reports a low grade lesion then the decision to treat is a 
clinical one. Treatment is not mandatory in such cases. The colposcopist will make a decision 
based on the likelihood that the lesion will regress, the age of the patient and if the patient is 
willing to return for future appointments. 
The aim of treating a CIN lesion is to remove the whole of the transformation zone to prevent 
the development of invasive disease. There are different methods available. Options include 
laser or cryotherapy (ablation) or diagnostic excision. Laser treatment uses a high energy 
beam of light to heat the intracellular water of the target cells, thus killing them. Cryotherapy 
works by freezing target cells resulting in irreversible cellular damage and death. LLETZ 
treatment works by cutting away the whole of the transformation zone with a wire loop that 
has been heated (Shambayati, 2011). All have similar treatment outcomes for the eradication 
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of CIN. Physical risks associated with colposcopy include lower abdominal pain, cramps, 
fainting and vaginal discharge (Sankaranarayanan et al., 2003). 
1.4.4.7 False positives and unnecessary referral to colposcopy 
From the 1st of September 2012 to the 31st of August 2013 in Ireland, 702 patients were 
referred to colposcopy based on an ASCUS cytology result, 146 based on an ASC-H and 799 
based on a LSIL result, all of which were reported as having a negative biopsy after 
colposcopy (CervicalCheck, 2013). The colposcopic biopsy is regarded as the gold standard 
on which a final result will be issued. However histological examination is by no means 
perfect. Arbyn et al. (2007) reported that factors related to colposcopy biopsy, sampling and 
interpretation errors were the most common cause of discrepancy between the cytology result 
and the corresponding histology result. Zuchna et al.(2010) found that the sensitivity of 
colposcopic-directed biopsy for the detection of CIN 2 was 52%, which confirms that many 
lesions may be difficult to detect. Another possible source of error that could account for the 
high volume of negative biopsies could be the number of false positive HPV DNA results. If 
the HPV infection is newly acquired the infection will likely resolve in the first 6 months 
(Adams et al., 2006). 
1.4.5 Risk of Psychological Harm 
For women, the receipt of an abnormal smear test frequently leads to a higher level of anxiety 
(Gray et al., 2006).  Often a result of an abnormal smear leads to fear on the part of the 
women that she has cancer. Gray et al. (2006) reported a high prevalence of anxiety among 
women with a low grade smear despite attempts to improve the way abnormal smear results 
are communicated. They determined that those who are at the highest risk of anxiety tend to 
be younger, have children, be smokers and have a high level of physical activity. 
25  
1.4.6 Vaccination 
There are two clinical approaches for the prevention of cervical cancer. The first is mass 
screening and treatment for pre-cancer, the second approach is vaccination to prevent 
infection of HPV. In 2010, two licensed HPV vaccines became available in Ireland, Cervarix 
and Gardasil. Cervarix is a bivalent vaccine against HPV types 16, 18 while Gardasil is a 
quadrivalent vaccine against HPV 6, 11, 16, 18. The efficacy of the HPV vaccine has been 
demonstrated in multiple studies (Baldur-Felskov et al., 2014, Munoz et al., 2010, Adams et 
al., 2006, Garland et al., 2016). All have shown a significant reduction in the rate of high 
grade histological abnormalities. Vaccination is a preventive approach as it is used with the 
intention of preventing HPV infection from occurring. Given the link between HPV and 
developing cervical cancer, women who have been vaccinated will have a reduced risk of 
developing the disease, however these women will still have to be screened, as vaccination 
does not cover all forms of the virus and may not be effective for women exposed to the virus 
prior to vaccination (Garland et al., 2016). 
1.4.7 Current and future screening practice 
Liquid based cytology (LBC) was introduced in the 1990’s as a means of replacing 
conventional cytology to improve cytology test performance. A LBC sample will be sent to 
the lab where it will be processed using either the Thinprep or SurepathTM methods. These 
two methods while similar involve different sample processing techniques. Thinprep uses a 
cell filtration system to remove unwanted cells (red and white blood cells). SurepathTM uses a 
density gradient centrifugation to remove unwanted cells. Both result in a circular monolayer 
of cells on a glass slide. In 2008 automated image analysis was introduced which allowed 
cytologist to be shown an area of interest on the slide that most likely contained abnormal 
cells. This resulted in a quick screening time for each sample and a reduced detection error 
(Arbyn et al., 2008). 
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In 2012 HPV testing was introduced by CervicalCheck as a test of cure following treatment 
at colposcopy. There are over 100 different types of HPV, 12 of which have been identified 
as carcinogenic and associated with a higher risk of progression to malignancy. The HPV 
virus/genome can be identified in exfoliated cells which allows for HPV testing to be 
performed on LBC samples. There are two common methods employed for HPV testing. The 
first is a nucleic acid amplification method and the second is a signal amplification method. 
Nucleic acid amplification involves the targeting and amplification of a particular HPV gene. 
Signal amplification involves the use of RNA probes to hybridise viral DNA. These 
RNA/DNA hybrids are then identified by a secondary structure. The Hybrid Capture 2 (HC2) 
HPV DNA assay from Qiagen was the first HPV test to become commercially available. It 
can identify 13 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) (Wong et al., 
2012). The Aptima E6 and E7 mRNA HPV test employs nucleic acid sequence base 
amplification for E6 and E7 viral oncoproteins. The over expression of E6 and E7 mRNA is 
associated with increased severity of disease (Haedicke et al., 2016). While these two tests 
can provide information on the patient’s HPV status they do not provide information on 
which types of HPV are present. The ability to identify which type of HPV is present allows 
for further risk stratification in HPV positive patients due to the risk posed by the various 
types of HPV. HPV 16 and 18 are associated with a higher risk of developing disease 
(Garland et al., 2016). The Roche Cobas 4800 HPV test is specifically designed to identify 
HPV 16 and 18 while also detecting the presence of HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 66 and 68 (Poljak et al., 2016). 
 
In 2015 HPV testing was utilised by CervicalCheck as part of a triage when low grade 
cytological abnormalities were detected on primary liquid based cytology screening. Women 
who present with LSIL but who are negative for HPV are at a very low risk of developing 
cervical cancer within the next 5 years and should return to routine screening. Women with 
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HSIL are at a higher risk of developing the disease and would be directly referred to 
colposcopy. The HPV test that has recently been introduced into the screening programme 
has high sensitivity values but low specificity values (Cobas test, 95.2% sensitivity, 24% 
specificity (Dillner et al., 2008, Rozemeijer et al., 2016)). The high sensitivity has led to 
HPV testing being considered as a primary screening replacement for cytology. Despite this 
high sensitivity there remains a low specificity as HPV is widespread in under 35 year olds. 
While the HPV DNA tests currently available as part of a screening programme can indicate 
the presence and specific genotype of HPV they cannot distinguish between the transient and 
acute infection of minor clinical relevance and a transforming infection which is clinically 
more significant. If used as a primary screening tool, HPV DNA testing could result in a high 
proportion of women being unnecessarily being referred to colposcopy. 
Molecular biomarkers have the potential to be used for the management of women who test 
positive for HPV. P16INK4a is seen as a biomarker that could be used to identify a 
transforming infection. The activation of E6 and E7 can be detected indirectly by the 
accumulation of P16INK4a protein within the exfoliated cells. P16 INK4a is not currently being 
used as part of any screening programme, however it does have the potential to be used as a 
primary screening test, in combination with or as a replacement for other triage tests (HPV 
testing). A recent study (Garland et al., 2016) reported sensitivity rates based on initial 
pathologist reviews of 76.4% to 80.01%. 
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1.4.7.5    Triage Tests 
The aim of a primary screening test is to identify patients most at risk, not to provide a 
diagnosis. At present the Pap test is the primary screening test followed by HPV testing 
followed by diagnosis on histology. Most of these tests are still subjective and a result is 
largely based on who is screening the sample. There are plans to adopt HPV testing as the 
primary screening method to identify patients most at risk. However, the identification of 
HPV does not correlate with the presence of disease as the infection is often transient. The 
application of primary HPV screening will require a high sensitivity for the detection of all 
high risk HPV types which will result in a reduction in specificity as it will include all the 
weaker carcinogenic HPV genotypes thus increasing the burden of hrHPV positive women 
needing follow up (Arbyn et al.,2009). To address this, additional triage tests are still 
required. 
The use of cytology as a triage test is one possibility. Cytology has proven itself to be an 
effective primary screening method for cervical cancer with a specificity of 96.5% but a 
sensitivity of between 30- 85% (Nanda  et al., 2000) 
Biomarkers which are widely expressed in transforming infections could be used as a triage 
test. The PALMS study conducted a large scale clinical trial to assess whether p16/ki-67 dual 
stained cytology could provide high sensitivity for CIN2+ in screening while maintaining 
high specificity. The report concluded that p16/ki-67 dual-stained cytology had superior 
sensitivity and non-inferior specificity over the Pap test for the detection of CIN2+ and could 
help with the limitations for primary HPV screening (Ikenberg et al., 2013). 
Other methods based on optical spectroscopy could represent a new approach for cervical 
cancer screening and this is the main topic of this PhD thesis. 
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1.5 Vibrational Spectroscopic techniques 
Vibrational spectroscopic techniques are potential tools for the non-invasive, label free 
investigation of biological samples at a molecular level (Bellisola et al., 2012,Downes et al., 
2010). Vibrational spectroscopy is a fast developing discipline that is showing a strong 
potential in the field of cervical cancer screening and was first proposed by Wong et al. 
(1991). Vibrational spectroscopy (FTIR and Raman) analyses vibrations within a molecule; 
these vibrations are characteristic of the molecular structure, resulting in a spectroscopic 
fingerprint (Lyng et al., 2015). 
1.5.1 Raman Spectroscopy 
Raman spectroscopy was named in honour of its inventor C.V. Raman along with K.S. 
Krishnan. Raman spectroscopy is based on the Raman Effect/ Raman scattering which is used 
to detect and measure the presence of certain molecules. Raman scattering occurs when the 
vibrational state of a molecule is changed after its interaction with a photon which results in a 
change in the frequency of the photon. Raman scattering can be further broken down into two 
types Stokes and anti-Stokes Raman scattering (Figure 1.14) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14 Jablonski diagram showing the change in vibrational energy of a molecule upon interaction with a 
photon. In Rayleigh scattering, the predominate form of light scattering, the electrons are excited to a virtual 
state before returning to the original vibrational energy level. In Stokes and Anti-Stokes Raman scattering, the 
electrons are excited to a virtual energy state, before returning to a higher and lower energy state (with 
respect to the original energy state) respectively (Biomed.tamu.edu. 2016) 
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In order for Stokes scattering to occur a molecule needs to be excited to a virtual energy level 
that comprises a distortion of an electron cloud so when it then returns to the first excited 
vibrational state, a photon with a lower energy (longer wavelength) is emitted. The energy 
difference between the incident and emitted photon excite the molecule to a higher vibrational 
state ( Gauglitz et al. 2003; Ball 2001). 
In anti-Stokes scattering the molecule is in a higher vibrational energy level so when 
subsequently excited to a virtual energy level, relaxes, and returns to the ground vibrational 
state. In this case, the energy difference between emitted and excited photon is converted to 
radiant energy and a vibrational quantum has been annihilated (Gauglitz et al. 2003; Ball 2001). 
For a molecular vibration to be Raman active, a change in net molecular polarizability must 
occur. The polarizability (α) represents the ability of an applied electric field, E, to induce a 
dipole moment, μ0, in an atom or molecule; a process represented mathematically by the 
equations below (Ball 2001): 
 
o   E 
 
 
Equation 1.1 Dipole moment. 
 
 
 
At the molecule’s nuclear geometry equilibrium the polarizability has a value, α0. In case of 
displacement, ∆r, away from the molecule’s equilibrium geometry, the instantaneous 
polarization α is given by: 
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  o 
 
   
r
 
  r 


Equation  1.2  Instantaneous  polarization  at  equilibrium  displacement  where 
  
 r 

represents the change in polarizability as a function of displacement. 
 
If the molecule is vibrating in a sinusoidal fashion, ∆r can be written as a sinusoidal function 
in terms of the frequency of the vibration, νs, and the time, t: 
∆𝑟𝑟 = 𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚  𝑐𝑐𝑐𝑐𝑐𝑐(2𝜋𝜋𝜋𝜋𝜋𝜋) 
 
Equation 1.3 Equilibrium displacement when  the  molecule vibrates   in  a sinusoidal 
fashion where rmax is the maximum vibrational amplitude. 
Light of a particular frequency, νo, has an associated electric field, E, which also has sinusoidal 
behaviour: 
E  Emax cos2 v0t 

Equation 1.4 Electric field where Emax is the maximum electric field frequency. 
 
Equations 1.1 to 1.4 can thus be written into equation 1.5 so that the first term represents the 
scattered phenomenon of a photon with the same intensity as the incident photon – Rayleigh 
scattering. The second term represents the Raman scattering of frequency v0+vs (anti-Stokes 
scattering) when the frequency of the scattered photon increases by molecular motion, vs; and 
v0-vs (Stokes scattering) when the frequency decreases. 
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    E cos(2 t)  E r 
 d  
cos(2 t) cos(2 t) ⇔ 
0 0    max 0 max  max 
 dr 

 
s 0 
 
 
⇔    E cos 2 v t   
E
max
r
max    cos 2 t v 
 
 
 v   cos 2 t v  v 
o o   max o 
2  r 
o s o s 
 
 
Equation 1.5 Scattered light component frequencies by oscillating polarization in which 
v0 is the frequency of incident light and vs is the frequency of the scattered molecular 
motion. 
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1.5.2 The Raman Spectrum 
The Raman spectrum of cells and tissues is made up of a superposition of many biochemical 
components including DNA, RNA, proteins, lipids and carbohydrates. A Raman plot is the 
intensity of the scattered light which is measured in arbitrary units vs. the Raman shift which 
is measured in wavenumbers (cm-1). The shift provides information on the vibrational, 
rotational and other low frequency transitions in a given sample. The full spectral range 
extends from 400-3500cm-1. The fingerprint region extends from 400-1800 cm-1 and the high 
wavenumber region extends from 2800-3500 cm-1 (Figure 1.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15 Raman spectrum of cervical cancer CaSki cell line. The variation of Raman shift wavelength is 
expressed in wavenumbers (cm-1) and can be observed along the X-axis whilst the intensity is represented 
along the Y-axis. The fingerprint and the high wavenumber (HW) regions of the spectrum are indicated by the 
arrows. 
 
 
Biological studies typically focus on the fingerprint region of the spectrum between 
wavenumbers 400cm-1 to 1800cm-1 (Figure 1.16). It is important to note that Raman peaks 
representing the Raman active molecules often overlap and can obscure one another. Some 
are narrow bands whereas others are broader. A tentative assignment of Raman peaks is 
presented in Table 1.1. 
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Figure 1.16 Raman spectra of a cervical Intermediate cell recorded in the fingerprint region 400-1800cm-1. 
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Table 1.1Tentative Peak Assignments for Raman spectra of cells and tissues (Movasaghi 
et al. 2007) 
 
Raman peak 
 
position [cm-1] 
Proteins Lipids Carbohydrates Nucleic acids 
482   Glycogen  
577   Glycogen  
622 C-C twist Phe    
643 C-C twist Tyr    
727 CH2 def C-C head  A 
752 Sym br. Trp    
781    U,C,T ring br 
826 Out of Plane 
 
ring br.Tyr 
  PO2 a.str 
851 Ring br. Tyr,C- 
 
C str. Pro 
   
852   Glycogen  
937   Glycogen  
985  C-C head   
1002 Sym. Ring br. 
 
Phe 
   
1033 C-H in plane 
 
Phe, C-C str 
   
1044   Glycogen  
1060 C-N str    
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1082 C-N str Chain C-C str C-O str, 
 
Glycogen 
 
1096  Chain C-C str C-C str  
1106   Glycogen  
1123 C-N str Chain C-C str C-O str  
1152 C-N str    
1207 C-C6H5 str. 
 
Phe, Trp 
   
1238 C-N str, Amide 
 
III 
   
1261   Glycogen  
1334   Glycogen  
1338 Trp   G 
1366  Sym. Str. CH3   
1381   Glycogen  
1450 CH2 def CH2 def   
1458   Glycogen  
1487 CH2 def   G,A 
1560 Tyr, Trp    
1575    A,G ring br 
1584 C=C str, C=C 
 
bend. Trp, Phe 
   
1605 C=C Phe, Tyr    
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1642 C=O str, C=C 
 
sym. Str. 
   
1669 C=O str. Amide 
 
I 
   
 
 
 
1.5.3 Raman Instrumentation 
The Raman microspectrometer used in this study (Labram XploRATM Raman spectrometer) 
(Figure 1.17 (A)) consists of a Raman spectrometer joined to an optical microscope which 
facilitates focusing of the Raman laser on particular areas of interest in the cells. A 532 nm 
green Argon ion laser (Figure 1.17 (B)) was used and focused through an x100 objective lens. 
The objective lens also allows for the collection of the Raman scattered light. The scattered 
light is then dispersed by the diffraction grating onto a charged coupled device, which 
converts it into an electrical signal which is projected as a spectrum. The grating used will 
determine the spectral resolution via the groove density of the grating. Typically 300-1800 
grooves/mm are used. The presence of a notch filter prevents the elastically scattered light 
(Rayleigh scattering) from reaching the detector (Figure 1.18). 
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Figure 1.17(A) Labram XploRATM Raman spectrometer. The spectrometer is linked to a confocal microscope, 
which allows the user to view the sample surface and direct the laser accordingly. Figure 1.17 (B) A 532 nm 
green Argon ion laser focused through an x100 microscope objective. 
 
 
Figure 1.18 Basic Schematic of Raman spectrometer. The argon ion laser is deflected by a series of mirrors 
onto the sample surface. Scattered light is collected by the objective lens and sent through a filter onto a 
holographic grating and finally onto a CCD (Laboratory,T.P.K. Spectroscopic Characterization, 2012) 
 
 
1.5.4 Raman Spectroscopy in Cancer Research 
Raman spectroscopy has the potential to play an important role in diagnostic cytology, 
histology, biopsy targeting, surgical targets, treatment monitoring and drug studies (Baker et 
al., 2018). A study conducted by Pirro et al used fibre based Raman spectroscopy for intra- 
operative guidance of brain surgery aiming to minimise the amount of brain tissue removal 
by identifying brain cancer (glioma) from normal brain tissue. They concluded that Raman 
spectroscopy could accurately differentiate normal brain from dense cancer and normal brain 
invaded by cancer cells, with a sensitivity of 93% and a specificity of 91% (Pirro et al., 
2017). 
 B 
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A study conducted by Brozek-Pluska et al, attempted to use Raman spectroscopy for imaging 
as well as diagnosis of breast cancer based on paraffin embedded tissue sections that were 
cancerous and non-cancerous from the same patient. They concluded that Raman bands 
associated with carotenoids, proteins and lipids dominated the spectra obtained from 
cancerous tissue when compared to non-cancerous tissue (Brozek-Pluska et al., 2012). 
Biofluids are an up and coming trend in the field of spectroscopy. Given the ease of 
collection and general acceptance by patients, biofluidscan give an accurate snap shot of a 
patient’s health (Baker et al., 2018). A recent study conducted by (Medipally et al., 2017) 
aimed to develop a high throughput Raman spectroscopy method for rapid screening of liquid 
blood plasma from prostate cancer patients. Sample preparation parameters were 
investigated, with the aim of identifying a combination that would reduce the overall 
acquisition time for spectra from peripheral blood plasma, reduce the complexity of sample 
preparation and retain the classification accuracy from Raman spectroscopic diagnostics. 
They identified spectral differences in the region around 1155 and 1523 cm-1 that were highly 
expressed in healthy volunteers compared to prostate cancer patients. Control versus cancer 
cases could be classified with similar discriminating features using both 785 and 532 nm laser 
lines and the discriminating features were resonant at 532 nm. A sensitivity and specificity of 
96.5% and 95% respectively was achieved (Medipally et al., 2017). 
A recent study conducted by Behl et al, attempted to standardise the protocol for Raman 
spectroscopy for oral cancer screening. Testing various collection methods the study was able 
to record high quality spectra from cells obtained from both the ventral side of the tongue and 
the buccal mucosa. The study utilised the Thinprep method of sample preparation cells were 
recorded on a glass substrate (Behl et al., 2017). 
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1.5.5 Raman Spectroscopy in Cervical Cancer Research 
In 1998, MahadevanJansen. et al (1998) developed an in vivo fiberoptic probe for the clinical 
diagnosis of cervical pre-cancers. They determined that an acquisition time of 90 seconds was 
required to obtain adequate spectra of the cervix however if they increased the power of the 
excitation source they could reduce that acquisition time to less than 20 seconds. Longer 
acquisition times increase signal to noise ratio however too long of an acquisition can result 
in burning of the sample resulting in a spectrum with ill-defined Raman bands not suitable for 
analysis. 
Another clinical trial by the same group (Utzinger, et al., 2001) showed that in vivo Raman 
spectra resemble ex vivo cervix tissue. This study was also completed using acquisition times 
of 60-180 seconds which is longer than is clinically accepted.A study conducted by 
Robichaux-Viehoever et al. (2007) utilized clinically feasible acquisition times of 5 seconds. 
The study concluded by stating that they were able to distinguish between benign and high 
grade dysplasia with a sensitivity and specificity of 89% and 81% respectively. A  probe 
based study investigated the effect of race, ethnicity, body mass index, parity and social 
economic status on Raman spectra from patients with a normal cervix and determined that 
only body mass index and parity resulted in significant variation within the spectral profile 
(Vargis et al., 2011). A study conducted by Krishna et al. (2006) used formalin fixed cervical 
tissues using Raman and FTIR spectroscopy. They reported the ability to distinguish between 
normal and malignant tissues based on differences in protein, lipids, and nucleic acid peaks 
and stronger amide III assignments, indicating disorder, helical secondary-protein structure in 
malignant conditions. A recent study Kanter et al. (2009) categorized the spectra according to 
the menstrual cycle and menopausal status and histopathological classification as determined 
by the pathologist. The results showed that incorporating the women’s hormonal status and 
particular point in the menstrual cycle and menopausal state resulted in a classification 
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accuracy of 94%. Kamemoto et al. (2010) reported the ability to distinguish normal cervical 
tissue from invasive cervical cancer tissue using frozen tissue sections. The discrimination 
was mainly based on collagen and CH stretching bands. A study conducted by Rashid et al. 
(2014) attempted to utilise formalin fixed paraffin embedded cervical tissue sections for 
Raman spectroscopy analysis. They concluded that they were effectively able to distinguish 
negative/normal tissues from pre-cancer tissue based on a reduction in glycogen and an 
increase in nucleic acids. The pre-cancer tissue loses differentiation with increased 
proliferation which resulted in reduced levels of glycogen while the cells that make up the 
normal tissue accumulated glycogen as they matured. Most Raman studies investigating 
cervical cancer fail to incorporate HPV into their analysis. Jess et al. (2007) outlined the 
clinical importance of Raman spectroscopy for identification of HPV infection.  Fixed and 
live cell lines were recorded which included PHK cells that express the E7 gene of HPV 16 
and CaSki cells which are a HPV 16 containing cervical carcinoma derived cell line. The 
results demonstrated a change in the Raman peaks most likely associated with DNA and 
protein which are consistent with an active HPV infection and changes associated with 
neoplasia. Ostrowska et al. (2010) used Raman and FTIR spectroscopy to study cervical 
cancer cell lines. HPV-negative (C33a) and low HPV copy number (SiHa) cell lines were 
investigated. Both cell lines were found to be biochemically similar but different when 
compared to mid (HeLa) and high (CaSki) HPV copy number cervical cancer cell lines. They 
reported variations in protein, nucleic acid and lipid bands. Using partial least squares 
regression analysis with HPV copy number as a target, the spectral profile of the cells could 
be used to evaluate the degree of HPV infection. Vargis et al. (2012) utilised both cell lines 
and cytology samples to investigate the potential of Raman microspectroscopy to detect the 
presence of HPV. They achieved discrimination between HPV negative normal human 
keratinocytes (NHEK), HPV negative cervical cancer cell line (C33a) and HPV positive 
42  
cervical cancer cell lines (HeLa and SiHa) with an accuracy of 89-93%. A study conducted 
by Rubina et al. (2013) used Raman spectroscopy to identify negative cervical cytology 
samples from cervical cancer samples. The results showed that the spectra were contaminated 
with blood and removal of this blood with the use of a red blood cell lysing agent, however, 
failed to improve the sensitivity values of 79%. Bonnier et al outlined the crucial need to 
adapt Raman spectroscopy protocols to reach suitable reproducibility for screening a large 
cohort of patients (Bonnier et al., 2014). The study demonstrated the use of H2O2 and 
industrial methylated spirits to remove contaminating blood residue which contributed to 
variability in the spectroscopic data sets. This was achieved without altering cell morphology 
or spectral features. Ultimately this work further demonstrated the potential of Raman 
spectroscopy to be used as a cervical cancer screening method based on improved sample 
preparation. A study conducted by (Duraipandian et al.,2018) outlined Raman spectroscopy 
ability to detect high-grade cervical cytology using morphologically normal appearing cells. 
They reported high rates of sensitivity and specificity for classifying HSIL cases based on 
intermediate and superficial cells. They also reported that intermediate and superficial cells 
could be mixed when recording and still be used for HSIL diagnosis as the biochemical 
difference between negative and HSIL samples were more than the biochemical differences 
between intermediate and superficial cells. A recent study defined the Raman spectral 
signatures of cervical exfoliated cells present in liquid-based cytology Pap test specimens and 
compared the signature of high-grade dysplastic cells to each of the normal cell types 
(Kearney et al., 2017). The study demonstrated that Raman spectroscopy can identify 
biochemical signatures associated with the most common cell types seen in liquid-based 
cytology samples; superficial, intermediate, and parabasal cells. In addition, biochemical 
changes associated with high grade dysplasia could be identified suggesting that Raman 
spectroscopy could be used to aid current cervical screening tests. 
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1.6 CERVIVA 
This body of work was performed as a continuation of on-going research on the application 
of Raman spectroscopy into cervical cancer screening which was conducted under the 
direction of the CERVIVA consortium (www.cerviva.ie). 
CERVIVA is an Irish research consortium that was founded in 2005 by Prof 
John O’Leary and Dr Cara Martin. The aim of CERVIVA is to provide research in the field 
of HPV associated diseases while supporting CervicalCheck and national agencies. 
CERVIVA is funded by the HRB, The Irish Cancer Society, and Friends of the Coombe and 
works closely with universities, government health agencies and biotechnology companies. 
1.7 Research Question and Hypothesis 
 Research Question: 
 
Can Raman spectroscopy be used as a tool for cervical cancer screening? 
 
 Hypothesis 
 
We hypothesise that Raman spectroscopy can be used to differentiate between 
normal and abnormal cervical cytology smear samples. 
1.8 Aims and Objectives 
 
 To conduct a study of variability due to hormonal effects in cervical Pap smear 
samples using Raman spectroscopy 
 To conduct a study on the removal of contaminating blood from cervical Pap smear 
samples and the implications for cervical cancer screening using Raman spectroscopy 
 To assess the utility of frozen biobanked samples for cervical cancer screening using 
Raman spectroscopy 
 To assess the utility of Raman spectroscopy as a triage test for cervical cancer 
screening 
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2 Materials and Methods 
 
2.1 Sample Cohort1 and 2 
Samples were obtained from patients attending the colposcopy department of the Coombe 
Women’s and Infants University Hospital (CWIUH). The inclusion criteria for patient 
recruitment was for first time colposcopy patients who had no previous history of disease and 
recruitment took place over a four year period (2014-2018).These patients made up sample 
cohort 1. Each patient was informed verbally and in writing on the purpose of the study and 
given the opportunity to opt in or out. Upon agreeing to take part in the study, written consent 
was obtained from each patient. Two copies of the same consent form were signed by the 
patient, one was kept with the patient’s clinical details, and the other was kept by CERVIVA 
at CWIUH. Each patient was assigned a random sample number to maintain patient 
confidentiality which is in keeping with general data protection regulation (GDPR). Upon 
receipt of the patient’s consent form, a nurse colposcopist would take the smear according to 
the standard operating procedure. Each patient was followed up for their corresponding 
histology result and monitored for a period of 12 months.’ 
Sample Cohort 2 was made up of LBC biobank samples provided by the National HPV 
Archive HPV research group, University of Edinburgh. The samples had been stored at -25oC 
for an unknown period of time. All clinical details outlining the patient’s cytology, HPV, 
colposcopy and histology status were provided.All biobank LBC samples were stored at - 
250C and shipped to the lab on dry ice. The samples were gradually allowed to come up to 
room temperature and then processed in the same way as non biobanked samples outlined in 
section 2.3. Numbers of samples for each study are detailed in the results chapters 3-6. 
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The number of samples selected and overall number of spectra recorded for each chapter was 
determined by the availability of samples recruited from CWIUH and the National HPV 
Archive HPV research group while ensuring that the same number of spectra was recorded 
for each category. This helped to ensure no bias with regards to leave one patient out cross 
validation and model prediction. As this was a pilot study and sample numbers were limited, 
power calculations were not applicable. 
2.2 HPV Testing 
 
2.2.1 CobasR 4800 HPV DNA Test 
The Cobas 4800 (Roche Diagnostics) is an automated system for the extraction of HPV DNA 
and the detection by real time PCR of 14 different high risk HPV types (16, 18 , 31,33, 35, 
39, 45, 51, 52, 56, 58, 59, 66 and 68) with the ability to genotype for HPV 16 and 18. The 
system consists of two parts, the first is a sample extraction and preparation instrument 
(X480) and the second is an analyser (z480) which carries out real time PCR on the processed 
samples (Figure 2.1). 
The system starts once the samples are loaded and a barcode is assigned to each sample. 
After sample loading, the reagents (SDS magnetic glass particles, wash buffer, lysis buffer 
positive control, negative control, PCR master mix, Proteinase K, Magnesium ions) and 
consumables (96 well plate, deep well plate, 1000 l tips and reagent reservoirs) are scanned. 
The rest of the process is automated, which involves 400 l of the LBC samples being 
collected and digested under denaturing conditions at elevated temperatures, before the cells 
are lysed by a chaotropic reagent which results in the release of HPV nucleic acids. These 
nucleic acids are negatively charged and will bind to the positively charged magnetic glass 
particles, which are held in place with a magnetic plate. The nucleic acids are then washed 
and separated from the glass particles before they are amplified and detected by real time 
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PCR. Approximately 200 nucleotides are targeted by the primers for the PCR reaction which 
are located within the L1 region of the HPV genome. The master mix contains primers 
designed for 14 different high risk genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 
and 68). Fluorescent oligonucleotides probes will then bind to the sequences within these 
primers during PCR. A meta-analysis of 23 industrialised countries using the Hybrid Capture 
2 (HC2) HPV assay indicate that the pooled sensitivity of primary HPV screening in the 
detection of CIN 2+ and CIN 3+ was 95.2% (95% CI: 92.5% to 97.1%) and 98.2% (95% CI: 
96.7% to 99.1%). The specificity reported in detecting CIN 2+ was 88% and CIN 3+ was 
 
87.6% (HIQA,2017). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1The Cobas® x480 instrument and z480 analyser. The cobas® x480 (left) is an automated system that 
extracts DNA from ThinPrep cervical cytology specimens. The z480 analyser (right) then amplifies and detects 
the presence of 14 different high risk HPV genotypes. 
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2.2.2 Aptima HPV mRNA test 
The Aptima assay (Hologic Gen-Probe, san Diego, Ca, USA) is an automated target 
amplification assay that detects the presence of E6/E7 mRNA from 14 high risk HPV types 
with the entire process being automated and carried out by a dedicated system, the Panther 
instrument (figure 2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Panther instrument which runs the Aptima HPV assay, and detects HPV mRNA from 14 high risk 
HPV types. All samples as well as assay reagents and consumables were loaded into the Panther system prior 
to beginning an assay run. Panther functions were controlled through the use of the on board computer, 
shown to the right of the main instrument. 
 
 
The first step involves the transfer of 1 ml of the test sample into transport media (STM) 
which causes the cells to lyse and prevents RNA degradation. The STM tubes are then placed 
into the sample racks and placed into the Panther instrument. HPV amplification reagents, 
HPV enzyme reagents, HPV internal control reagent and HPV selection reagents are loaded 
into the instrument. Positive and negative calibrators are present within the system. The 
samples are then run. mRNA is isolated using capture oligomers which are bound to 
magnetic micro particles. The oligomers bind to the target sequences in the mRNA target, 
before the complex is removed from the solution using magnets while the supernatant is 
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aspirated. The complex is then washed before the mRNA is amplified through the use of an 
MMLV reverse transcriptase and T7 RNA polymerase. The reverse transcriptase is used to 
generate a DNA copy of the target mRNA sequence containing a promoter sequence for T7 
RNA polymerase. T7 RNA polymerase produces multiple copies of RNA amplicon from the 
DNA copy template. Detection of the amplicon is achieved by HPA using single-stranded 
nucleic acid probes with chemiluminescent labels that are complementary to the amplicon 
which are detected through an illuminometer. The detection step is completed by the 
software which analyses the signal in order to produce the assay results. 
2.3 ThinPrep slide preparation 
A slide was prepared for each sample using a ThinPrep 2000 processor (Hologic Inc; 
Marlborough, MA 01752, America). The Thin Prep processor starts by homogenizing the 
sample by spinning the filter, creating shear forces in the fluid that are strong enough to 
disaggregate randomly joined material, break up blood, mucus and non-diagnostic debris. 
The cells are then collected onto the membrane of the filter and transferred onto a glass slide 
to create a circular monolayer deposit of cells 20 mm in diameter and a few microns in 
thickness. The slide is then ejected automatically into a fixative bath of 95% ethanol. 
2.4 H2O2 treatment 
LBC samples can contain varying levels of blood according to a blood scale index (0-3). 
Blood can also be present even though it may not be visible to the human eye, however it has 
previously been shown that Raman spectroscopy can detect these low levels of hemoglobin 
present (Bonnier et al., 2014) thus blood is deemed a limiting factor and should be removed. 
An in house method of utilizing H2O2 for the removal of blood was applied to all samples 
regardless of whether there was visual evidence of blood present in the LBC samples or not 
(Bonnier et al., 2014). The H2O2 method works by oxidizing the hemoglobin present within 
the blood. The ThinPrep slides were covered in H2O2 for 30 seconds before washing in 70% 
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industrial methylated spirits (IMS) for 3 minutes, followed by multiple dips in 100% IMS to 
remove any remaining H2O2. The slides were then allowed to air dry and ready for 
spectroscopic analysis. 
2.5 Raman Measurements 
All samples used as part of this study were recorded on a HORIBA Jobin Yvon XploRATM 
system (Villeneuve d’Asq, France), which is connected to an Olympus microscope Bx41 
equipped with a X10 and X100 objectives (MPlanN, Olympus). The equipped laser is a 532 
nm green argon ion laser with a spot size of 1-2 μm. The power of the laser was set at 100%. 
The confocal hole and slit was set at 100 μm with a 1200 lines/mm grating. The 1200 grating 
gives a spectral resolution of 3 cm-1 per pixel. 
The Raman spectrometer was calibrated to the spectral line of silicon, 520 cm-1. The dark 
current, the reference spectrum of polystyrene and of the NIST standard and the daily laser 
intensity were recorded. A CCD detector (Andor, 1024x256 pixels) was used and Labspec 
v6.0 software (Horiba Jobin Yvon) was used to operate the Raman spectrometer. One Raman 
spectrum was recorded from the nucleus of each cell for 30 seconds and averaged over two 
accumulations. This helps to increase the intensity of the scattered photons and reduces noise. 
The number of cells recorded from each sample depended on the quality of the cells present 
on the slide. A suitable cell would present on the slide as a single cell not obscured by 
surrounding material with the nucleus and cytoplasm being well defined. As all the cells 
recorded (Superficial and Intermediate) were morphologically normal, they were consistent 
in their size and shape and overall appearance (section 1.2.1). A good quality Pap smear 
would allow 25 cells to be recorded per sample. The coordinates of each cell was recorded in 
each sample and saved using the Labspec software. A typical slide could take between 35-40 
minutes to complete recording. Chapter 3 involved the recording of dyskaryotic cells from 15 
HPV positive, high grade dyskaryotic samples. As these cells were not morphologically 
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normal and could be present in low numbers it took additional time (20-30 minutes) to screen 
for these abnormal cells. Samples were also recorded randomly (ie. not recorded in batches 
according to any biological class) across a four year time period. This helped avoid any batch 
effects in our recording. 
2.6 Pap stain 
The Pap stain was carried out on each ThinPrep slide after Raman spectral recording. The 
protocol was carried out in the following manner. Each slide was soaked in a bath of equal 
parts distilled water and glycerol for 10 minutes. The slides were then washed in distilled 
water for 2 minutes. The slides were then submerged in hematoxylin for 2 minutes and 
washed in running hot tap water for 2 minutes. 1 % acetic was then added and washed off in 
distilled water for 1 minute. The slides were then submerged in 70% and 95% industrial 
methylated spirits (IMS), followed by 3 minutes in OG6. The slides were then washed in 
100% IMS for 2 minutes followed by Xylene for 1 minute. The slides were then mounted in 
Coverquick and cover slipped. The Pap stain was only performed once the spectroscopic 
analysis was complete. 
2.7 Raman Spectral Processing 
All sample data was pre-processed regardless of when or how the samples were recruited to 
avoid bias. Data was normalised and analysed using Matlab software (Mathworks) and 
specific scripts developed and adapted for uploading of the spectra and their pre-processing, 
including smoothing (Savitzky-Golay K=5, K=13) baseline correction (Rubberband) , vector 
normalization and glass subtraction 
2.7.1 Smoothing 
Smoothing is employed for the removal of high frequency components. Savitzky- Golay 
filtering is a common technique employed (Gautam et al., 2015). The goal of smoothing is to 
52  
remove rough changing components of the spectra and to highlight slow changes in intensity 
so that it’s easier to see trends in data. 
2.7.2 Base Line Correction 
A common problem when using Raman spectroscopy is fluorescence. When a sample 
fluoresces the fluorescing photons can be detected by the photon detector thereby distorting 
the Raman spectrum obtained from the test sample resulting in an elevation of intensity 
which can obscure biological peaks particularly those in the fingerprint region. Rubberband 
baseline correction is employed to correct this change in intensity. First the spectrum is 
divided up into a given number of ranges. The lowest point in each range is determined, then 
the initial baseline is built out of those points. All the points on the spectrum are then drawn 
down by the difference between the lowest point on the baseline. 
2.7.3 Vector normalization 
Raman spectra can exhibit a change in intensity levels even when recording the same sample 
due to different Raman conditions such as a change in laser alignment or power levels. 
Raman spectra from the same sample could have different intensity levels. Normalization is 
the process that corrects for this change in intensity by making sure the intensity of a given 
band (1004 cm-1) of the same material is similar across all the spectra recorded under slightly 
different conditions. Vector normalisation involves calculating the norm which is defined as 
the square root of the sum of the squared intensities of the spectrum. Each of the Raman 
intensities corresponding to a Raman shift is divided by the norm to obtain the normalized 
spectrum (Gautam et al., 2015).This is a standard operating procedure for all Raman 
spectroscopic analysis. 
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2.7.4 Glass subtraction 
Glass is the only substrate used in cytopathology as it is inexpensive and allows the 
processing of hundreds of samples a day. Its use in Raman spectroscopy, however, is 
hampered by the fact that glass exhibits broad peaks at 550 and 1100cm-1 which overlap with 
the biological spectra in the fingerprint region thus resulting in the need for the spectra to be 
corrected for glass background. 
There are two ways that the contribution of glass to the spectra can be reduced. The first 
involves the fine focus of the laser on the target cell’s nucleus. Focusing the laser on the 
upper portion of the nucleus to increase the distance between the laser and the glass slide 
reduces the glass contribution to the spectra. The second involves the use of an in house 
developed algorithm based on non-negativity constrained least squares (NNLS). In NNLS, 
the coefficients are not allowed to become less than zero. Using a matrix of 300 glass spectra 
(Figure 2.3), and a set of cellular components (nucleic acids, proteins, and carbohydrates), a 
non-negative vector is found that estimates the contributions of the cellular components and 
glass to the recorded cell spectrum. This vector is then multiplied by the glass matrix and cell 
components, before being subtracted from the original recorded cell spectrum (Figure 2.4). 
After these pre-processing steps, the data was mean centered and subjected to partial least 
squares discriminant analysis (PLSDA). It is possible to use other forms of substrate such as 
calcium fluoride which don’t require subtraction, as this does not contribute a Raman signal 
to the spectrum in the fingerprint region. This substrate is very expensive, however, and as it 
is thicker than a glass slide, Thinprep technology cannot be used for slide preparation. 
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Figure 2.3 300 glass spectra recorded in the fingerprint region 400-1800cm-1 
 
 
Figure 2.4 100 Intermediate cell spectra before (blue) and after (red) pre-processing for glass removal. 
-1 
-1 
55  
2.8 Partial least squares discriminant analysis (PLSDA) 
Partial least squares discriminant analysis (PLSDA) is a chemometric technique used to 
optimise the separation between different groups of samples. It is a supervised form of 
multivariate analysis which works as a linear classifier. Its aim is to maximise the variance 
between groups and to minimise the variation within each group. The loadings/latent 
variables (LVs) can be plotted to give information on the source of the variation between 
groups. PLSDA was chosen over multivariate techniques for a number of reasons. The first 
being that it can analyse data with numerous variables and it works well on data that is noisy. 
The limitations of PLSDA can be, that it can over fit a model meaning that it can classify 
training data well but not new data. This can be corrected for by using a validation data set or 
a method of cross validation (Ballabio et al., 2013). Mean centering (dividing all the 
variables by the mean) was performed on the pre-processed spectra before PLSDA modelling 
to adjust for the variance between large and small unit variables, leaving the relevant variance 
(between the samples) for analysis. 
2.9 Cross –Validation 
Cross-validation is a model validation technique used to assess how results will generalize to 
a new dataset. It is mainly used to determine prediction (how well a model will predict in 
practice). The main reason for using cross validation instead of conventional validation is that 
conventional validation requires a 70:30 split of the data. 70% for training and 30% for 
testing (Dobbin K et al., 2011). However in most cases there isn’t enough data available to 
separate out 70% for training and 30% for testing without losing modelling or test capability, 
hence the use of cross validation (Kohavi., 1995). Cross validation is performed by dividing 
samples into validation groups. Each group is then removed from the training set one at a 
time. The model is then calibrated on the remaining training samples and is then used to 
predict samples of the cross validation group (Ballabio et al., 2013). In this study one 
methods of cross validation was performed. 
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Leave one patient out = A test set is determined by leaving out each patient sample 
one at a time and comparing it to the training set. Every sample is tested. This helps 
ensures bias is avoided. 
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Chapter 3 
 
 
 
 
 
 
A study of hormonal effects in cervical smear 
samples using Raman spectroscopy. 
 
 
 
 
 
 
 
 
Adapted from: Traynor D, Kearney P, Ramos I, Martin CM, O'Leary JJ, Lyng FM. A study 
of hormonal effects in cervical smear samples using Raman spectroscopy. J. 
Biophotonics. 2018;e201700240. 
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3.1 Introduction: 
 
Until recently the primary method for cervical screening was based on the Papanicolaou 
test (Pap test). The Pap test requires cells to be scraped from the cervix, fixed to a glass slide, 
stained and reviewed by a trained cytologist. Cellular abnormalities are identified by the 
cytologist based on cellular morphology and staining characteristics and classified according 
to the degree of dysplasia (Low grade or High grade). The advantage of the Pap test is that it is 
a widely accepted screening based test with a high specificity of 95-98% and a sensitivity of 74-
96% (Kitchener et al., 2011). The variability in the rates of sensitivity can be due to sampling 
technique; the subjectivity of the cytology based screening and can result in a high rate of 
gynaecological referral and patient recall which adds to cost and patient stress. Persistent 
infection with high risk human papillomavirus (HPV), such as HPV types 16, 18, is accepted as 
the major cause of cervical pre-cancer and cancer (Walboomers et al., 1999 ). HPV DNA testing 
has a higher sensitivity (>95%) but lower specificity (~ 84%) than the Pap test (Cuzick et al., 
2013) and these tests are expensive, time-consuming and provide no information on cervical 
cytopathology. Current gold standard methods for detection of cervical cancer and pre-cancer 
are therefore limited and there is an unmet clinical need for new objective screening or 
diagnostic tests. Optical spectroscopic techniques, such as Raman or infrared spectroscopy, are 
label-free, non-invasive and have several advantages over traditional approaches, including 
objectivity, speed and cost. These methods can provide quantitative information based on the 
spectroscopic signature of the biochemical components of the sample allowing diagnosis to be 
based on biochemical changes rather than on morphological changes. The focus of the present 
study is on Raman spectroscopy, which is based on inelastic light scattering. The coupling of 
the light generates vibrations within the material and these vibrations are characteristic of the 
chemical structure, the energy of the scattered light is reduced by an amount equal to the 
vibrational  energy and  from  this  a  rapid,  label  free,  non-destructive  measurement  of the 
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complete biochemical fingerprint of a biological sample can be obtained.   Over the past       15 
years, the potential of Raman spectroscopy together with multivariate statistical analysis has 
been demonstrated for the detection of a variety of cancers, including cervical cancer (Diem et 
al., 2013, Lyng et al., 2015). In initial infrared spectroscopy studies on cervical cytopathology 
samples ( González-Solís et al., 2013, Wong et al., 1991), spectra were recorded from cell pellets 
rather than from single cells and the presence of metaplastic cells, endocervical columnar cells, 
polymorphs, blood, cervical mucus and debris were all identified as confounding factors (Wong 
et al., 2002, Chiriboga et al., 1998, Cohenford et al., 1997, Diem et al., 2002, Wood et al., 
1998). Recent studies by Ramos et al. (2016) and Bonnier et al. (2014) addressed the variability 
in Raman spectra from cervical smear samples and reported a new method to clear blood 
residue contamination before Raman spectroscopy based on pre- treatment of the slides with 
hydrogen peroxide. This method significantly minimised variability and resulted in the 
collection of highly reproducible data and was employed in this study to reduce variability 
based on the presence of blood residue. Physiological factors such as hormonal changes during 
the menstrual cycle or during menopause may also be potential sources of variability in the 
normal cervix. 
The cellular make up of an individual woman’s smear is dependent on which day during 
the menstrual cycle the sample was taken. Days 1-4 are classed as the menstruation phase of 
the cycle when bleeding will occur and smear samples are generally not taken during this phase. 
Days 5-13 are classified as the proliferative phase. During this phase oestrogen levels reach 
their peak resulting in complete maturation of the squamous epithelium and the cervical smear 
will present with a higher ratio of superficial cells to intermediate cells. Days 14-28 are 
classified as the secretory phase where progesterone production reaches its peak and prevents 
complete maturation of the epithelium. The cervical smear will present with a higher ratio of 
intermediate  cells  to  superficial  cells.  During  menopause,  levels  of  both  oestrogen   and 
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progesterone will drop dramatically and there is a gradual arrest of the maturation of the 
squamous epithelium. This results in the loss of superficial and intermediate cells leading to 
the final atrophic stage where the squamous epithelium is composed entirely of parabasal cells. 
The use of hormone based contraceptives (HC) will affect the natural hormone mediated 
maturation process of the cervical epithelium. A study by Romeo et al. (2002) used infrared 
spectroscopy to investigate hormonal influences on cervical cells throughout the menstrual 
cycle and showed spectral changes such as increases in the 1200-1000 cm-1 region due to 
glycogen increases around ovulation (mid cycle). Cervical cells from women on HC did not 
show the same degree of spectral changes as cells from women not on HC. Despite the 
variability throughout the menstrual cycle, principal component analysis (PCA) showed good 
discrimination between high grade dysplasia and normal samples collected at different phases 
of the menstrual cycle. 
 
A more recent study by Kanter et al,(2009) has shown that hormonal differences due 
to the menstrual cycle can influence the Raman spectra acquired from the cervix in vivo. 
Spectra were divided into four groups, pre-menopausal proliferative phase (days 1-14), pre- 
menopausal secretory phase (day 15-28+), peri-menopausal and post-menopausal. Spectral 
differences were mainly observed at 1250, 1300 and 1320 cm-1, most likely due to changes in 
the proteins collagen and elastin (Movasaghi et al.,2007). Incorporating hormonal status into 
their dysplasia classification algorithm increased the classification accuracy from 88% to 94%. 
The main objective of our study was to investigate hormone associated changes in the Raman 
spectra of cytologically negative ThinPrep cervical smear samples related to; (1) the menstrual 
cycle, (2) the onset of menopause and (3) the use of hormone based contraceptives. A further 
objective was to determine if any changes observed would interfere with the ability to 
discriminate normal and high grade dyskaryotic cervical smear samples caused by HPV 
infection. 
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3.2 Materials and methods 
 
3.2.1 Sample collection and ThinPrep slide preparation 
Cervical smear samples collected in PreservCyt solution were obtained from the Cytology 
Department at the Coombe Women and Infants University Hospital (CWIUH), Dublin, Ireland 
(recruitment period 2014-2018), after routine cytological screening had been performed. 
Ethical approval for use of encoded samples for the study was granted by the CWIUH Research 
Ethics Committee (no. 28-2014). Clinical data which was recorded relating to the samples 
included cytology result, date of last menstrual period, age at time of smear test and reported 
use of hormonal based contraceptives. No information on smoking status was available. A total 
of 60 cervical smear samples, 45 confirmed as cytology negative and 15 confirmed high grade 
dyskaryosis (high grade squamous intraepithelial lesion (HSIL)) samples, were used for this 
study. A slide was prepared for each sample as outlined in section 2.3 and 2.4. 
3.2.2 HPV Testing 
HPV testing was carried out as outlined in section 2.2.1 
 
3.2.3 Raman Microspectroscopy 
Raman recording was carried out as outlined in section 2.5-2.6. 25 cells were recorded from 
each cytologically confirmed negative test sample and 35 dyskaryotic cells were recorded in 
total from the 15 confirmed HSIL samples. 
3.2.4 Data Pre-Processing and Analysis 
Data Pre-processing and analysis was preformed as outlined in section 2.7-2.9 
 
From the data provided by the patient about their last menstrual period and the day on which 
the sample was taken, the day of the menstrual cycle the smear was taken was calculated. It 
was assumed that each patient follows the standard 28 day cycle. Samples were only available 
from days 7-24 of the cycle. Table 3.1 shows the sample details including day of the menstrual 
cycle, menopausal status and use of hormone based contraceptive (HC). 
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Table 3.1 Sample details including day of the menstrual cycle, menopausal status and use of hormone based 
contraceptive 
 
 
 
Sample number 
Cytology 
 
Result 
 
Day of cycle 
 
Postmenopausal 
 
HPV Result 
 
Contraceptive 
1 Negative 7 No Negative None 
2 Negative 9 No Negative None 
3, 4, 5, 6, 7 Negative 10 No Negative None 
8, 9 Negative 11 No Negative None 
10, 11, 12, 13, 14 Negative 12 No Negative None 
15, 16, 17, 18, 19, 20, 21, 22 Negative 13 No Negative None 
23, 24 Negative 16 No Negative None 
25, 26 Negative 20 No Negative None 
27 Negative 21 No Negative None 
28 Negative 24 No Negative None 
 
29, 30, 31, 32, 33, 34, 35 
Negative Not 
 
applicable 
 
Postmenopausal 
Negative  
None 
36, 37, 38, 39, 40, 41, 42, 43, 
 
44, 45 
Negative Not 
 
applicable 
 
No 
Negative Hormone based 
 
Contraceptive 
46, 47, 48, 49, 50, 51, 52, 53, 
 
54, 55, 56, 57, 58, 59, 60 
High Grade Not 
 
applicable 
 
No 
Positive  
None 
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3.3 Results 
 
3.3.1 Proliferative and Secretory Phase and Postmenopausal Cellular Presentation on 
Pap smear. 
The proliferative and secretory phase presentation of a Pap smear are shown in Figure 3.1(A) 
and Figure 3.1(B) respectively. A higher ratio of superficial (pink stained) to intermediate (blue 
stained) cells in the proliferative phase compared to a higher ratio of intermediate (blue stained) 
to superficial (pink stained) cells in secretory phase can be observed. A postmenopausal Pap 
smear is shown in Figure 3.1(C). A lack of cellular material, mucus and cellular debris can be 
observed which caused difficulties in recording good quality spectra. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 (A) Proliferative phase presentation of a Pap smear. Note the higher ratio of superficial (pink 
stained) to intermediate (blue stained) cells, (B) Secretory phase presentation of a Pap smear. Note the higher 
ratio of intermediate (blue stained) to superficial (pink stained) cells, (C) Postmenopausal presentation of a 
Pap smear. Note the lack of cellular material, mucus and cellular debris.  Bar = 35 m. 
C 
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3.3.2 Raman signature of Proliferative Phase Vs Secretory Phase 
The spectral data from the Pap smears was divided up according to the day of the menstrual 
cycle the sample was taken on. Figure 3.2(A) shows the mean Raman spectra of cells from 
days 7 to 24 of the menstrual cycle. Increases in the Amide I (1640-1650 cm-1)(see Table 1.1), 
Phenylalanine and Tyrosine (1605-1610 cm-1) and glycogen (480 cm-1) bands over time were 
observed. The latent variables (LV) scores scatter plot Figure 3.2(B) shows reasonable 
separation between the proliferative phase (blue) and the secretory phase (red). Some 
overlapping is observed which is most likely due to the fact that each woman will differ slightly 
between the days of the menstrual cycle and the levels of oestrogen and progesterone present. 
The LV1 loadings shown in Figure 3.2(C) highlight areas similar to those highlighted in the 
mean Raman spectra Figure 3.2(A). The discrimination is mainly based on glycogen (480, 937, 
1381, 1458 cm-1) which is more present in the secretory samples (red) due to the higher levels 
of progesterone which promotes sub nuclear glycogen accumulation (Nair et al., 2010) and 
proteins (CH2 def, 1450 cm
-1) and Amide I (1669 cm-1) which are higher in samples collected 
from the proliferative phase of the cycle. The prediction plot from the PLSDA model Figure 
3.2(D) shows reasonably good classification of menstrual cycle phase (proliferative phase or 
secretory phase) with sensitivity of 83% and specificity of 86%. 
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Figure 3.2 (A) Mean Raman spectra of intermediate and superficial cells from days 7 to 24.  Shading denotes 
the standard deviation. Glycogen (480 cm-1), Amide I (1640-1650 cm-1), Phenylalanine and Tyrosine (1605-1610 
cm-1) show increases in intensity over time   (B) LV scores scatter plot of  Proliferative Phase, Days 7-14 (Blue) 
Vs Secretory Phase, Days 15-24 (Red ), (C) LV1 loadings show that discrimination is based on based on glycogen 
(480, 937, 1381, 1458 cm-1) and proteins (CH2 def, 1450 cm-1) and Amide I (1669 cm-1) , (D) PLSDA prediction 
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plot which has a sensitivity of 83% and specificity of 86%. 
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3.3.3 Raman signature of postmenopausal samples 
Most women are generally screened for cervical cancer up until the age of 65. Between the 
ages of 48-55 most women are said to be menopausal. Hence it is important to determine if Pap 
smears collected from postmenopausal women will have a similar Raman signature to non- 
postmenopausal women. Mucus and cellular debris present on postmenopausal samples 
obscure the little cellular material that is present on the slide and make it very difficult to obtain 
good spectra hence the number of spectra recorded is severely reduced and it is difficult to 
draw any firm conclusions. Figure 3.3(A) shows the mean and standard deviation spectra of 
the 22 postmenopausal cells recorded. Figure 3.3(B) shows good discrimination between the 
two sample types. The loadings shown in Figure 3.3(C) shows that the discrimination is based 
on glycogen (852, 1106, 1138 cm-1) and nucleic acids (781 cm-1) proteins (1450 cm-1) and 
Amide I (1669 cm-1). Figure 3.3(D) shows the PLSDA prediction plot which has a sensitivity 
of 100% and specificity of 95%. 
Atrophic samples were not available as part of this study. No firm conclusions can be drawn 
from this data set except that postmenopausal samples can represent a problem for Raman 
based screening based on their Pap smear presentation due to mucus, cellular debris and lack 
of cellular material. 
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Figure 3.3 (A) Mean Raman spectra from postmenopausal samples. Shading denotes the standard deviation, 
(B) LV scatter scores plot of postmenopausal (blue) and non-menopausal (red), (C) LV1 loadings, (D) PLSDA 
prediction plot 
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3.3.4 Raman signature associated with women on hormone based contraceptives. 
The clinical details obtained indicated if the patient was on some form of hormone based 
contraceptive (HC). However information on which type of contraceptive they are currently on 
was not included. The aim of this part of the study was to determine if Pap smears collected 
from women on HC will have a similar Raman signature to women who are not on HC. Figure 
3.4(A) shows that the levels of glycogen (482 cm-1 and 855-939 cm-1) in the HC positive 
samples are lower when compared to the controls. The controls were made up of the samples 
collected throughout the menstrual cycle which were HC negative. Tryptophan and 
Phenylalanine at peak position (1584-1605 cm-1) and Amide I at peak (1669 cm-1) are higher 
in HC samples compared to the control. The lower levels of glycogen in the HC samples could 
be linked to lower levels of progesterone due to its role in promoting sub-nuclear glycogen 
accumulation. The same could be said for the higher levels of proteins detected (Phenylalanine, 
Tryptophan, and Amide I). There is also a consistent change in the shoulder of Amide I, which 
is a change in Amide I protein position and folding between HC positive and negative samples. 
Overall protein synthesis may be increased due to the constant level of hormones present. 
The LV scores scatter plot Figure 3.4(B) shows good separation between HC positive 
samples and HC negative samples. There is a small amount of overlapping which could be due 
to a number of factors. Multiple types of contraceptive are available which contain different 
types and levels of hormones, including implants, injectable contraceptive, progesterone pills, 
oestrogen and progesterone pills, combined oral and the patch all of which work by maintaining 
a constant level of hormones in the body thus preventing the rise and fall of oestrogen and 
progesterone. Hence they may work differently and individual patients will also respond 
differently to the levels of hormones present. The loadings 3.4(C) from LV1 show that glycogen 
(483 and 1386 cm-1) and proteins and lipids (1146, 1450, 1566 cm-1) and Amide I (1669 cm-1) 
are the main discriminating factors between HC positive and HC negative samples 
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Figure 3.4 (A) Mean Raman spectra from HC positive and HC negative cells. Shading denotes the standard 
deviation, (B) LV scatter scores plot of HC negative (blue) and HC positive (red), (C) LV1 loadings, (D) PLSDA 
prediction plot. 
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3.3.5 Phase of Menstrual Cycle vs High Grade Dyskaryosis 
It is important to determine if the changes observed throughout the menstrual cycle as seen in 
Figure 3.2(A) would affect the ability of Raman spectroscopy to discriminate HSIL from 
normal cells affected by the normal maturation of the cervical epithelium controlled by both 
the rise and fall of progesterone and oestrogen. For this part of the study, spectra from HSIL 
cells Figure 3.5(A) were recorded from 15 HPV positive, high grade dyskaryotic samples and 
compared to an equivalent number of spectra from negative samples from days 7-21 of the 
menstrual cycle, all of which were HPV negative. Figure 3.5(B) shows the mean spectra from 
negative samples from days 7-21 of the menstrual cycle and spectra recorded from HSIL cells. 
The LV scores scatterplot in Figure 3.5(C) shows that HSIL cells separate well from normal 
cells on the first LV. This shows that regardless of when a sample is taken during day 7-21 of 
the menstrual cycle, HSIL cells can still be effectively discriminated from cytology negative 
cells using Raman spectroscopy. Spectral changes due to the hormonal influence of oestrogen 
and progesterone seem to be less than the spectral changes due to the biochemical changes in 
the dyskaryotic cells. The loadings from LV1 in Figure 3.5(D) show that glycogen (495, 1080, 
1120, 1380, 1458 cm-1), nucleic acids (780 and 1487 cm-1), Amide III and Amide I proteins 
(1239 cm-1 and 1669 cm-1 respectively) and tryptophan and phenylalanine (1605 cm-1) mainly 
contribute towards the discrimination between normal and HSIL cells. As the HSIL cells are a 
result of a high risk HPV infection, the biochemical difference in glycogen, proteins and nucleic 
acids can be attributed to the downstream effects of the HPV infection. The predictions plot 
Figure 3.5(E) from the PLSDA model shows excellent classification of the negative samples 
(all menstrual cycle phases) and the dyskaryotic samples with sensitivity of 98% and a 
specificity of 97%. However even with a high sensitivity and specificity between the menstrual 
cycle and dyskaryotic cells, recording from dyskaryotic cells is not efficient for Raman 
spectroscopy due to the minimal number of dyskaryotic cells present per sample and the 
difficulty in locating and recording from them. 
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Figure 3.5 (A) Pap stained HSIL cells. Bar = 35 m, (B) Mean Raman spectra from negative samples from days 7- 
21 of the menstrual cycle (red) and spectra from HSIL positive samples (blue). Shading denotes the standard 
deviation, (C) LV scores scatter plot of HSIL positive samples (red) and negative samples (blue), (D) LV1 
loadings, (E) PLSDA  prediction plot. 
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3.3.6 HC positive samples vs High Grade Dyskaryosis 
It is important to determine if the use of HC will also affect the ability of Raman spectroscopy 
to discriminate normal HC positive cells from HSIL cells. Figure 3.6(A) shows the mean 
Raman spectra of HC positive negative samples and spectra from HSIL cells. The LV scores 
scatterplot in Figure 3.6(B) shows that spectra from HC positive samples separate from spectra 
from HSIL cells from high grade dyskaryotic samples on the first LV component with minimal 
overlap. Figure 3.6(C) shows the LV1 loadings which indicate that the main differences 
between the HC positive cells and HSIL cells are very similar to those found for the HC 
negative and high grade dyskaryotic samples. Glycogen (482, 1261 and 1381 cm-1), nucleic 
acids (781 cm-1), and proteins (1450, 1560 and 1669 cm-1) again contribute towards the 
discrimination. As before, it appears that the overtaking of the host cell machinery by HPV 
causes more of a biochemical change within the cell than the biochemical changes associated 
with the use of HC. Our results are backed up by a study conducted by (Daniel et al., 2017) 
which used a linear combination of non-negative least squares from the main biochemicals 
associated with tissue and cell composition and confirmed that nucleic acids, glycogen and 
protein were the main discriminating factors between negative and HSIL. 
The predictions plot from the PLSDA model shows excellent classification of the negative 
samples (HC positive) and the HSIL cells from high grade dyskaryotic samples Figure 3.6(D) 
with sensitivity of 96% and specificity of 98%. 
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Figure 3.6 (A) Mean Raman spectra from negative HC positive samples (red) and spectra from HSIL cells (blue). 
Shading denotes the standard deviation, (B) LV scores scatter plot of HSIL samples (red) and negative HC 
positive samples (blue), (C) LV1 loadings, (D) PLSDA prediction plot. 
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3.4 Discussion 
This study has shown that the day a Pap smear is taken during days 7-21 of the 
menstrual cycle will have an effect on the spectra with regard to the level of glycogen and 
proteins. It should be noted, however, that this study assumes that each patient recruited follows 
the standard 28 day cycle, and that the patient details recorded for each sample were correct. It 
is possible for women have a longer or shorter cycle, hence this variation may have influenced 
our analysis. Postmenopausal samples represent a problem for Raman based screening due to 
their lack of cellular material and presence of cellular debris and mucus. 
The use of HC causes the most variability. Further study would be required to determine 
which hormone is causing the discrimination between HC positive and HC negative samples. 
These findings suggest that the use of oral contraceptives and the day on which the Pap smear 
was taken during the menstrual cycle should be incorporated into the data analysis to reduce 
variability between patient samples. Incorporating this effect into our model would require us 
to establish a standard effect of the various types of HC used within the population to identify 
any specific changes associated with a particular type/brand. For example a pure oestrogen and 
a pure progesterone based HC might produce different effects particularly related to the level 
of glycogen present within the cells as progesterone promotes sub-nuclear glycogen 
accumulation. Once the standard effect of all HC was established it would then be used to set 
a new baseline for the various molecular components (glycogen, Amide I etc) that could be 
used to distinguish normal from dyskaryotic cells. Our results can be backed up by other studies 
(Kanter et al., 2009) which showed that hormonal status influences Raman spectra from the 
cervix in vivo and that incorporating hormonal status into their classification algorithm 
increased the accuracy from 88% to 94%. Despite this, however, the variability between days 
of the menstrual cycle or use of HC did not hinder the ability of Raman spectroscopy to 
discriminate cytology negative cells from HSIL cells. The biochemical changes induced in 
HSIL cells due to an active HPV infection were more pronounced than the biochemical changes 
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due to the menstrual cycle or the use of hormone based contraceptives. This makes sense given 
that that a chronic HPV infection alters cell cycle regulation, transcribes viral oncogenes and 
is producing and shedding HPV virons (Johansson C et al., 2012) thus altering the biochemical 
signature of the infected cells when compared to normal/negative cells. However, going 
forward, it would not be practical to try and record spectra from these HSIL cells due to time 
constraints and the minimal number of cells present per sample. 
 
 
3.5 Conclusion 
 
This study highlights the scope of Raman spectroscopy for cervical screening despite the 
presence of biochemical changes associated with the menstrual cycle and the use of HC. It is 
acknowledged that the study is limited in focussing only on HSIL positive samples and a further 
study would be required to include low grade (LSIL) samples. 
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Chapter 4 
 
 
 
Improved removal of blood contamination from 
Thinprep cervical cytology samples for Raman 
spectroscopic analysis 
 
 
 
 
 
 
 
 
 
Adapted from: Traynor D, Kearney P, Ramos I, Martin CM, O'Leary JJ, 
 
Lyng FM. Improved removal of blood contamination from Thinprep cervical cytology 
samples for Raman spectroscopic analysis J. Biomed. Opt. 23(5), 055001 (2018) 
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4.1 Introduction 
 
The most common method for cervical screening is based on the Papanicolaou test (Pap test) 
which is designed to screen for signs of pre-cancer and cancer of the cervix. The Pap test 
requires cells to be scraped from the cervix, fixed to a glass slide, stained and reviewed by a 
trained cytologist. Cellular abnormalities are identified based on cellular morphology and 
staining characteristics and classified according to the degree of dysplasia. The ThinPrep liquid 
based cytology method involves the patient’s cells being transferred into a specimen vial 
containing PreservCyt transport medium. PreservCyt is an alcohol based solution that preserves 
cell morphology and breaks down biological components such as mucin and blood. The normal 
smear pattern is made up of epithelial and non-epithelial components (Figure 4.1(A)). The 
epithelial cell components include parabasal cells, intermediate cells, superficial cells, 
endocervical and endometrial cells. Non-epithelial cell components include red blood cells, 
lymphocytes, histiocytes, polymorphs, mucus and bacteria. Red blood cells are 7-8 m in size 
and stain red or pink with the Pap stain. They are often found in cervical samples, either due to 
menstruation or inflammation and their presence can also be used as an indicator of disease 
(pre-cancer)(Kitchener et al., 2011). A patient’s cervix with a high grade lesion will often bleed 
on contact with the cervical brush and as a result the smear becomes contaminated with blood. 
The presence of blood in the sample will often dilute diagnostic cells, cover and surround cell 
groups, increase screening time and make microscopic interpretation difficult (Figure 4.1(B)). 
PreservCyt contains a lysis agent for mucus and red blood cells but excessive blood in the 
sample vial will prevent a satisfactory smear being produced. High volumes of red blood cells 
will prevent the collection of epithelial cells onto the polycarbonate filter membrane during 
processing resulting in a ringed halo effect with red blood cells deposited mostly around the 
edges of the smear with very few epithelial cells present (Figure 4.1(C)). 
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Figure 4.1 (A) Pap smear after staining. Note the presence of intermediate (blue), superficial (pink) cells and 
lymphocytes (indicated by arrows), (B) Bloody smear pattern with red blood cells, obscuring diagnostic cells. 
Bar = 35 m. (C) Pap smear contaminated with blood showing ringed halo effect. 
 
Cytology laboratories often annotate Pap smears according to a blood scale index whereby 0 
indicates no visible evidence of blood present and 3 indicates an extremely bloody sample 
(Figure 4.2). Samples presenting as a 2 or 3 on the blood scale are often either rejected as being 
unsatisfactory or treated with a wash solution to lyse more of the red blood cells to increase the 
number of epithelial cells present on the slide. This blood scale grading is subjective and is 
only based on a visual appearance of a sample. The advantage of the Pap test is that it is a 
widely accepted screening based test. However, despite a high specificity of 96.5%, a lower 
sensitivity of 85% can be due to sampling, technical and inter-observer errors associated with 
the subjectivity of the test (Kitchener et al., 2011). Over the past 20 years, Raman spectroscopy 
has shown potential for the diagnosis of cervical cancer both in vivo and ex vivo (Utzinger et 
al., 2001, Mahadevan-jansen, 2010, Mo et al., 2009, Duraipandian et al., 2012, Kong et al., 
2015,Santos, et al 2017). Raman spectroscopy is based on inelastic light scattering in which a 
sample is illuminated by monochromatic laser light and interactions between the incident 
photons and molecules in the sample result in the scattering of the light. The coupling of the 
light generates vibrations within the sample which are characteristic of the chemical structure. 
 B  
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The energy of the scattered light is reduced by an amount equal to the vibrational energy which 
is called the Raman shift. This means that the position, peaks and shape of the Raman bands 
carry information about the molecular makeup of the sample. The Raman spectrum of cells and 
tissues is made up of contributions from many biochemical components including DNA, RNA, 
proteins, lipids and carbohydrates (Santos et al 2017) To date, most likely due to confounding 
factors such as blood contamination, there have been relatively few studies on Raman 
spectroscopy of cervical smear samples (Lyng et al., 2015, Diem et al., 2013, Vargis et al., 
2012, Rubina et al, 2013, Bonnier et al., 2014, Ramos, et al 2015, Kearney et al., 2017). Rubina 
et al described the influence of blood on the Raman spectra of cervical cell pellets and how this 
might lead to false interpretations. Classification efficiency of 86% and 84% was reported for 
normal and abnormal samples respectively and this decreased to 78% and 79% after samples 
were treated with red blood cell lysis buffer to reduce blood contamination. A previous study 
by our group (Bonnier et al., 2014) addressed many of the issues involved in recording Raman 
spectra from liquid based cytology (ThinPrep) samples and described a new method to remove 
blood contamination before Raman spectroscopy based on pre-treatment of the slides with 
hydrogen peroxide. This was shown to minimise variability and to result in the collection of 
highly reproducible data with excellent discrimination between negative and high grade samples. 
However, only blood scale 0 and blood scale 1 samples were used for this study as the treatment 
was not found to be effective for excessively contaminated blood scale 2 and 3 samples. (Kerr et 
al.,2016) investigated the effect of blood contamination on Raman spectra of urine cytology 
samples. They determined that spectra recorded from samples with a low level of blood 
appeared free from contamination due to the effective removal of many of the red blood cells 
using the lysing agent CytoLyt. However, for excessively bloody samples several additional 
Raman peaks associated with blood were observed leading to the conclusion that excessively 
bloody samples are not suitable for diagnostics with Raman micro-spectroscopy. The aim of 
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the present study was to extend our previous study (Bonnier et al., 2014) to samples annotated 
as blood scale 2-3 which would have previously been excluded, to investigate if these 
excessively bloody samples could be treated to render them suitable for Raman spectroscopy. 
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Figure 4.2ThinPrep vials graded according to the blood scale index. 0 indicates no visible evidence of blood and 
3 indicates an extremely bloody sample 
 
 
 
4.2 Materials and Methods 
 
4.2.1 Samples and blood treatment 
The Coombe Women and Infants University Hospital (CWIUH), Dublin Ireland, for 
spectroscopic analysis with the final clinical report prepared by the cytologist and / or 
pathologist, provided cervical liquid based cytology (LBC) samples. This study was approved 
by the Research Ethics Committee at the Coombe Women and Infants University Hospital. A 
set of 30 samples were selected, 15 high grade intraepithelial neoplasia (HG) samples which 
received a cervical intraepithelial neoplasia (CIN) 2 or CIN 3 result on their associated biopsy 
from pathology and 15 negative samples (TN) which received a negative result from cytology. 
All cytology samples were evaluated by eye according to the blood scale index and annotated 
as being either a grade 0, 1, 2 or 3. All samples were tested for HPV as outlined in section 
2.2.1-2.2.2. All negative samples (TN) tested negative for the presence of HPV DNA and 
mRNA.  All HG samples tested positive for both HPV DNA and mRNA. 
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HeLa cervical cancer cells were also prepared and fixed as for Thinprep samples in PreservCyt. 
These samples were seeded with blood to mimic excessively bloody cytology samples. This 
was achieved by adding blood to the samples until they visually represented a blood scale 2-3 
index sample. 
Each Thinprep sample vial was mixed for 3 minutes to break up cellular clumps. The sample 
was then poured into a 50 ml centrifuge tube and centrifuged for 5 minutes at 300 rpm. The 
supernatant was removed and 1 ml of H2O2 was added and mixed for 30 seconds. 20 ml of 
PreservCyt was added to neutralise the H2O2. The sample was then centrifuged for 5 minutes 
at 600 rpm. Most of the supernatant was removed. The cell pellet was re-suspended multiple 
times with a 1ml pipette to break up cell clumps. 20ml of PreservCyt was then added and the 
contents poured back into the original vial. 
4.2.2 Thinprep slide preparation 
 
The samples were then prepared as outlined in section 2.3 
4.2.3 Raman spectroscopy 
 
All Raman analysis was performed as outlined in sections 2.5 and 2.7 
4.2.4 Data pre-processing and analysis 
 
All Raman data was pre-processed and analyzed as outlined in sections 2.7.-2.9 
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4.3 Results/ Discussion 
 
Figure 4.3(A) shows an untreated Pap smear, blood scale 3. The slide was coated in blood and 
cellular debris. Figure 4.3(B) shows Raman spectra recorded from 5 cells present on the slide. 
Overall very few cells were present and often burned on contact with the laser. A high 
background was observed together with Raman bands associated with blood at 754, 1311, 
1374, 1398, 1588, 1640 cm-1. The high background can be attributed to the cellular debris or a 
sub unit of the oxidized hemoglobin on the surface of the cell nuclei which has a weak 
fluorescence signal. When a sample fluoresces the fluorescing photons can be detected by the 
photon detector in the Raman spectrometer overwhelming the weaker Raman signal and 
obscuring the Raman peaks. Figure 4.3(C) shows the same sample from Figure 4.3(A) after 
undergoing the blood removal method. Any blood residue has been oxidised with the H2O2 
treatment and cellular debris has been reduced allowing for high quality spectra to be recorded 
as demonstrated in Figure 4.3(D). 
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Figure 4.3 (A) Untreated Pap smear, blood scale 3 shows blood and cellular debris masking diagnostic cells. Bar 
= 35 m, (B) Raw Raman spectra recorded from five cells (each colored spectrum is from an individual cell) 
from a untreated Pap smear (C) Treated Pap smear. Arrows indicate Intermediate cells and Superficial cells . 
Bar = 35 m. (D) 25 Raman spectra recorded from individual cells (each colored spectrum is from an individual 
cell) on a treated Pap smear. 
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In order to determine if the Raman specific method of blood removal using H2O2 had any effect 
on the spectra recorded without any external confounding factors such as inflammation, HPV 
infection etc, the protocol was performed on HeLa cervical cancer cells. HeLa cells were 
seeded with blood to mimic cytology samples with blood scale index 2-3 and HeLa cells with 
no added blood acted as controls. Both sample types were treated with H2O2 and slides prepared 
as for the ThinPrep cytology samples. Figure 4.4(A) shows the mean Raman spectra recorded 
from 30 HeLa cells with and without blood contamination (blood scale 2-3) and treated with 
H2O2. The mean spectra display strong similarities with only minor changes at 1242 cm
-1 
(Amide III), 1350 cm-1 (DNA/RNA, CH def. in proteins and carbohydrates), 1430 cm-1 (protein, 
lipids), and 1669 cm-1 (Amide I). Figure 4.4(B) shows the mean Raman spectra of negative 
cytology samples (TN) with and without blood contamination (blood scale 2-3) and treated 
with H2O2. The mean spectra display strong similarities with small changes at 1242 cm
- 1, 1350 
cm-1, 1430 cm-1 and 1669 cm-1 as observed for the HeLa cells. These small changes in the 
spectra were consistent throughout all samples tested including the HG samples (Figure 
4.4(C)). 
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Figure 4.4 (A) Mean Raman spectra of HeLa cervical cancer cells treated with blood (blood scale 2-3) and 
subsequently treated with H2O2 (red) and HeLa cervical cancer cells not treated with blood but treated with 
H2O2 (blue), (B) Mean Raman spectra of true negative samples (TN), blood scale 2-3, treated with H2O2 (red) 
and blood scale 0, treated with H2O2, (C) Mean Raman spectra of high grade (HG) samples, blood scale 2-3 
treated with H2O2 (red) and blood scale 0, treated with H2O2. 
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PLSDA classification of negative cytology samples and high grade cytology samples, blood 
scale index 0, is shown in figure 5. Figure 4.5(A) is a latent variables (LV) scores scatter plot 
of LV1 and LV2 which shows good discrimination along LV1. The loadings shown in figure 
4.5(B), show that the discrimination is based around Raman peaks at 482, 851, 936, 1128, 1338, 
1449, 1572, 1655 and 1669 cm-1 which are mainly related to DNA, proteins and glycogen. 
Figure 4.5(C) is a PLSDA prediction plot showing good classification of negative and high 
grade samples with a sensitivity of 92% and a specificity of 93% (Table 4.1). 
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Figure 4.5 (A) LV score scatter plot of 136 spectra acquired from 15 TN samples and 136 spectra acquired from 
15 HG samples (blood scale index 0), (B) LV 1 loadings, (C) PLSDA prediction plot showing good discrimination 
between TN (blue) and HG (yellow) ThinPrep cytology samples. 
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PLSDA classification of TN and HG cytology samples, blood scale index 2-3, is shown in 
Figure 4.6. Both negative and high grade samples have undergone the Raman specific blood 
removal method. Figure 4.6(A) is a LV scores scatter plot of treated TN and HG samples which 
show overlap between the samples. The LV1 loadings shown in figure 4.6(B), shows that the 
discrimination is based around Raman peaks at 482, 549, 851, 936, 1145, 1182, 1237, 1338, 
1449,1576, and 1669 cm-1 and are similar to the loadings shown in figure 4.5(B). The PLSDA 
prediction plot is shown in figure 4.6(C) and has a sensitivity of 89% and a specificity of 88% 
(Table 4.1). 
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Figure 4.6 (A) LV score scatter plot of 185 spectra acquired from 15 TN cytology and 185 spectra acquired from 
15 HG cytology samples (blood scale index 2-3), (B) LV1 loadings. (C) PLSDA prediction plot showing some 
discrimination between TN (blue) and HG (yellow) Thinprep cytology samples, blood scale 2-3 and treated with 
H2O2. 
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In order to determine if excessively bloody samples could be treated the same way as non- 
bloody samples in terms of data analysis, the Raman spectral data from the two groups (blood 
scale 0 and blood scale 2-3) was combined. Figure 4.7(A) shows the LV scores scatter plot 
which highlights decreased discrimination between TN and HG cytology. However the 
loadings shown in Figure 4.7(B) remain similar to the loadings shown in figure 4.5(B) and 
4.6(B) with Raman peaks at 482, 851, 1129, 1184, 1251, 1338, 1449, and 1669 cm-1. The 
PLSDA prediction plot is shown in Figure 4.7(C) and has a sensitivity of 82% and a 
specificity of 87% (Table 4.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 (a) LV score scatter plot of 321 spectra from TN cytology and 321 spectra HG cytology samples 
(combined blood scale 0 and blood scale 2-3), (b) LV1 loadings. (c) PLSDA prediction plot showing some 
discrimination between TN (blue) and HG (red) Thinprep cytology samples, combined blood scale 0 and blood 
scale 2-3 and treated with H2O2 
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Table 4.1 Sensitivity and specificity from PLSDA classification of TN and HG cervical cytology samples with and without 
blood contamination and combined.  
 Sensitivity Specificity 
Negative Vs High Grade  (blood scale 0) 92% 93% 
Negative Vs High Grade (blood scale 2-3) 89% 88% 
Combined (blood scale 0 and 2-3) 82% 87% 
 
 
 
Interestingly, the loadings (482, 851, 936, 1149, 1338 and 1669 cm-1) remain almost the same 
between all three data sets, blood scale 0, blood scale 2-3 and combined, confirming that 
glycogen, DNA and proteins are the main discriminating features between negative cytology 
and high grade cytology samples regardless of blood contamination. As previously stated, HPV 
can integrate its viral DNA into the host cell’s DNA located in the cell nucleus resulting in the 
transcription of its viral oncogenes and control over the cell’s life cycle. This results in 
increased proliferation which would alter protein, glycogen and nucleic acid levels present 
within the cell. However, as mentioned earlier, some spectral features undergo minor changes 
following the blood removal method. As these features overlap with the discriminating 
features, this results in a reduction in classification efficiency when excessively bloody (blood 
scale index 2-3) samples and non-bloody samples (blood scale index 0) samples are combined 
for analysis. Comparing sensitivity and specificity of the test groups shows that blood scale 0 
samples with no blood contamination performed best with a sensitivity of 92% and specificity 
of 93% when compared to excessively bloody blood scale 2-3 samples which had a sensitivity 
of 89% and specificity of 88%. Combining the blood scale 0 and blood scale 2-3 samples for 
analysis resulted a sensitivity of 82% and specificity of 87%. The high specificity indicates a 
good ability to accurately exclude negative samples (few false positives), however the 
reduction in sensitivity indicates a reduced ability to accurately detect high grade samples and 
an increased likelihood of false negatives. 
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Despite the reduction in classification efficiency, the values are higher than previously reported 
for samples with blood contamination. Rubina et al. (2013) reported a classification efficiency 
of 78% and 79% for normal and abnormal bloody samples treated with red blood cell lysis 
buffer. As far as it is reported this study did not attempt to combine both treated and non-treated 
samples together to improve their sensitivity and specificity. In addition, Kerr et al. (2016) 
concluded that excessively bloody samples were not suitable for diagnostics with Raman 
spectroscopy. 
4.4 Conclusion 
This study demonstrates for the first time that excessively bloody (blood scale 2-3) Thinprep 
cervical smear samples can be used for diagnostics with Raman spectroscopy following a 
hydrogen peroxide treatment in the collection vial. However, the presence of excessive blood 
contamination (blood scale index 2-3) did result in reduced in sensitivity and specificity for 
classification of negative and high grade samples. A higher sensitivity and specificity could be 
achieved by keeping excessively bloody samples separate from non-bloody samples for 
analysis. Although this study has focused only on cervical cytology samples, thyroid, urine and 
serous fluid cytology samples may also benefit from such an approach for Raman spectroscopic 
analysis. Serous fluid for cytological examination are often contaminated with a high level 
blood (pericardium, pleura and peritoneum fluids) and often require additional treatment 
methods such a density gradient technique to remove red blood cells which can result in a loss 
of diagnostic cellular material. The application of our blood treatment method would prevent 
this loss of material and allow Raman spectroscopy to be performed. 
While these results are promising for the development of Raman spectroscopy for cervical 
cancer screening, Raman spectroscopy in its current form does not have the ability to replace 
cytology for cervical cancer screening However it could be used to supplement the Pap test or 
as a possible new triage test after HPV testing. 
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Chapter 5 
 
 
 
The potential of biobanked liquid based cytology 
samples for cervical cancer screening using Raman 
spectroscopy. 
 
 
 
 
 
 
 
Adapted from: Traynor, D. (2019)The potential of biobanked liquid based cytology 
samples for cervical cancer screening using Raman spectroscopy- J. 
Biophotonics.;12:e201800377. 
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5.1 Introduction 
 
Every year millions of cervical Pap tests are performed throughout the world in countries for 
purposes of cervical screening. Most Pap tests are performed through use of liquid based 
cytology (LBC) where cervical cells are collected before deposition into a volume of liquid 
preservative. As not all the material is required for cytological assessment, the surplus, which 
would ordinarily be discarded, can be stored within tissue biobanks with due process of 
governance. Biobanks constitute a valuable source of material which may support a number 
of studies including those on the natural history of disease, evaluation of screening practices, 
vaccination effectiveness or the development of new technologies to support screening and 
disease management (Fox et al., 2017, Marquez-Curtis et al., 2017, Peakman et al.,2010). 
Different collection media for liquid based cytology exist however one of the more common 
media is PreservCyt (Hologic). PreservCyt is a methanol based solution that preserves cell 
morphology via fixation. Fixation is routinely employed as it allows a “snapshot” of a cell’s 
physical and biochemical state to be assessed; methanol is an organic solvent that preserves 
cells through dehydration and precipitation of proteins (Troiano et al., 2009). Fixation is 
important given that sample collection and assessment is not performed concurrently. In 
addition to supporting routine screening, fixation of cells also supports long term storage of 
residual material in biobanks. 
Current methods for detection of cervical cancer and pre-cancer (CIN) are limited and there is 
an unmet clinical need for new screening or diagnostic tests. Recently Raman spectroscopy 
has shown potential as a tool for screening and diagnosis of cervical lesions and cancer (Lyng 
et al., 2015, Ramos et al., 2016 Rubina et al., 2015). 
Due to confounding factors such as sample collection, blood contamination and sample 
variability, few studies have been performed using Raman spectroscopy on cervical cytology 
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samples and none to our knowledge have investigated the potential of utilising biobanked 
LBC samples. The aim of this feasibility study was to assess the utility and performance of 
Raman spectroscopy for the detection of CIN using biobanked LBC samples. Samples stored 
at -80oC and -25oC were assessed and the ability of Raman spectra to delineate disease from 
no disease was determined. Additionally, Raman spectroscopy was assessed in un-banked 
LBC samples as a comparator. 
5.2 Methods 
5.2.1 Sample collection 
Two classes of samples were used for the study, classed as disease and no disease. Samples 
with no disease were defined as cytology negative and HPV negative whereas samples with 
disease were those associated with a cytological HSIL result and a histologically confirmed 
CIN3 result and HPV positivity according to HPV DNA and mRNA status. All samples were 
recruited from patients presenting at a colposcopy clinic for the first time, and had no prior 
history of disease. Samples were collected from each patient according to the standard 
operating procedure issued by Cervical Check, Ireland’s national cervical cancer screening 
programme, and the NHS Scottish cervical screening programme. Both procedures are 
similar and all samples were biobanked using the same methodology. 
133 samples were used in total for this study of which 64 were LBC biobanked samples; 32 
with no disease (cytology negative) and 32 with disease (HSIL). Biobanked samples were 
provided by the Scottish HPV Archive, a research tissue biobank set up to facilitate HPV 
associated research. 
Ethical approval for use of the samples was obtained from the East of Scotland Research 
Ethics Service - Tayside committee. Biobanked LBC samples used for this study had been 
sedimented with the cellular pellet transferred into a 4.5 ml vial for long term storage in 
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PreservCyt. After transit, samples were re-constituted to a volume of 20 ml fresh PreservCyt 
solution to resemble the original LBC specimen from which the sample was derived. 
A further 64 non biobanked “fresh” LBC samples, 32 with no disease (cytology negative) and 
32 with disease (HSIL), were collected in PreservCyt solution from the Coombe Women and 
Infants University Hospital (CWIUH), Dublin, Ireland, as part of routine cytological 
screening. Ethical approval for use of coded samples for the study was granted by the 
CWIUH Research Ethics Committee (no. 28-2014). A further 5 fresh LBC samples with 
disease (HSIL) were collected and split into two separate vials. One vial from each sample 
underwent the standard biobanking process and was stored for 3 weeks, while the other was 
stored at room temperature. 
5.2.2 ThinPrep 
The samples were prepared as outlined in section 2.3 and 2.4 
 
5.2.3 Raman spectroscopy 
All Raman analysis recorded as outlined in section 2.5-2.6 with 25 cells recorded from each 
sample. Cell selection was performed as outlined in section 2.5 Raman measurements. 
5.2.4 Data pre-processing and analysis 
Data was pre-processed and analysed as outlined in section 2.7-2.9 
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5.3 Results 
5.3.1 -25oC Vs -80oC biobanked LBC samples 
The samples stored at -25oC presented with intact cellular morphology (Figure 5.1(A)) and 
allowed for high quality spectra to be recorded (Figure 5.1(B)). The samples stored at -80oC 
presented with cell lysis, cellular debris and very little cellular material which prevented the 
recording of spectra (Figure 5.1(C)). One possible explanation for this, is the freeze thaw 
effect which is commonly used to lyse bacteria and mammalian cells. Storing cells at -80 oC 
in PreservCyt without any Dimethyl Sulfoxide and bring up to room temperature can cause 
the cells to contract during the thawing process resulting in cell lysis. As a result, only 
biobanked samples previously stored at -25oC were used for this study. 
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Figure 5.1 (A) Pap smears stored at -25oC present with intact cellular morphology. Note the presence of 
superficial and intermediate cells (arrows) on the unstained slide which were selected for Raman spectral 
recording. (B) High quality spectra recorded from 25 morphologically normal intermediate and superficial cells 
in the spectral range 400-1800cm-1. (C) Pap smears stored at -80oC. Note lack of cellular material and presence 
of cellular debris. 
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5.3.2 Negative Vs HSIL (fresh LBC samples) Model 
In order to determine if biobanked LBC samples could be used to discriminate no disease 
(cytology negative) from disease (HSIL) using Raman spectroscopy, fresh (non biobanked) 
LBC samples were first examined as a control. Figure 5.2(A) shows mean spectra of 
Negative (Red) Vs HSIL (Blue). Figure 5.2(B) is a latent variables (LV) scores scatter plot of 
LV1 (Blue) and LV2 (Orange) which shows good discrimination along LV1 and LV2. The 
loadings shown in Figure 5.2(C), show that the discrimination is based around Raman peaks 
at 484 (glycogen), 575 (glycogen), 881 (nucleic acids), 1004 (proteins Phenylalanine), 1139, 
1238 (proteins Amide III), 1487 (proteins), 1575 (nucleic acids), 1605 (proteins) and 1669 
cm-1 (proteins Amide I). The LV2 loadings show discrimination is based around 1238 
(proteins), 1381 (glycogen), 1450 (proteins and lipids), 1642 (proteins) and 1669cm-1 
(proteins) (see table 1.1) (Movasaghi et al.,2007). The PLSDA prediction plot shown in 
Figure 5.2(D) and has a sensitivity of 86% and a specificity of 90% for HSIL. Comparing 
these results to the results from chapter 3 section 3.3.5, which reported a sensitivity of 98% 
and a specificity of 97%, a slight reduction. This is mainly due to a change in cell selection. 
In chapter 3, spectra were recorded from morphologically abnormal cells while in chapter 5, 
spectra were recorded from morphologically normal cells. Abnormal cells would have a 
different biochemical signature due to a chronic HPV infection that cause morphological 
change in the cell. However, given the difficulty in locating unstained abnormal cells as 
previously discussed, this slight reduction in sensitivity and specificity is acceptable. 
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5.3.3 Negative Vs HSIL (Biobanked LBC samples) Model 
In order to determine if the biobanked samples can be used in a similar fashion to the fresh 
samples, negative and HSIL biobanked samples were compared. Figure 5.3(A) shows the 
mean spectra of biobanked Negative samples Vs HSIL. Figure 5.3(B) is a latent variables 
(LV) scores scatter plot of LV1 and LV2 which shows good discrimination along LV1 and 
LV2.The loadings from LV1 are shown in Figure 5.3(C) and show that discrimination is 
based around Raman peaks, 622 (proteins), 640 (proteins),775 (proteins), 850 (proteins), 
1122 (proteins),1152 (proteins), 1207 (proteins), 1450 (proteins), 1560 (proteins), 1605 
(proteins), 1642 (proteins) and 1669 cm-1 (proteins). LV2 loadings show discrimination is 
based on 1123 (proteins, lipids, carbohydrates), 1338 (proteins) and 1605 cm-1 (proteins) 
Raman peaks assigned to phenylalanine 1004 cm-1 show a slight shift between 1003-1004 cm- 
1 which is most likely attributed to the methanol based fixation method which suggests a 
change in the conformation of the phenylalanine protein (Meade et al.,(2010). The PLSDA 
prediction plot shown in Figure 5.3(D) and has a sensitivity of 91% and a specificity of 92% 
for HSIL. 
104  
08 
 B 
06 
04 
02 
 
02 
400 600 800   
 
 
-1 
  
0.2 2 
 
 
0.15 
 
1.5 
 
 
 
 0.5 
 
 
 
-0.5 
 
 
 
 
-1 
 
 
0. 
 
 
0. 
 
 
0. 
 
 
0. 
 
 
 
 
 
-0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
600 800 1000 1200 1400 1600 
100 200 300 400 500 600 700 800 900 1000 
Sample 
Wavenumber cm -1 
 
Figure 5.3 (A) mean spectra of biobanked Negative (red) Vs HSIL (blue). (B) latent variables (LV) scores scatter 
plot of LV1 and LV2, TN (yellow) Vs HSIL (blue). (C) LV1 (blue) LV2 (orange) .(D) PLS_DA prediction plot HSIL 
(blue), negative (yellow) . 
L
V
 1
 (
2
1
.8
1
%
),
 L
V
 2
 (
1
0
.7
5
%
) 
Y
 C
V
 P
re
d
ic
te
d
 1
 (
C
la
s
s
 1
) 
105  
5.3.4 Biobanked Vs non-Biobanked samples 
Five fresh HSIL patient samples were split into two separate vials. One vial from each 
sample was frozen as described earlier and the other stored at room temperature. Figure 
5.4(A) show the mean spectra for biobanked HSIL samples and the same samples kept at 
room temperature for 3 weeks after collection. The mean spectra appear identical. There does 
not appear to be a difference between the fresh and biobanked samples. While the mean 
spectra appear very similar,  PLSDA can maximize the separation between the two groups 
and present the discrimination in the form of loadings, as outlined in section 2.8. The latent 
variable scatter scores plot (Figure 5.4(B)) shows slight discrimination between the sample 
types which is most likely due to internal sample variability (Serafin-Higuera et al., 2016) 
(LBC samples are variable by nature) and the low number of spectra recorded (60 for room 
temperature/biobanked). The PLSDA prediction plot (Figure 5.4(C)) has a sensitivity of 29% 
and specificity of 88% for biobanked samples indicating poor discrimination between the two 
groups. The low sensitivity highlights that the model was not able to separate between 
positive samples (biobanked) and negative samples (non-biobanked) samples. A loadings plot 
was not included as this would only show the internal sample variability and not any 
biochemical changes associated with the biobanking process. A limiting factor on this study 
is the low sample number, this is due to the fact that this section was performed last and no 
additional non frozen HSIL samples were available to record. 
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5.3.5 Mixed Model 
In order to determine if we could mix fresh and biobanked samples together and still 
achieve a sensitivity and specificity similar to the fresh and biobanked models, 15 biobanked 
HSIL samples were mixed with 15 fresh HSIL samples and compared with 15 negative 
biobanked/ 15 fresh negative samples. The samples were recorded individually (ie. not 
mixed) and the spectra from fresh and biobanked samples were pooled into negative and 
HSIL categories for analysis.  Figure 5.5(A) shows the latent variable scatter scores plot of 
the model and we can see clear discrimination between the sample types across LV1 and 
LV2. The LV1 loadings (Figure 5.5(B)) show that discrimination is based on 482, 
(glycogen), 1443 (proteins, lipids) 1487 (proteins), 1605 (proteins) 1669cm-1 (proteins) while 
LV2 shows the discrimination is based around 486 (glycogen), 851 (proteins), 1152 
(proteins), 1381 (glycogen), 1450 (proteins/lipids), 1575 (nucleic acids) and 1669 cm-1 
(proteins). The loadings show similarities to both the fresh and biobanked loadings, but 
overall show that glycogen and proteins are the main discriminating factor between negative 
and HSIL samples. PLSDA prediction plot has a sensitivity of 94% and a specificity of 95% 
for CIN 3 (Figure 5.5(C)). 
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5.4 Discussion 
From the results it is clear that samples biobanked at -80oC are not suitable for screening 
using Raman spectroscopy due to a lack of cellular material and the presence of cellular 
debris. The samples biobanked at -20oC provided high quality smears with intact cellular 
material and no cellular debris which made them suitable for Raman spectroscopic analysis. 
Spectral differences between fresh negative and HSIL samples were observed with regards to 
glycogen, nucleic acids and proteins. HSIL cells often contain little to no glycogen, hence the 
use of dilute acetic acid to visualize abnormal cells in colposcopy (CervicalCheck., 2013). 
The discrimination associated with changes in proteins and DNA is consistent with the 
neoplastic changes that occur in HSIL supported by persistent HPV infection such as 
increased cell cycling with coincident increase in replication and levels of nucleic acids 
(Serafin-Higuera et al.,2016). The PLSDA prediction plot gives a sensitivity of 86% and a 
specificity of 90% for HSIL. 
Negative Vs HSIL biobanked sample results showed that discrimination was driven solely by 
proteins.  Raman peaks associated with nucleic acids/ DNA are not as strongly present as 
they are in the non-biobanked samples. Long term storage of biobanked samples is likely to 
have led at least to an element of nucleic acids degradation which would explain why nucleic 
acid is not discriminatory between negative and HSIL samples. Negative Vs HSIL (non- 
biobanked ) showed that discrimination was based on Proteins, glycogen and nucleic acids 
which included negative cells, the same category of negative cells from our biobanked 
samples. Therefore, the lack of nucleic acids as a discriminatory factor cannot be associated 
with the recording of negative cells. 
However the PLSDA prediction plot (Figure 3(D)) does show slightly higher sensitivity 
(91%) and specificity (92%) rates when compared to fresh samples (86% sensitivity and 90% 
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specificity) indicating that biobanking at -20oC does not preclude discrimination of negative 
and HSIL samples on Raman spectroscopy. 
The same patient samples that had been split in two with half biobanked and the other half 
stored at room temperature showed no discrimination between the samples. Hence the 3 week 
period of biobanking at -20oC had no detrimental effects on the physical or biochemical 
properties of the samples. The mixed model showed that biobanked and fresh LBC samples 
could be combined with an improved sensitivity of 94% and specificity of 95%. A limitation 
of this study is the inability to use biobanked LBC samples stored at -800C for Raman 
spectroscopic analysis as most biobanks will have samples stored at -800C for long term 
storage hence the true potential of using biobanks as a source of patient samples could be lost.  
Further research in this area should involve the use of different biobanked specimens 
(bronchial and thyroid fine needle aspirations) to investigate any detrimental effects the 
biobanking process may have on cytological specimens (Al-Abbadi et al.,2013,O’Dea et al., 
2018). 
5.5 Conclusion 
Raman spectroscopy can effectively discriminate disease free cervical LBC samples from 
those with disease (HSIL) and this is possible using biobank cervical LBC samples stored at - 
25oC. Pooling samples stored at -25 oC with fresh samples does not affect the sensitivity and 
specificity of Raman spectroscopy for the discrimination of disease. This study demonstrates 
that biobanks of cervical LBC samples are a useful resource for future Raman spectroscopy 
studies and will facilitate the further assessment of this technology which shows highly 
encouraging performance for the detection of cervical disease. 
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Chapter 6 
 
 
 
 
 
 
The potential application of Raman spectroscopy to be 
used as a triage test for cervical cancer in a primary 
HPV screening environment. 
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6.1 Introduction 
 
The current primary method for cervical screening employed by CervicalCheck (Ireland's 
national screening program) is the Papanicolaou test (Pap test) and reflex HPV testing 
(HIQA, 2017). The Pap test is a widely accepted screening based test with a high specificity 
of 95-98% and a sensitivity of 74-96% (Kitchener et al., 2011).The aetiological role of HPV 
infection among women with cervical cancer is clearly established (Petry et al., 2017,Youssef 
et al., 2016, De Vincenzo et al., 2014). HPV is a double stranded DNA virus that infects the 
skin, mucous membrane and the anogenital tract (Zheng and Baker, 2006). It is an extremely 
common sexually transmitted infection that occurs in most sexually active men and women. 
It is estimated that 80% of all sexually active women will become infected with HPV (Winer 
et al., 2003) There are over 100 known HPV types which are classified according to their 
potential to induce malignant transformations. HPV 16, 18, 31, 35, 39, 45, 50, 51, 53, 55, 56, 
58, 59, 64, and 68 are classified as high risk type HPV (hrHPV). HPV 16, 18, 31, and 45 
account for 80% of all cervical cancers (Schiffman et al., 2009). The HPV genome is made 
up of 8,000 base pairs. It has five early genes E1, E2, E5, E6, E7 and two late genes, L1 and 
L2 (Fouad and Aanei, 2017). The target cells for the initial HPV infection are the immature 
basal cells of the epithelium. The virus gains entry through micro-abrasions in the epithelium. 
The initial number of copies of the HPV genome in the nucleus of the immature basal cells is 
low with a low level of viral proteins being produced. At this stage there is no morphological 
change within the nucleus of these infected basal cells hence the infection is now referred to 
as a latent infection (Zheng and Baker, 2006). A latent infection would result in a positive 
HPV DNA result however there would be no cytological abnormality present and no lesion to 
see or treat at colposcopy. As infected basal cells differentiate and move up the epithelium 
viral transcription increases which eventually results in the release of the virus as the infected 
differentiated cells are shed from the epithelium. In most cases patients will develop 
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immunity against the HPV virus after a period of months or years destroying the virus in the 
process (Youssef et al., 2016). These patients will eventually become HPV DNA negative. A 
situation can arise where the virus presents at a non-permissive epithelial site in which viral 
genomes exist as particles on the surface of the epithelium and this prevents genome 
transcription thereby preventing the development of disease. This would still result in a HPV 
DNA positive test result due to the presence of HPV nucleic acids. In this situation and in the 
case of a latent infection both would represent a non-transcriptionally active HPV infection. 
If a patient fails to remove the infection it can become persistent. Persistent infection with high 
risk HPV is required for the development of HSIL. Failure to destroy the infection can result 
in a rapid increase in the production of E6/ E7 messenger RNA (mRNA) transcripts (Zheng 
and Baker, 2006). E6/E7 proteins will disrupt normal cell cycle regulation, control over 
apoptosis mechanisms and genetic instability (McGrath et al., 2017). Genetic instability will 
result in distorted chromosome distribution and structure and eventually result in a change in 
DNA content, therefore genetic instability is critical for the development of cervical cancer, 
hence it is not the HPV virus itself that causes disease but the presence of E6/E7 mRNA viral 
proteins. Hence this persistent form of infection can be termed a transcriptionally active HPV 
infection. This implies that a test designed to detect the over expression of E6 and E7 mRNA 
could be more accurate than a test that only detects the presence of viral DNA (Poljak et al., 
2016). Since the association between infection by high risk HPV types and high grade cervical 
cancer precursors and cervical cancer is so strong, HPV testing was introduced by 
CervicalCheck in 2012 (HIQA, 2017). The HPV virus/genome can be identified in exfoliated 
cells which allows for HPV testing to be performed on liquid based cytology (LBC) samples. 
Since April 2015 CervicalCheck employs reflex HPV DNA testing on all cytologically 
confirmed cases of LSIL, in order to identify patients that are hrHPV positive and more likely 
to develop disease (Figure 6.1). Patients who test positive will be referred to colposcopy for 
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further examination and treatment. Any patients who test negative will be returned to routine 
screening despite the initial low grade cytology result as they are at a very low risk of 
developing disease in the next five years (HIQA, 2017). In a European study it was confirmed 
that hrHPV based primary screening (Figure 6.2) provides better protection against cervical 
cancer than cytology (Ronco et al., 2014). It works by initially removing all hrHPV DNA 
negative patients and returning them to routine screening, thus only patients with an increased 
risk of disease will go onto cytological evaluation. This reduces the number of negative samples 
a cytologist would have to screen thereby reducing the associated workload of mass screening. 
If the cytologist then identifies an abnormality and classifies it as LSIL/HSIL that patient will 
then be referred to colposcopy. hrHPV testing used as a primary screening tool has limitations 
in that it can’t differentiate between transcriptionally active and non transcriptionally active 
forms of the virus.. This inability to distinguish between the different forms of HPV infection 
will result in a larger number of samples requiring additional tests and an increase in the number 
of patients referred to colposcopy. This underlines the need for more specific triage tests which 
could include Raman spectroscopy. The main objective of this study was to assess the ability 
of Raman spectroscopy to be used as a triage test in a primary HPV screening environment 
(Figure 6.3). 
115  
Referral to 
colposcopy 
 
High risk HPV DNA 
detected 
Return to routine screening 
HPV DNA not 
detected 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Process flowchart for HPV reflex testing. Patients will start with an initial Pap smear. If LSIL is 
detected the patient samples will automatically undergo a HPV DNA test to help rule out a false positive result. 
If the patient then tests positive for hrHPV DNA they will be refereed to colposcopy. 
 
 
 
Figure 6.2 Process flowchart for hrHPV primary testing. Patient samples will be initially tested for the presence 
for hrHPV. All negative samples will be returned to routine screening while positive samples will undergo 
cytological evaluation. If LSIL/HSIL is reported the patient will be referred to colposcopy. All negative samples 
will receive a repeat smear in 6 months and eventually be returned to routine screening. 
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Non-transcriptionally 
active HPV infection 
 
 
Figure 6.3 Process flow chart for Raman Spectroscopy as a triage to primary HPV screening. Patient samples 
will be initially tested for hrHPV. Patients that test negative will return to routine screening. Patients that 
test positive will undergo Raman spectroscopic analysis to identify patients with a transcriptionally active 
HPV infection and refer them to colposcopy, Patients identified with a non-transcriptionally active HPV 
infection will be returned to routine screening. 
 
 
6.2 Methods 
30 HPV DNA and mRNA positive LBC samples and 30 HPV DNA positive and mRNA 
negative LBC samples were collected in PreservCyt solution from the Coombe Women and 
Infants University Hospital (CWIUH), Dublin, Ireland, after routine cytological screening 
and HPV testing had been performed. Ethical approval for use of encoded samples for the 
study was granted by the CWIUH Research Ethics Committee (no. 28-2014). HPV 
DNA/mRNA positive samples represent the transcriptionally active form of infection and 
HPV DNA positive mRNA negative samples represented the non-transcriptionally active 
form. A further 14 encoded samples were recruited to validate the classification model which 
were made up of a mixture of non-transcriptionally active and transcriptionally active sample 
types. 
6.2.1 ThinPrep 
The samples were then prepared as per section 2.3 and 2.4 
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6.2.2 Raman spectroscopy 
All Raman analysis recorded as outlined in section 2.5-2.6 .In order to discriminate 
transcriptionally active samples from non-transcriptionally active samples, a classification 
model was developed from known samples. 30 transcriptionally active samples and 30 non 
transcriptionally active samples were recorded (see table 6.1) with 520 cell nuclei being 
recorded in total for each sample type with approx. 30 nuclei per sample. 
6.2.3 Data pre-processing and analysis 
All data was pre-processed as outlined in section 2.7-2.9 
 
6.2.4 Prediction 
Since PLSDA is a supervised technique meaning prior knowledge of a sample’s HPV status 
is known to build the model, it is important to also include a test set to further validate the 
model. The test set was made up of 14 coded samples (transcriptionally active/ non 
transcriptionally active). Two methods were employed to validate the model. The first tested 
all sample spectra individually to identify how well the model predicts the coded samples, the 
second method involved getting the mean of each sample and identifying how well the model 
predicts the mean of each sample. Samples with transcriptionally active HPV infection acted 
as the positive class as the aim of screening is to identify patients most at risk and who will 
require further treatment. Samples with non-transcriptionally active HPV infection acted as a 
negative class as they are deemed to be at a lower risk of developing cervical cancer in the 
next 5 years and can return to routine screening. 
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6.3 Results and Discussion 
 
6.3.1 Transcriptionally Active Vs Non-Trancriptionally Active 
Figure 6.4 (A) shows the mean spectra for non-transcriptionally active samples and 
transcriptionally active samples. While both samples appear very similar there are differences 
at Raman peak positions 782 cm-1 (nucleic acids) and 1238cm-1 and 1670cm-1 (Proteins 
Amide I, Amide III) (table 1.1). Figure 6.4(B) shows latent variables (LV) scores scatter plot 
of LV1 and LV2 which shows good discrimination along LV1.The loadings from LV1 are 
shown in figure 6.4 (C) and show that discrimination is based around Raman peaks, 483 
(glycogen), 727 (Proteins-CH2 def), 782 (nucleic acids- U,C,T, ring br), 851 (proteins-ring br. 
Tyr, C-C str), 937 (glycogen), 1002-1004 (Proteins- phenylalanine), 1121 (proteins C-N str, 
lipids-Chain C-C str, Carbohydrates- C-O str, 1204 (proteins-C-C6H5 str, Phe, Trp), 1335 
(glycogen), 1443 (proteins- CH2 def) 1450 (proteins -CH2 def, lipids CH2 def), 1642 (C=O  
str, C=C sym. Str) and 1670 cm-1 (C=O str. Amide I). The PLSDA prediction plot shown in 
Figure 6.4 (D) has a sensitivity of 88% and a specificity of 88%. The results show that it is 
possible for Raman spectroscopy to distinguish non-transcriptionally active forms of the HPV 
infection from the transcriptionally active forms. The LV1 loadings show that discrimination 
is mostly based around glycogen and proteins. Glycogen is often found to be lower in 
malignant tissue when compared to normal tissue. The high rate of proliferation in malignant 
tissue caused by the HPV infection prevents the accumulation of glycogen within the cell 
(Lyng et al., 2015). In the regions assigned to proteins there is a marked difference. Raman 
peaks assigned to phenylalanine 1004 cm-1 show a slight shift between 1003-1004 cm-1, 
which is most likely attributed to the methanol based fixation method which suggests a 
change in the conformation of the phenylalanine protein (Meade et al 2010). This shift 
appears to occur at random and is not sample specific. Overall protein seems to be the main 
discriminating factor between the non- transcriptionally active and transcriptionally active 
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samples. This is most likely down to the altered protein expression due to the persistent HPV 
infection taking control of the host cell machinery resulting in the over expression of E6/ E7 
viral proteins 
Table 6.1 Non-transcriptionally active Vs Transcriptionally active patient summary 
 
 
Sample Number HPV DNA HPV mRNA 
1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16, 
 
17,18,19,20,21,22,23,24,25,26,27,28,29,30 
Positive Negative 
31,32,33,34,35,36,37,38,39,40,41,42,43,44 
 
45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60 
Positive Positive 
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Figure 6.4 (A) Mean spectra of samples with non transcriptionally active HPV infection (green) Vs samples with 
transcriptionally active HPV infection (blue). B) Latent variables (LV) scores scatter plot of LV1 and LV2 of 
samples with non-transcriptionally active HPV infection (green) and transcriptionally active HPV infection 
(blue). C) LV1 loadings. (D) The PLSDA prediction plot. 
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6.3.2 Prediction 
 
6.3.2.1 Method 1 
Table 6.2 Result of Prediction Method 1 showing how Raman spectroscopy predicted each cell between non- 
transcriptionally active and transcriptionally active categories along with the correct classification. 
 
Sample Number Model prediction ( 
Non-Transcriptionally 
active cells) 
Model prediction 
(Transcriptionally 
active ) 
Correct Classification 
001 0 16 Transcriptionally active 
002 15 16 Transcriptionally active 
003 1 12 Transcriptionally active 
004 4 33 Transcriptionally active 
005 7 25 Transcriptionally active 
006 0 19 Transcriptionally active 
007 2 17 Transcriptionally active 
008 3 16 Transcriptionally active 
009 4 44 Transcriptionally active 
010 10 6 Transcriptionally active 
011 29 0 Non-transcriptionally 
active 
012 26 3 Non-Transcriptionally 
active 
013 21 3 Non-transcriptionally 
active 
014 22 2 Non-Transcriptionally 
active 
 
Sensitivity 85% 
Specificity 92% 
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6.3.2.2 Method 2 
Table 6.3 Result of Prediction Method 2 showing how Raman spectroscopy predicted the mean values of each 
sample between non-transcriptionally active and transcriptionally active categories along with the correct 
classification. 
 
Sample Number Model prediction (Non- 
transcriptionally active 
Mean Cells) 
Model prediction 
(transcriptionally active 
Mean Cells) 
Correct Classification 
001 0 1 Transcriptionally active 
002 0 1 Transcriptionally active 
003 0 1 Transcriptionally active 
004 0 1 Transcriptionally active 
005 0 1 Transcriptionally active 
006 0 1 Transcriptionally active 
007 0 1 Transcriptionally active 
008 0 1 Transcriptionally active 
009 0 1 Transcriptionally active 
010 1 0 Transcriptionally active 
011 1 0 Non-transcriptionally 
active 
012 1 0 Non-transcriptionally 
active 
013 1 0 Non-transcriptionally 
active 
014 1 0 Non-transcriptionally 
active 
 
 
Sensitivity 90% 
Specificity 100% 
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6.3.2.3 Comparison of Raman classification, Cytology result, Histology result and HPV 
status . 
Table 6.4 Raman classification, Cytology result, Histology result and HPV status for the independent test set 
 
Sample 
Number 
Raman 
Classification 
Cytology Histology Cobas HPV 
DNA Test 
Aptima HPV 
mRNA Test 
001 Transcriptionally 
active 
HSIL CIN 2 Positive Positive 
002 Transcriptionally 
active 
HSIL CIN3 Positive Positive 
003 Transcriptionally 
active 
HSIL CIN 3 Positive Positive 
004 Transcriptionally 
active 
HSIL CIN 2 Positive Positive 
005 Transcriptionally 
active 
HSIL CIN1 Positive Positive 
006 Transcriptionally 
active 
HSIL CIN2 Positive Positive 
007 Transcriptionally 
active 
HSIL CIN2 Positive Positive 
008 Transcriptionally 
active 
HSIL CIN3 Positive Positive 
009 Transcriptionally 
active 
HSIL CIN2 Positive Positive 
010 Non     
Transcriptionally 
active 
LSIL CIN1 Positive Positive 
011 Non-  
transcriptionally 
active 
LSIL Negative Positive Negative 
012 Non-  
transcriptionally 
active 
Negative Negative Positive Negative 
013 Non-  
transcriptionally 
active 
LSIL Negative Positive Negative 
014 Non-  
transcriptionally 
active 
Negative Negative Positive Negative 
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From the prediction results it is clear that both method 1 and 2 provided successful validation 
of the classification model. Method 1 shows that 9 out of 10 samples with transcriptionally 
active HPV infection were successfully predicted and 4 out of 4 samples with a non- 
transcriptionally active HPV infection were predicted correctly. Sample 010 was the only 
sample to be wrongly predicted. 10 out of 16 cells were predicted to be non-transcriptionally 
active when they were from a transcriptionally active sample. Sample 002 also highlights the 
need to record multiple spectra from the same sample. Even though the sample was classified 
correctly via method 1 there was only 1 cell in the difference between non-transcriptionally 
active and transcriptionally active. This demonstrates that not all the cells within a given 
sample may classify correctly. This could be down to a number of factors such as sampling 
technique, and the size of the infected area and the presence of HPV mRNA in every cell 
tested. One possible way to address this issue is to predict the independent test set samples 
using the mean spectra from each sample thereby reducing the variability within the data. If 
the mean spectra show the biochemical changes associated with the transcriptionally active 
infection then correct classification should be achieved . Overall this method gave the model 
a sensitivity and specificity of 85% and 92% respectively. It is not possible to know from this 
study if the level of abnormality (LSIL/HSIL) affects the number of cells predicting into each 
category as all transcriptionally active samples tested were reported as HSIL. Future work 
would involve testing LSIL samples that are reported as transcriptionally active to see if this 
would affect the number of cells correctly predicted between the two groups. 
Method 2 showed an improved result with a sensitivity of 90% and a specificity of 100% 
The mean spectra were used for each sample rather than individual cell spectra. This reduced 
the variability within the dataset resulting in the increase in sensitivity and specificity. 
However sample 010 was again misclassified. A limitation of this study is the relatively low 
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number of latent samples used for prediction. As the main source of sample recruitment was a 
colposcopy clinic, most patient referrals were based on HSIL hence most patients had a 
transcriptionally active HPV infection so it was difficult to recruit patients who had a non- 
transcriptionally active infection. 
Table 6.4 shows the Raman classification, cytology result, histology result and HPV DNA/ 
mRNA  status for the independent test set samples. Samples 001-009 show a strong 
correlation between Cytology, Histology and HPV testing which are backed up by the Raman 
classification result of transcriptionally active. Sample 010’s cytology and histology result 
report a LSIL or CIN1 lesion. The positive Aptima mRNA test result indicates that this 
patient has a transcriptionally active infection meaning that this patient would be at a higher 
risk of developing disease in the next 3-5 years. Given the Raman classification of a negative 
result (non transcriptionally active) and all other tests indicate a transcriptionally active 
infection, it suggests that this Raman result is a false negative. Samples 011-014 were all 
classified as a non-transcriptionally active by Raman spectroscopy which is backed up by the 
histology and HPV mRNA tests. The cytology LSIL result could be down to false positives 
caused by an inflammatory condition or the regression of a non-transcriptionally active HPV 
infection. Either way these patients are at a lower risk of developing cancer in the next 3-5 
years and should be returned to routine screening. Apart from sample 010, Raman 
spectroscopy was successful in identifying transcriptionally active and non -transcriptionally 
active HPV infections which is backed up by the standard screening approach of cytological, 
histological and HPV DNA/mRNA testing. 
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6.4 Conclusion 
The advantage of employing Raman spectroscopy as a triage test in a primary hrHPV 
screening environment is that it would prevent the unnecessary referral of patients with a 
non-transcriptionally active HPV infection for cytological evaluation while ensuring that 
patients with an increased risk of disease are referred to colposcopy. All analysis could be 
performed on the same initial Pap test thereby reducing costs and preventing unnecessary 
additional sample collection and delays. Raman spectroscopy can provide a cheap rapid non- 
destructive method to identify patients most at risk without subjectivity. Future work on this 
subject should involve using a primary screening cohort of samples which would provide a 
larger sample base of non-transcriptionally active samples for testing compared to 
colposcopy based recruitment. 
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7.1 Conclusions 
 
Cervical cancer remains one of the most common cancers affecting women worldwide. Most 
developed countries operate a cervical screening programme, which are based on the 
cytological evaluation of cervical cells. While this method generally operates with a high 
specificity (96.5%), it suffers from a variability in its sensitivity rates (30-85%) (Nanda et al., 
2000). The variability in sensitivity is mainly due to the subjectivity of the associated test. 
New technology is, therefore, needed. HPV testing has been incorporated into most cervical 
cancer screening programmes as either a form of management and triage or as a test of cure. 
Currently, there are plans to introduce HPV screening as a primary method of screening in 
Ireland for cervical cancer. This clearly indicates that cervical cancer screening programmes 
are attempting to move away from tests based on visual interpretation, which are prone to 
subjectivity and human error and more towards molecular tests which are more objective. 
The overall goal of cervical screening research is to create new triage tests that identify 
women who are HPV positive but who are also at a higher risk of developing cervical cancer. 
The triage tests should also be able to identify women who are HPV positive but also at a 
lower risk of developing cervical cancer in the next five years and return them to routine 
screening. Costs should be reduced and the rates of sensitivity and specificity for disease 
should increase. 
The research question of this thesis was to assess the potential of Raman spectroscopy as a 
new test for cervical cancer screening by investigating the potential hurdles associated with 
the disease and technology. Chapter 1 acts as an introduction to the thesis and outlines the 
natural history of the disease, the clinical aspects of screening and introduces the Raman 
spectroscopy technology. Chapter 2 outlines the materials and methods which were employed 
for this thesis. 
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Chapter 3 investigated potential hormonal effects in cervical smear samples using Raman 
spectroscopy. The findings from this chapter suggest that the menstrual cycle will have an 
effect on the Raman spectra recorded with regards to the levels of glycogen and proteins. 
Postmenopausal samples proved to be problematic for Raman spectroscopy due to a lack of 
cellular material and the presence of cellular debris. The use of hormone-based 
contraceptives resulted in the most variability within the spectra. However all these hormone 
based changes did not hinder the ability of Raman spectroscopy to discriminate cytology 
negative cells from HSIL cells. Overall, this study highlighted the scope of Raman 
spectroscopy for cervical cancer screening despite the presence of biochemical changes 
associated with the menstrual cycle and the use of hormone-based contraceptives. Previous 
work published by Kanter et al (2009) showed that hormonal differences due to the 
menstrual cycle can influence the Raman spectra acquired from the cervix in vivo.  Our 
study  reports  similar  findings,  however  our  study  also  addressed  the  use  of  hormone 
based contraceptives, and if these hormone induced changes will hinder the ability of  
Raman spectroscopy to identify dyskaryotic cells, which is the primary goal when 
developing  a  screening test  for  cervical cancer. 
Chapter 4 outlines a study which aimed to improve on our previous published work (Bonnier 
et al. 2014) on a method for removal of blood contamination from Thinprep cervical cytology 
samples for Raman spectroscopic analysis. Liquid based cytology Thinprep specimens were 
treated by adding hydrogen peroxide directly to the vial followed by a process of centrifugation 
and pipetting. Good quality Raman spectra were recorded from negative and high-grade 
cytology samples which initially presented with heavy blood contamination. This study 
demonstrated for the first time the improved potential of Raman spectroscopy for analysis of 
ThinPrep specimens regardless of blood contamination. This technique is a continuation of 
our previous work (Bonnier et al 2014), however it is novel in that it is not  restricted to blood 
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scale 0-1 samples and can be applied to all samples on the blood scale index (blood scale 0- 
4). 
Chapter 5 assessed the potential of using biobanked liquid based cytology samples for 
cervical cancer screening using Raman spectroscopy. The aim of this study was to assess the 
ability of Raman spectroscopy to screen for histologically confirmed cases of CIN using 
biobanked (LBC) samples.  Two temperatures for long-term storage were assessed, -80oC and 
-25oC. The utility of Raman spectroscopy for the detection of CIN was compared for fresh 
 
LBC samples and biobanked LBC samples. Two groups of samples were used for the study 
with one group associated with disease (CIN3) and the other associated with no disease 
(cytology negative). The data indicated that samples stored at -80oC are not suitable for 
assessment by Raman spectroscopy due to a lack of cellular material and the presence of 
cellular debris. However, the technology can be applied to fresh LBC samples and those 
stored at -25oC and is effective in the discrimination of negative samples from those where 
CIN 3 has been confirmed. This study demonstrates for the first time that cervical cytology 
samples stored within biobanks at temperatures that preclude cell lysis can act as a useful 
resource for Raman spectroscopy and will facilitate research and translational studies in this 
area. To our knowledge, this is the first study of its kind to investigate the application of 
biobanked LBC samples for Raman spectroscopy analysis. 
Chapter 6 investigated the potential application of Raman spectroscopy as a triage test for 
cervical cancer screening in a primary HPV screening environment. This study outlined the 
two possible outcomes of a HPV infection and divided samples into two separate categories, 
non-transcriptionally active and transcriptionally active. The latent stage of infection 
represents an initial low level of viral proteins being produced, which would still result in a 
positive HPV DNA based test even though there would be no cytological abnormality present 
and no lesion to see or treat at colposcopy, hence this would result in an unnecessary patient 
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referral. In most cases, a patient would develop immunity against the HPV virus and clear the 
virus in the process. If the patient fails to remove the infection, it can result in the rapid 
expression of E6 and E7 mRNA transcripts resulting in a transcriptionally active infection. At 
this stage, a patient would test positive for both HPV DNA and mRNA and should be 
referred to colposcopy for treatment. The aim for this chapter was to determine if Raman 
spectroscopy could identify individuals with a transcriptionally active HPV infection in a 
primary HPV screening environment to prevent unnecessary referral of those with a non 
transcriptionally active HPV infection. In a blind validation study, the results showed that 
Raman spectroscopy could successfully identify transcriptionally active samples with a 
sensitivity of 90% and a specificity of 100%.  A number of previous works (Vargis et al., 
2012 Ostrowska et al., 2010 ,Jess et al., 2007) investigated the ability of Raman spectroscopy 
to identify HPV infection. However, most of these studies utilised HPV infected cell lines 
rather than ‘real world’ cytology samples. With the current trend of HPV molecular testing 
taking over as a primary method of cervical cancer screening it is not sufficient to just detect 
the presence of HPV, additional information is required on whether the infection is non- 
transcriptionally active or transcriptionally active. If Raman spectroscopy is to be considered 
as a possible triage test for cervical screening. Our study advances the Raman spectroscopy 
technique for cervical cancer screening but also highlights the potential of Raman 
spectroscopy to advance screening technology beyond conventional methods in a cost 
effective, label free and non-destructive manner. 
Previous studies involving Raman spectroscopy for cervical cancer diagnosis ( Rashid et 
al.,2014, Krishna at al., 2006, Kamemoto et al., 2010 and Tan et al 2010) all utilised fixed 
tissue sections for their studies however tissue sections are not suitable for a screening based 
test given the invasive nature of obtaining an excision biopsy. 
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A study conducted by Rubina et al. (2013) utilised patient cytology samples in a cell pellet 
form but was not able to report a sensitivity higher than 79% for disease detection due to 
confounding factors such as blood which have been addressed in this thesis. Numerous 
studies (Mahadevan-Jansen.,et al 1998, Utzinger.,et al 2001 and Robichaux-Viehoever et 
al.,2007) employed a Raman probe for sample recording with the latter reporting a sensitivity 
and specificity of 89% and 81% respectively between negative and HSIL. While this 
represents a higher sensitivity/specificity rate compared to other studies involving Raman 
spectroscopy, it fails to account for long acquisition times of 60-180 seconds or more and the 
ability for a clinician to locate and hold the Raman probe against an area of interest on the 
cervix. While this probe based method shows potential, the studies reported in this thesis 
obtained sensitivity rates between 86-90% and specificity rates of 95-100% for disease across 
multiple studies with a larger sample base. 
An advantage of this study over others is that it utilises an already established processing 
method (Thinprep) for Raman spectroscopic analysis. The technology/ processing method is 
already established in all cytology labs, and therefore requires no alterations or additional 
costs with regards to sample processing. This means that the Raman spectroscopy method 
can fit easily into the current routine workflow. An added benefit of using the Thinprep 
method is that after completion of the Raman spectral screening of a given sample, the same 
slide could be stained and screened by a cytologist, which could act as a failsafe or as an 
additional triage test. Interestingly, in all the studies described in this thesis, Raman spectra 
were recorded from morphologically normal intermediate and superficial cells on Thinprep 
Pap smears. It was not necessary to find the morphologically abnormal cells on each slide as 
is required for cytological screening. 
Therefore, this study is unique in that it does not require abnormal cells for screening, it can 
utilise an already validated sample processing method (Thinprep), it is non-destructive which 
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allows additional tests to be performed on the same Thinprep slide used for Raman 
spectroscopy and would be a cheaper alternative to HPV testing (Cobas/Aptima). 
Overall, this study has confirmed our hypothesis that Raman spectroscopy can be utilised for 
cervical cancer screening. We have investigated hormonal effects, removal of contaminating 
blood from cervical Pap smear samples, utility of frozen biobanked samples for cervical 
cancer screening using Raman spectroscopy and the utility of Raman spectroscopy as a triage 
test for cervical cancer screening. 
7.2 Future Work 
 
There is currently a lot of interest in using Raman spectroscopy as a diagnostic aid as the 
technique makes it possible to extract information about a given sample non-invasively, non- 
destructively and in a label free manner. Spectra can be accumulated, corrected for un-wanted 
signal (glass), processed and analysed rapidly. Raman spectroscopy can currently satisfy 
many of the criteria required for transforming a vibrational spectroscopic technique into a 
diagnostic clinical based test. However, there are limitations with the current Raman 
spectroscopy technology. The Raman spectrometer is comprised of three separate 
components, which include a light source, light delivery system with collection and a 
dispersive element and a detector all of which will have to become robust, compact and be 
able to operate efficiently within a lab or clinical based setting. This project was completed 
manually, which involved lining up the laser with the centre of the selected cell nucleus and 
recording a Raman spectrum. For a clinical based setting or future studies, this process should 
become automated. In order for the Raman method to become automated, a standard 
operating procedure would have to be established which would be based on a series of 
algorithms that allow for the highest quality spectra with high signal to noise ratio to be 
recorded. These algorithms would have to account for variations in sample quality and cell 
type. An automated cell recognition routine would also have to be developed which could 
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work in tandem with the Raman spectroscopy routine to identify specific cell nuclei and align 
the target nuclei with the Raman laser source. The test samples would have to consist of a 
monolayer of cells free of debris and blood contamination. 
In the studies presented in this thesis, sample recruitment was based at a colposcopy clinic 
and limited to patients with no previous history of disease; future studies should involve a 
larger more comprehensive sample base, which includes patients with a previous history of 
disease. Also future samples should be recruited from a screening population. Given the 
introduction of the HPV vaccine with the first round participants about to enter the screening 
programme, future studies should also incorporate this demographic. 
This body of work was performed as a continuation of on-going research on the application 
of Raman spectroscopy into cervical cancer screening which was conducted under the 
direction of the CERVIVA consortium (www.cerviva.ie) and the Technological University 
Dublin. All findings from this thesis are being used to implement a clinical utility study of 
the Raman technology using 1,000 patient samples, funded by the Health Research Board. 
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1 | INTRODUCTION  
 
There were an estimated 527 600 new cervical cancer cases 
and 265 700 deaths from cervical cancer worldwide in 2012 
[1]. Until recently, the primary method for cervical screen- 
ing was based on the Papanicolaou test (Pap test). The Pap 
test requires cells to be scraped from the cervix, fixed to a 
glass slide, stained and reviewed by a trained cytologist. 
Cellular abnormalities are identified by the cytologist based 
on cellular morphology and staining characteristics and clas- 
sified according to the degree of dysplasia (low grade or  high 
grade). The advantage of the Pap test is that it is a non-
invasive and widely accepted screening based test with 
a high specificity of 95% to 98% and a sensitivity of 74% to 
96% [2]. The variability in the rates of sensitivity can be  due 
to sampling technique; the subjectivity of the cytology- based 
screening and can result in a high rate of gynaecolo- gical 
referral and patient recall, which adds to cost and patient 
stress. Persistent infection with high-risk human pap- 
illomavirus (HPV), such as HPV types 16 and 18, is accepted 
as the major cause of cervical pre-cancer and can- cer [3, 4]. 
HPV DNA testing has a higher sensitivity  (>95%) but lower 
specificity (~84%) than the Pap test [5] and these tests are 
expensive, time-consuming and provide no information on 
cervical cytopathology. Current gold standard methods for 
detection of cervical cancer and pre- 
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Raman spectroscopy is a powerful tool that 
has the potential to be used as a screening 
method for cervical cancer. It is a label-free, 
low-cost method providing a biochemical 
fingerprint of a given sample. The objective 
of this study was to address patient-to- 
patient variability contributed by hormonal 
effects due to the menstrual cycle, the  use of 
hormone-based contraceptives (HC) and the 
onset of menopause, and to determine if 
these changes would affect the ability to successfully identify dyskaryotic cells. 
Raman spectra were recorded from unstained ThinPrep cervical samples (45 cytol- 
ogy negative and 15 high-grade dyskaryosis (high-grade squamous intraepithelial 
lesion, HSIL) samples using a HORIBA Jobin Yvon XploRA system. HPV DNA 
testing was also performed. Clinical data collected included date of the last men- 
strual period, the use of HC and/or menopausal status. Spectral changes were 
observed depending on  the  day  of  the  menstrual  cycle  and  on  the  use  of  HC. 
Despite this, HSIL could be discriminated from normal cells regardless of the day 
on which the sample was taken or the use of  HC. 
 
KEYWORDS  
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cancer are, therefore, limited and there is an unmet clinical 
need for new objective screening or diagnostic tests. Optical 
spectroscopic techniques, such as Raman or infrared spec- 
troscopy, are label-free, non-invasive and have several 
advantages over traditional approaches, including objectiv- 
ity, speed and cost. These methods can provide quantitative 
information based on the spectroscopic signature of the bio- 
chemical components of the sample allowing diagnosis to  be 
based on biochemical changes rather than on morpholog- ical 
changes. The focus of the present study is on Raman 
spectroscopy, which is based on inelastic light scattering. The 
coupling of the light generates vibrations within the material 
and these vibrations are characteristic of the chemi- cal 
structure, the energy of the scattered light is reduced by an 
amount equal to the vibrational energy and from this a rapid, 
label-free, non-destructive measurement of the com- plete 
biochemical fingerprint of a biological sample can be 
obtained. Over the past 15 years, the potential of Raman 
spectroscopy together with multivariate statistical analysis 
has been demonstrated for the detection of a variety of can- 
cers, including cervical cancer [6, 7]. In initial infrared spec- 
troscopy studies on cervical cytopathology samples [8–10], 
spectra were recorded from cell pellets rather than from sin- 
gle cells and the presence of metaplastic cells, endocervical 
columnar cells, polymorphs, blood, cervical mucus and 
debris were all identified as confounding factors [11–16]. 
Recent studies by Ramos et al. [17] and Bonnier et al. [18] 
addressed the variability in Raman spectra from cervical 
smear samples and reported a new method to clear blood res- 
idue contamination before Raman spectroscopy based on pre- 
treatment of the slides with hydrogen peroxide. This method 
significantly minimised variability and resulted in the collec- 
tion of highly reproducible data and was used in this study to 
reduce variability based on the presence of blood residue. 
Physiological factors such as hormonal changes during the 
menstrual cycle or during menopause may also be potential 
sources of variability in the normal cervix. 
The cellular make up of an individual woman’s smear is 
dependent on which day during the menstrual cycle the 
sample was taken [19]. Days 1 to 4 are classed as the men- 
struation phase of the cycle when bleeding will occur and 
smear samples are generally not taken during this phase. 
Days 5 to 13 are classified as the proliferative phase. During 
this phase, oestrogen levels reach their peak resulting in 
complete maturation of the squamous epithelium and the 
cervical smear will present with a higher ratio of superficial 
cells to intermediate cells. Days 14 to 28 are classified as  the 
secretory phase where progesterone production reaches its 
peak and prevents complete maturation of the epithelium. 
The cervical smear will present with a higher ratio of inter- 
mediate cells to superficial cells. During menopause, levels 
of both oestrogen and progesterone will drop dramatically 
and there is a gradual arrest of the maturation of the squa- 
mous epithelium. This results in the loss of superficial and 
intermediate cells leading to the final atrophic stage where the 
squamous epithelium is composed entirely of parabasal cells. 
The use of hormone-based contraceptives (HC) will 
affect the natural hormone mediated maturation process of 
the cervical epithelium. A study by Romeo et al. [20] used 
infrared spectroscopy to investigate hormonal influences on 
cervical cells throughout the menstrual cycle and showed 
spectral  changes  such  as  increases  in  the   1200   to   1000 
cm
−1 
region due to glycogen increases around ovula- tion 
(mid cycle). Cervical cells from women on HC did not show  
the  same  degree  of  spectral  changes  as  cells from 
women not on HC. Despite the variability throughout the 
menstrual cycle, principal component analysis (PCA) showed 
good discrimination between high-grade dysplasia and 
normal samples collected at different phases of the menstrual 
cycle. 
A more recent study by Kanter et al. [21] has shown   that 
hormonal differences due to the menstrual cycle can 
influence  the  Raman  spectra  acquired  from  the  cervix   in 
vivo. Spectra were divided into 4 groups, namely, pre- 
menopausal proliferative phase (days 1-14), pre-menopausal 
secretory phase (day 15-28+), peri-menopausal and post- 
menopausal.  Spectral  differences were  mainly observed at 
1250, 1300 and 1320 cm
−1
, most likely due to changes in 
the proteins collagen and elastin [22]. Incorporating hor- 
monal status into their dysplasia classification algorithm 
increased the classification accuracy from 88% to 94%. 
The main objective of our study was to investigate 
hormone-associated changes in the Raman spectra of cyto- 
logically negative ThinPrep cervical smear samples related 
to: (1) the menstrual cycle, (2) the onset of menopause and 
(3) the use of HC. A further objective was to determine if any 
changes observed would interfere with the ability to 
discriminate normal and high-grade dyskaryotic (high-grade 
squamous intraepithelial lesion, HSIL) cervical smear sam- 
ples caused by HPV infection. 
 
 
2 |  MATERIALS AND METHODS 
 
2.1 | Sample collection and ThinPrep slide 
preparation 
Cervical smear samples collected in PreservCyt solution were 
obtained from the Cytology Department at  the Coombe 
Women and Infants University Hospital (CWIUH), Dublin, 
Ireland, after routine cytological screening had been 
performed. Ethical approval for use of anonymised samples 
for the study was granted by the CWIUH Research Ethics 
Committee (no. 28-2014). Clinical data which were  recorded 
relating to the samples included cytology result, date of last 
menstrual period, age at time of smear test and reported use 
of HC. No information on smoking status was available.    A    
total    of    60    cervical    smear    samples, 
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TABLE 1    Sample details including day of the menstrual cycle, menopausal status and use of HC 
 
Sample number Cytology result Day of cycle Postmenopausal HPV result Contraceptive 
1 Negative 7 / Negative None 
2 Negative 9 / Negative None 
3, 4, 5, 6, 7 Negative 10 / Negative None 
8, 9 Negative 11 / Negative None 
10, 11, 12, 13, 14 Negative 12 / Negative None 
15, 16, 17, 18, 19, 20, 21,  22 Negative 13 / Negative None 
23, 24 Negative 16 / Negative None 
25, 26 Negative 20 / Negative None 
27 Negative 21 / Negative None 
28 Negative 24 / Negative None 
29, 30, 31, 32, 33, 34, 35 Negative / Postmenopausal Negative / 
36, 37, 38, 39, 40, 41, 42, 43, 44, 45 Negative / / Negative HC 
46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 High grade / / Positive None 
 
45 confirmed as cytology negative and 15 confirmed HSIL 
samples, were used for this study. 
A slide was prepared for each sample using a ThinPrep 2000 
processor (Hologic Inc., Marlborough, Massachusetts). The 
Thin Prep processor starts by homogenising the sample by 
spinning the filter, creating shear forces in the fluid that are 
strong enough to disaggregate randomly joined material, break 
up blood, mucus and non-diagnostic debris. The cells are then 
collected onto the membrane of the filter and transferred onto a 
glass slide to  create  a  circular  monolayer  deposit  of  cells  20 
mm in diameter and a few microns in thickness. The slide is then 
ejected automatically into a fixative bath of 95% ethanol. 
The presence of blood residues on ThinPrep slides is a 
limiting factor that needs to be removed in order to collect 
data with minimal variability [19]. Therefore, the slides were 
treated with a 30% solution of H2O2 at room temperature for 
3 min. The slides were then placed into a 70% solution of 
industrial methylated spirits (IMS) for 3 min followed by 
multiple dips into 100% IMS to remove any remaining cellu- 
lar debris and H2O2. The slide was then air dried. 
 
 
2.2 | HPV testing 
One millilitre of the remaining test sample was tested for 
HPV using the Cobas 4800 HPV test. The Cobas 4800 test is 
an automated extraction and real-time PCR system that is 
capable of identifying 14 different high-risk HPV types as 
well as the ability to genotype for HPV 16/18. The Cobas 
4800 test starts by first collecting 400 μL of the test sample 
and heating it up to start the denaturing process. The cells are 
then lysed by a chaotropic reagent. The lysis step releases the 
HPV nucleic acids. These nucleic acids are negatively 
charged which bind to positively charged magnetic glass par- 
ticles that are held in place by a magnetic plate. The nucleic 
acids are then washed and separated from the glass particles, 
before they are amplified and detected by RT-PCR. 
Sequences of approximately 200 nucleotides are targeted by 
primers for the PCR reaction. The nucleotides are located 
within the L1 region of the HPV genome, with the master mix 
containing the primers designed for 14 different high- risk  
HPV  genotypes  (16,  18,  31,  33.35,  39,  45,  51,  52, 
56, 58, 59, 66 and 68). Fluorescent oligonucleotides are then 
added which can bind to the sequences within these primers 
during the PCR. The detection of these fluorescent oligonu- 
cleotides will give either a positive or negative result. 
 
2.3 |   Raman microspectroscopy 
Raman studies were performed using a HORIBA Jobin Yvon 
XploRA system (Villeneuve d’Ascq, France) which incorpo- 
rates the Olympus microscope Bx41. As source, a 532 nm 
laser of ~12 mW power was focused onto the sample using a 
100× objective (MPlan; Olympus, NA = 0.9) giving a spot 
size of 1 to 2 μm. The confocal hole was set at 100 μm for all 
measurements, the specified settings for confocal operation. 
The system was pre-calibrated to the 520.7 cm
−1 
spectral line 
for silicon. The 1200 lines per mm grating was used. The 
backscattered light was measured using an air-cooled CCD 
detector (Andor, 1024-256 pixels). The spectrometer was con- 
trolled by Labspec V5.0 software (Villeneuve d'Ascq, France). 
For each cell, one spectrum was recorded from the nucleus for 
2 accumulations of 30 seconds in the spectral range of 400 to 
1800 cm
−1
. Spectra were recorded only from the cell nucleus 
as these have been found to be more reproducible and consis- 
tent than  spectra from the  cell  cytoplasm [23]. On average, 
30 cells were recorded from each sample (superficial and 
intermediate cells). The x,y co-ordinates of each cell were 
recorded on the Raman microscope. After Raman acquisition 
was complete and following Pap staining, each cell could be 
re-visited and assigned as superficial or intermediate. The  15 
HSIL smears were screened for HSIL cells and spectra 
recorded accordingly. 
 
2.4 |  Data pre-processing and analysis 
Data were normalised and analysed using Matlab software 
(Mathworks, Natick, Massachusetts, USA) and specific scripts 
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FIGURE 1   (A) Proliferative phase presentation of a Pap smear. Note the higher ratio of superficial (pink stained) to intermediate (blue stained) cells, 
(B) secretory phase presentation of a Pap smear. Note the higher ratio of intermediate (blue stained) to superficial (pink stained) cells, (C) postmenopausal 
presentation of a Pap smear. Note the lack of cellular material, mucus and cellular debris. Bar =  35 μm 
 
developed and adapted for uploading of the spectra and their 
pre-processing, including smoothing  (Savitzky-Golay  K = 5, K 
= 13), baseline correction (rubberband) and vector normali- 
sation. An in house method for glass removal based on non- 
negativity constrained least squares was used to remove the 
spectral  features  of  glass  [23].  The  algorithm  weights  the 
values of glass as well as cell components in the acquired 
spectra from the cell and further subtracts the glass from the cell 
spectra applying non-negative constraints. 
Classification methods find mathematical models that are 
able to recognise the membership of each sample to its 
appropriate  class  on  the  basis  of  a  set  of measurements. 
 
 
 
 
FIGURE 2 (A) Mean Raman spectra of intermediate and superficial cells from days 7 to 24. Shading denotes the SD, (B) LV scores scatter plot of 
proliferative phase, days 7 to 14 (blue) vs secretory phase, days 15 to 24 (red), (C) LV1 loadings, (D) PLS-DA prediction plot 
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TABLE 2   Tentative peak assignments [22] 
 
Raman shift (cm−1) Proteins Lipids Carbohydrates Nucleic acids 
482   Glycogen  
577   Glycogen  
622 C─C twist Phe    
643 C─C twist Tyr    
727 CH2 def C─C head  A 
752 Sym br. Trp    
781    U,C,T ring br 
826 Out of plane ring br. Tyr   PO2 a.Str 
851 Ring br. Tyr, C─C str.  Pro    
852   Glycogen  
937   Glycogen  
985  C─C head   
1002 Sym. Ring br. Phe    
1033 C─H in plane Phe, C─C str    
1044   Glycogen  
1060 C─N str    
1082 C─N str Chain C─C str C─O  str, glycogen  
1096  Chain C─C str C─C str  
1106   Glycogen  
1123 C─N str Chain C─C str C─O str  
1152 C─N str    
1207 C─C6H5 str. Phe, Trp    
1238 C─N str, amide III    
1261   Glycogen  
1334   Glycogen  
1338 Trp   G 
1366  Sym. Str. CH3   
1381   Glycogen  
1450 CH2 def CH2 def   
1458   Glycogen  
1487 CH2 def   G,A 
1560 Tyr, Trp    
1575    A,G ring br 
1584 C─C str, C─C bend. Trp, Phe    
1605 C─C Phe, Tyr    
1642 C─O str, C─C sym. Str.    
1669 C─O str. Amide I    
 
When the classification model has been calibrated, the mem- 
bership of unknown samples to one of the defined classes 
can be predicted. Although PCA-LDA is the standard 
method used to maximise the variations in the X direction, 
PLS-DA by rotating both the X and Y axes allows even small 
variations to be captured. This was necessary to identify the 
normal biochemical changes associated with the menstrual 
cycle. Partial least squares discriminant analysis (PLS-DA) 
was used to build classification models in this study together 
with leave-one patient-out cross-validation. PLS-DA analysis 
was performed using the PLS toolbox (Eigenvector Research, 
Washington, USA) in the Matlab (Mathworks Inc.) environment. 
From the data provided by the patient about their last 
menstrual period and the day on which the sample was taken, 
the day of the menstrual cycle the smear was taken was 
calculated. It was assumed that each patient follows the stan- 
dard 28 -day cycle. Samples were only available from days  7 
to 24 of the cycle. Table 1 shows the sample details includ- 
ing day of the  menstrual  cycle,  menopausal  status  and  use 
of HC. 
 
 
3 | RESULTS AND DISCUSSION  
 
3.1 | Proliferative and secretory phase and 
postmenopausal cellular presentation on pap smear 
The proliferative and secretory phase presentation of a Pap 
smear are shown in Figure 1A,B, respectively. A  higher ratio   
of  superficial   (pink  stained)  to  intermediate   (blue 
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FIGURE 3 (A) Mean Raman spectra from postmenopausal samples. Shading denotes the SD, (B) LV scatter scores plot of postmenopausal (blue) and non- 
menopausal (red), (C) LV1 loadings, (D) PLS-DA prediction plot 
stained) cells in the proliferative phase compared to a higher 
ratio of intermediate (blue stained) to superficial (pink 
stained) cells in secretory phase can be observed. A post- 
menopausal Pap smear is shown in Figure 1C. A lack of 
cellular material, mucus and cellular debris can be observed 
which caused difficulties in recording good quality spectra. 
 
3.2 | Raman signature of proliferative phase vs 
secretory phase 
The spectral data from the Pap smears were divided up accord- 
ing to the day of the menstrual cycle the sample was taken on. - 
Figure 2A shows  the mean Raman spectra  of cells from days  7 
to 24 of the menstrual cycle. Increases in the Amide I (1640- 
1650 cm
−1
) (see Table 2), Phenylalanine and Tyrosine (1605- 
1610 cm
−1
) and glycogen (480 cm
−1
) bands over time were 
observed. The latent  variables  (LV)  scores  scatter  plot  (Figure 
2B) shows reasonable separation between the prolifera- tive 
phase (blue) and the secretory phase (red). Some overlap- ping is 
observed which is most likely due to the fact that each woman 
will differ slightly between the days of the menstrual cycle and 
the levels of oestrogen and progesterone present. The LV1 
loadings  shown  in Figure  2C highlight  areas  similar   to 
those highlighted in the mean Raman spectra (Figure 2A). The 
discrimination is mainly based on glycogen (480, 937, 1381 and 
1458 cm
−1
) that is more present in the secretory samples (red) due 
to the higher  levels  of progesterone,  which  promotes sub- 
nuclear glycogen accumulation [24], and proteins (CH2 def, 1450 
cm
−1
) and Amide I (1669 cm
−1
) which are higher in sam- ples 
collected from the proliferative phase of the cycle. The pre- 
diction plot from the PLS-DA model (Figure 2D) shows 
reasonably good classification of menstrual cycle phase (prolif- 
erative phase or secretory phase) with sensitivity of 83% and 
specificity of 86%. 
 
3.3 | Raman signature of postmenopausal samples 
Most women are generally screened for cervical cancer up 
until the age of  65  years.  Between  the  ages  of  48  and  55 
years, most women are said to be menopausal. Hence, it is 
important to determine if Pap smears collected from post- 
menopausal women will have a similar Raman signature to 
non-postmenopausal women. Mucus and cellular debris pre- 
sent on postmenopausal samples obscure the little cellular 
material that is present on the slide and make it very diffi- cult 
to obtain good spectra, hence the number of spectra 
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FIGURE 4 (A) Mean Raman spectra from HC positive and HC negative cells. Shading denotes the SD, (B) LV scatter scores plot of HC negative (blue) 
and HC positive (red), (C) LV1 loadings, (D) PLS-DA prediction plot 
 
recorded is severely reduced and it is difficult to draw any 
firm conclusions. Figure 3A shows the mean and SD spec- 
tra of the 22 postmenopausal cells recorded. Figure 3B shows 
good discrimination between the 2 sample types. The 
loadings shown in Figure 3C show that the discrimination is 
based on glycogen (852, 1106 and 1138 cm
−1
) and nucleic 
acids (781 cm
−1
)  proteins  (1450 cm
−1
)  and  Amide  I  (1669 
cm
−1
). Figure 3D shows the PLS-DA prediction plot which 
has a sensitivity of 100% and specificity of 95%. 
Atrophic samples were not available as part of this study. 
No firm conclusions can be drawn from this data set except 
that postmenopausal samples can represent a problem for 
Raman-based screening based on their Pap smear presentation 
due to mucus, cellular debris and lack of cellular material. 
 
 
3.4 | Raman signature associated with women on HC 
The clinical details obtained indicated if the patient was on 
some form of HC. However, information on which type of 
contraceptive they are currently on was not included. The aim 
of this part of the study was to determine if Pap smears 
collected from women on HC will have a similar Raman 
signature to women who are not on HC. 
Figure 4A shows that the levels of glycogen (482 and 
855-939 cm
−1
) in the HC-positive samples are lower when 
compared to the controls. The controls were made up of the 
samples collected throughout the menstrual cycle which were 
HC-negative. Tryptophan and Phenylalanine at peak position  
(1584-1605 cm
−1
)  and   Amide   I   at   peak   (1669 cm
−1
) are 
higher in HC samples compared to the control. The lower 
levels of glycogen in the HC samples could be linked to lower 
levels of progesterone due to its  role in promoting sub-
nuclear glycogen accumulation [24]. The same could be said 
for the higher levels of proteins detected (Phenylalanine, 
Tryptophan and Amide I). There is also a consistent change 
in the shoulder of Amide I, which  is a change in Amide I 
protein position and folding between HC-positive   and   HC-
negative   samples.   Overall, protein 
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FIGURE 5 (A) Pap stained HSIL cells. Bar = 35 μm, (B) mean Raman spectra from negative samples from days 7 to 21 of the menstrual cycle (red) and 
spectra from HSIL samples (blue). Shading denotes the SD, (C) LV scores scatter plot of HSIL samples (red) and negative samples (blue), (D) LV1 
loadings, (E) PLS-DA prediction plot 
 
 
synthesis may be increased due to the constant level of hor- 
mones present. 
The LV scores scatter plot (Figure 4B) shows good sepa- 
ration between HC-positive and HC-negative samples. There 
is a small amount of overlapping which could be due to a 
number of factors. Multiple types of contraceptive are avail- 
able, which contain different types and levels of hormones, 
including implants, injectable contraceptive, progesterone 
pills, oestrogen and progesterone pills, combined oral and the 
patch all of which work by maintaining a constant level of 
hormones in the body thus preventing the rise and fall of 
oestrogen and progesterone. Hence, they may work differ- 
ently and individual patients will also respond differently to 
the levels of hormones present. The loadings (Figure 4C) 
from LV1 show that glycogen (483 and 1386  cm
−1
) and pro- 
teins and lipids (1146, 1450 and 1566 cm
−1
) and Amide I 
(1669 cm
−1
) are the main discriminating factors between HC-
positive and HC-negative samples (Figure 4D). The PLS-DA 
prediction plot shows excellent classification with a 
sensitivity of 100% and specificity of 100%. 
 
3.5 | Phase of menstrual cycle vs HSIL 
It is important to determine if the changes observed 
throughout the menstrual cycle as seen in Figure 4 would 
affect  the  ability  of  Raman  spectroscopy  to  discriminate 
HSIL from normal cells affected by the normal maturation of 
the cervical epithelium controlled  by both the rise and  fall 
of progesterone and oestrogen. For this part of the  study, 
spectra from HSIL cells (Figure 5A) were recorded from 15 
HPV-positive, HSIL samples and compared to an equivalent 
number of spectra from negative samples from days 7 to 21 
of the menstrual cycle, all of which were HPV-negative. 
Figure 5B shows the mean spectra from neg- ative samples 
from days 7 to 21 of the menstrual cycle and spectra recorded 
from HSIL cells. The LV scores scatterplot in Figure 5C 
shows that HSIL cells separate well from nor- mal cells on 
the first LV. This shows that regardless of  when a sample is 
taken during day 7 to 21 of the menstrual cycle, HSIL cells 
can still be effectively discriminated from cytology negative 
cells using Raman spectroscopy. Spectral changes due to the 
hormonal influence of oestrogen and progesterone seem to 
be less than the spectral changes due  to the biochemical 
changes in the dyskaryotic cells. The loadings  from  LV1  
in  Figure  5D  show  that  glycogen 
(495,  1080,   1120,   1380   and  1458 cm
−1
),  nucleic   acids 
(780 and 1487 cm
−1
), Amide III and Amide  I  proteins  (1239 
and 1669 cm
−1
, respectively) and tryptophan and 
phenylalanine (1605 cm
−1
) mainly contribute towards the 
discrimination between normal and HSIL cells. As the HSIL 
cells   are   a   result   of   a   high   risk   HPV   infection, the 
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FIGURE 6 (A) Mean Raman spectra from negative HC positive samples (red) and spectra from HSIL cells (blue). Shading denotes the SD, (B) LV scores 
scatter plot of HSIL samples (red) and negative HC positive samples (blue), (C) LV1 loadings, (D) PLS-DA prediction plot 
 
biochemical difference in glycogen, proteins and nucleic 
acids can be attributed to the downstream effects  of the HPV 
infection. The predictions plot (Figure 5E) from the PLS-DA 
model shows excellent classification of the nega- tive 
samples (all menstrual cycle phases) and the dyskaryo- tic 
samples with sensitivity of 98% and a specificity of 97%. 
 
3.6 |  HC-positive samples vs HSIL 
It is important to determine if the use of HC will also affect 
the ability of Raman spectroscopy to discriminate normal 
HC-positive cells from HSIL cells. Figure 6A shows the 
mean Raman spectra of HC-positive and HC-negative sam- 
ples and spectra from HSIL cells. The LV scores scatterplot 
in Figure 6B shows that spectra from HC-positive samples 
separate from spectra from HSIL cells from HSIL samples on 
the first LV component with minimal overlap. Figure 6C 
shows the LV1 loadings which indicate that the main differ- 
ences between the HC-positive cells and HSIL cells are very 
similar to those found for the HC negative and HSIL sam- 
ples.  Glycogen  (482,  1261  and  1381 cm
−1
),  nucleic acids 
(781  cm
−1
) and proteins (1450, 1560 and 1669  cm
−1
)  again 
contribute towards the discrimination. As before, it appears 
that the overtaking of the host cell machinery by HPV causes 
more of a biochemical change within the cell than  the 
biochemical changes associated with the use of HC. The 
predictions plot from the PLS-DA model shows excellent 
classification of the negative samples (HC-positive) and the 
HSIL cells from HSIL samples (Figure 6D) with sensitivity 
of 96% and specificity of 98%. 
Kanter et al. [22] showed that hormonal status influences 
Raman spectra from the cervix in vivo and that incorporating 
hormonal status into their classification algorithm increased 
the accuracy from 88% to 94%. However, the present study 
and that of Romeo et al. [20] on exfoliated cervical cells 
showed good discrimination between normal and abnormal 
samples regardless of phase of the menstrual cycle and of 
whether the woman was taking oral contraceptives or not. 
 
 
4 |  CONCLUSION 
 
This study has shown that the day a Pap smear is taken dur- 
ing days 7 to 21 of the menstrual  cycle will  have  an  effect 
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on the spectra with regard to the level of glycogen and pro- 
teins. It should be noted, however, that this study assumes 
that each patient recruited follows the standard 28-day  cycle, 
and that the patient details recorded for each sample were 
correct. It is possible for women have a longer or shorter 
cycle, hence this variation may have influenced our analysis. 
Postmenopausal samples represent a problem for Raman 
based screening due to their lack of cellular material and 
presence of cellular debris and mucus. The use of HC causes 
the most variability. Furthermore, study would be required to 
determine which hormone is causing the dis- crimination 
between HC-positive and HC-negative samples. These 
findings suggest that the use of oral contraceptives and the 
day on which the Pap smear was taken during the menstrual 
cycle should be incorporated into the data analy- sis to reduce 
variability between patient samples. 
Despite this, however, the variability between days of the 
menstrual cycle or use of HC did not hinder the ability of 
Raman spectroscopy to discriminate cytology negative cells 
from HSIL cells. The biochemical changes induced in HSIL 
cells due to an active HPV infection were more pronounced 
than the biochemical changes due to the menstrual cycle or 
the use of HC. It is acknowledged that the study is limited in 
focussing only on HSIL samples and a further study would 
be required to include low-grade samples. In conclusion, this 
study highlights the scope of Raman spectroscopy for cervi- 
cal screening despite the presence of biochemical changes 
associated with the menstrual cycle and the use of HC. 
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Abstract. There is an unmet need for methods to help in the early detection of cervical precancer. Optical spec- 
troscopy-based techniques, such as Raman spectroscopy, have shown great potential for diagnosis of different 
cancers, including cervical cancer. However, relatively few studies have been carried out on liquid-based cytol- 
ogy (LBC) pap test specimens and confounding factors, such as blood contamination, have been identified. 
Previous work reported a method to remove blood contamination before Raman spectroscopy by pretreatment 
of the slides with hydrogen peroxide. The aim of the present study was to extend this work to excessively bloody 
samples to see if these could be rendered suitable for Raman spectroscopy. LBC ThinPrep specimens were 
treated by adding hydrogen peroxide directly to the vial before slide preparation. Good quality Raman spectra 
were recorded from negative and high grade (HG) cytology samples with no blood contamination and with heavy 
blood contamination. Good classification between negative and HG cytology could be achieved for samples with 
no blood contamination (sensitivity 92%, specificity 93%) and heavy blood contamination (sensitivity 89%, speci- 
ficity 88%) with poorer classification when samples were combined (sensitivity 82%, specificity 87%). This study 
demonstrates for the first time the improved potential of Raman spectroscopy for analysis of ThinPrep spec- 
imens regardless of blood contamination. © 2018 Society of Photo-Optical Instrumentation Engineers (SPIE) [DOI: 10.1117/1.JBO 
.23.5.055001] 
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1    Introduction 
Cervical cancer is the fourth most common cancer in women 
worldwide with an estimated 528,000 cases and 266,000 deaths 
in 2012.1 The link between cervical cancer and high risk human 
papilloma virus (HPV) infection and the molecular control of 
the cell cycle is firmly established.2 The presence of an HPV 
infection does not automatically mean the development of 
cervical cancer or precancer [cervical intraepithelial neoplasia 
(CIN)]. However, the HPV virus can integrate its viral DNA 
into the host cell’s DNA located in the cell’s nucleus. This inte- 
gration disrupts the host cell’s control of cell growth and rep- 
lication and can lead to malignant transformation.3 The most 
common method for cervical screening is based on the papani- 
colaou test (pap test), which is designed to screen for signs of 
precancer and cancer of the cervix. The pap test requires cells to 
be scraped from the cervix, fixed to a glass slide, stained, and 
reviewed by a trained cytologist. Cellular abnormalities are 
identified based on cellular morphology and staining character- 
istics and classified according to the degree of dysplasia. The 
ThinPrep liquid-based cytology (LBC) method involves the 
patient’s cells being transferred into a specimen vial containing 
PreservCyt transport medium. PreservCyt is an alcohol-based 
solution that preserves cell morphology and breaks down 
biological components, such as mucin and blood. The normal 
smear pattern is made up of epithelial and nonepithelial compo- 
nents [Fig. 1(a)]. The epithelial cell components include para- 
basal cells, intermediate cells, superficial cells, endocervical 
and endometrial cells. Nonepithelial cell components include 
red blood cells, lymphocytes, histiocytes, polymorphs, mucus, 
and bacteria. Red blood cells are 7 to 8 μm in size and stain  red 
or pink with the pap stain. They are often found in cervical 
samples, either due to menstruation or inflammation and their 
presence can also be used as an indicator of disease (precancer).4 
A patient’s cervix with a high-grade (HG) lesion will often bleed 
on contact with the cervical brush and, as a result, the smear 
becomes contaminated with blood. The presence of blood in the 
sample will often dilute diagnostic cells, cover and surround cell 
groups, increase screening time, and make microscopic 
interpretation difficult [Fig. 1(b)]. PreservCyt contains a lysis 
agent for mucus and red blood cells but excessive blood in   the 
sample vial will prevent a satisfactory smear being produced. 
High volumes of red blood cells will prevent the collection of 
epithelial cells onto the polycarbonate filter membrane during 
processing resulting in a ringed halo effect with red blood  cells 
deposited mostly around the edges of the smear with   very few 
epithelial cells present [Fig.  1(c)]. 
Cytology laboratories often annotate pap smears according to 
a blood scale index, where 0 indicates no visible evidence of 
blood present and 3 indicates an extremely bloody sample (Fig. 
2). Samples presenting as a 2 or 3 on the blood scale are 
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Fig. 1 (a) Pap smear after staining. Note the presence of intermediate (blue), superficial (pink) cells, and 
lymphocytes (indicated by arrows), (b) bloody smear pattern with red blood cells, obscuring diagnostic 
cells. Bar ¼ 35 μm. (c) Pap smear contaminated with blood showing ringed halo effect. 
 
often either rejected as being unsatisfactory or treated with a 
wash solution to lyse more of the red blood cells to increase the 
number of epithelial cells present on the slide. This blood scale 
grading is subjective and is only based on a visual appear- ance 
of a sample. The advantage of the pap test is that it is a 
noninvasive and widely accepted screening-based test. How- 
ever, despite a high specificity of 96.5%, a lower  sensitivity  of 
85% can be due to sampling, technical and interobserver errors 
associated with the subjectivity of the test.4 Over the  past 20 
years, Raman spectroscopy has shown potential for the 
diagnosis of cervical cancer both in vivo and ex vivo.5–12 Raman 
spectroscopy is based on inelastic light scattering in which a 
sample is illuminated by monochromatic laser light and inter- 
actions between the incident photons and molecules in the sam- 
ple result in the scattering of the light. The coupling of the light 
generates vibrations within the sample, which are characteristic 
of the chemical structure. The energy of the scattered light is 
reduced by an amount equal to the vibrational energy, which is 
called the Raman shift. This means that the position, peaks, and 
shape of the Raman bands carry information about the molecu- 
lar makeup of the sample. The Raman spectrum of cells and 
tissues is made up of contributions from many biochemical com- 
ponents, including DNA, RNA, proteins, lipids, and carbohy- 
drates.12 To date, most likely due to confounding factors, such 
as blood contamination, there have been relatively few studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 ThinPrep vials graded according to the blood scale index, 
where 0 indicates no visible evidence of blood and 3 indicates an 
extremely bloody sample. 
on Raman spectroscopy of cervical smear samples.13–19 Rubina 
et al.16 described the influence of blood on the Raman spectra of 
cervical cell pellets and how this might lead to false interpreta- 
tions. Classification efficiency of 86% and 84% was reported for 
normal and abnormal samples, respectively, and this decreased 
to 78% and 79% after samples were treated with red blood cell 
lysis buffer to reduce blood contamination. A previous study by 
our group17 addressed many of the issues involved in recording 
Raman spectra from LBC (ThinPrep) samples and described a 
method to remove blood contamination before Raman spectros- 
copy based on pretreatment of the slides with hydrogen perox- 
ide. This was shown to minimize variability and to result in the 
collection of highly reproducible data with excellent discrimina- 
tion between negative and HG samples. However, only blood 
scale 0 and blood scale 1 samples were used for this study     as 
the treatment was not found to be effective for excessively 
contaminated blood scale 2 and 3 samples. Kerr et al.20 inves- 
tigated the effect of blood contamination on Raman spectra of 
urine cytology samples. They determined that spectra recorded 
from samples with a low level of blood appeared free from con- 
tamination due to the effective removal of many of the red blood 
cells using the lysing agent CytoLyt. However, for excessively 
bloody samples, several additional Raman peaks associated with 
blood were observed leading to the conclusion that excessively 
bloody samples are not suitable for diagnostics with Raman 
microspectroscopy. The aim of the present study was to extend 
our previous study17 to samples annotated as blood scale 2 and 3 
to investigate if these excessively bloody samples could be 
treated to render them suitable for Raman  spectroscopy. 
 
2 Materials and Methods 
2.1 Samples and Blood Treatment 
Cervical LBC samples were provided by Coombe Women and 
Infants University Hospital, Dublin, Ireland, for spectroscopic 
analysis with the final clinical report prepared by the cytologist 
and/or pathologist. This study was approved by the Research 
Ethics Committee at Coombe Women and Infants University 
Hospital. A set of 30 samples were selected, 15 HG intraepithe- 
lial neoplasia samples, which received a CIN 2 or CIN 3, result 
on their associated biopsy from pathology, and 15 negative sam- 
ples (TN), which received a negative result from cytology. All 
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cytology samples were evaluated by eye according to the blood 
scale index and annotated as being either a grade 0, 1, 2, or 3. 
HeLa cervical cancer cells were also prepared and fixed as 
for ThinPrep samples in PreservCyt. These samples were seeded 
with blood to mimic excessively bloody cytology samples. This 
was achieved by adding blood to the samples until they visually 
represented a blood scale 2 and 3 index sample. 
Each ThinPrep sample vial was mixed for 3 min to break up 
cellular clumps. The sample was then poured into a 50-ml cen- 
trifuge tube and centrifuged for 5 min at 300 rpm. The super- 
natant was removed and 1 ml of H2O2 was added and mixed for 
30 s. About 20 ml of PreservCyt was added to neutralize the 
H2O2. The sample was then centrifuged for 5 min at 600 rpm. 
Most of the supernatant was removed. The cell pellet was 
resuspended multiple times with a 1-ml pipette to break up  cell 
clumps. The 20 ml of PreservCyt was then added and     the 
contents poured back into the original vial. 
 
2.2 ThinPrep Slide Preparation 
The samples were then prepared using the ThinPrep 2000 
processor (Hologic Inc., Marlborough, Massachusetts). The 
ThinPrep process begins with the patient’s gynecological sam- 
ple being collected by the clinician using either a cervical broom 
or brush. The brush/broom is then rinsed in the specimen vial 
containing PreservCyt transport medium (ThinPrep Pap Test; 
Cytyc Corporation, Boxborough, Massachusetts). The ThinPrep 
sample vial is then capped, labeled, and sent to the lab to be 
processed. The ThinPrep processor homogenizes the sample  by 
spinning the filter and creating shear forces that breaks up any 
clumped material (blood, mucin, and nondiagnostic material). 
The cells are then transferred onto a polycarbonate filter 
membrane of the TransCyt filter and transferred onto a 
glass slide to produce a circular monolayer of cells ∼20 mm  in 
diameter. The slide is then ejected into a fixative bath of 95% 
ethanol. 
 
 
2.3 Raman Spectroscopy 
All Raman analyses was performed using a HORIBA Jobin 
Yvon XplorRA™ system (Villeneuve d’Ascq, France), which 
incorporates an  Olympus  microscope  BX41  equipped  with 
a ×100 objective (MPlan, Olympus, NA 0.9).  A 532-nm  diode 
laser source was used. Laser power was set to 100% resulting 
in 16 mW at the objective. The confocal hole coupled to a slit 
aperture of 100 μm was set at 100 μm for all the mea- 
surements. The system was precalibrated to the 520.7 cm−1 
spectral line for silicon. About 1200 lines/grating mm were 
used. The backscatter light was measured using an air-cooled 
CCD detector (Andor, 1024 × 256 pixels). The spectrometer 
was controlled by Labspec V5.0 software. Two accumulations 
of 30 s were performed on each cell nucleus selected. Raman 
spectra were acquired from the nuclei of randomly selected 
morphologically normal superficial and intermediate cells from 
each unstained pap smear. 
 
 
 
 
Fig. 3 (a) Untreated pap smear,  blood  scale  3,  stars  indicate  recorded  nuclei  in  field-of-view. Bar 
¼ 35 μm. (b) Raman spectra recorded from untreated pap smear. (c) Treated pap smear, stars indi- cate 
recorded nuclei in field-of-view. Bar ¼ 35 μm. (d) Raman spectra recorded from treated pap smear. 
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Fig. 4 (a) Mean Raman spectra of HeLa cervical cancer cells treated with blood (blood scale 2 and 3) 
and subsequently treated with H2O2 (red) and HeLa cervical cancer cells not treated with blood but 
treated with H2O2 (blue), (b) mean Raman spectra of true negative samples (TN), blood scale 2 and 3, 
treated with H2O2 (red) and blood scale 0, treated with H2O2, (c) mean Raman spectra of HG samples, 
blood scale 2 and 3 treated with H2O2 (red) and blood scale 0, treated with H2O2. 
 
 
2.4 Data Preprocessing and Analysis 
Data were normalized and analyzed using MATLAB software 
(Mathworks) and specific scripts developed and adapted for 
uploading of the spectra and their preprocessing, including 
smoothing (Savitzky–Golay K  5,  K   13) baseline correc-   tion 
(rubberband) and vector normalization. The spectra were also 
corrected for the glass background using a linear least- squares 
method with non-negative constraints. The least-squares model 
was developed using spectra from the ThinPrep glass slides and 
selected pure biochemicals (e.g., actin, collagen, RNA, DNA, 
etc.) that approximate the biochemical composition of cervical 
cells. The data were mean centered and subjected to partial least 
squares discriminant analysis (PLS-DA). PLS-DA involves the 
creation of latent variables to maximize the cova- riation 
between known datasets and the response variable which they 
are regressed against. PLS-DA is a form of analysis that has the 
ability to distinguish between known classifications of sam- ples 
(negative, HG) and its aim is to find latent variables and 
directions to maximize separation in a multivariate space. To 
validate the method leave one patient out cross validation was 
performed. This involves data from one patient sample being 
removed from the model and the process is repeated until all 
samples have been left out  once. 
3 Results 
Figure 3(a) shows an untreated Pap smear, blood scale 3. The 
slide was coated in blood and cellular debris. Figure 3(b) shows 
Raman spectra recorded from cells present on the slide. Very 
few cells were present and often burned on contact with the 
laser. A high background was observed together with Raman 
bands associated with blood at 754, 1311, 1374, 1398, 1588, 
1640 cm−1. The high background can be attributed to the cel- 
lular debris or a subunit of the oxidized hemoglobin on the 
surface of the cell nuclei, which has a weak fluorescence.11 
Figure 3(c) shows the same sample from Fig. 3(a) after under- 
going the blood removal method. Any blood residue has been 
oxidized with the H2O2 treatment and cellular debris has been 
reduced allowing for high quality spectra to be recorded as 
demonstrated in Fig. 3(d). 
In order to determine if the Raman specific method of blood 
removal using H2O2 had any effect on the spectra recorded with- 
out any external confounding factors, such as inflammation, 
HPV infection, etc., the protocol was performed on HeLa cer- 
vical cancer cells. HeLa cells were seeded with blood to mimic 
cytology samples with blood scale index 2 and 3 and HeLa cells 
with no added blood acted as controls. Both  sample types were 
treated with H2O2 and slides prepared as for the ThinPrep 
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cytology samples. Figure 4(a) shows the mean Raman spectra 
recorded from 30 HeLa cells with and without blood contami- 
nation (blood scale 2 and 3) and treated with H2O2. The mean 
spectra display strong similarities with only minor changes at 
1242 cm−1 (Amide III), 1350 cm−1 (DNA/RNA, CH def. in 
proteins and carbohydrates), 1430 cm−1 (protein, lipids), and 
1669 cm−1 (Amide I). Figure 4(b) shows the mean Raman spec- 
tra of negative cytology samples (TN) with and without blood 
contamination (blood scale 2 and 3) and treated with H2O2. The 
mean spectra display strong similarities with small changes at 
1242, 1350, 1430, and 1669 cm−1 as observed  for  the  HeLa 
cells. These small changes in the spectra were consistent 
throughout all samples tested including  the  HG  samples  [Fig. 
4(c)]. 
PLS-DA classification of negative cytology samples and HG 
cytology samples, blood scale index 0, is shown in Fig. 5. 
Figure 5(a) is a latent variables (LV)  scores scatter plot of  LV1 
and LV2, which shows good discrimination along LV1. The 
loadings, as shown in Fig. 5(b), show that the discrimina- 
tion is based around Raman peaks at 482, 851, 936, 1128, 1338, 
1449, 1572, 1655, and 1669 cm−1, which are mainly related to 
DNA, proteins, and glycogen. Figure 5(c) is a PLS-DA predic- 
tion plot showing good classification of negative and HG sam- 
ples with a sensitivity of 92% and a specificity of 93% (Table 1). 
PLS-DA classification of TN and HG cytology samples, blood 
scale index 2 and 3, is shown in Fig. 6. Both negative 
and HG samples have undergone the Raman-specific blood 
removal method. Figure 6(a) is a LV scores scatter plot of treated 
TN and HG samples, which show overlap between the samples. 
The LV1 loadings, as shown in Fig. 6(b), show that the discrimi- 
nation is based around Raman peaks at 482, 549, 851, 936, 
1145,  1182, 1237, 1338,  1449, 1576, and 1669 cm−1  and are 
similar to the loadings shown in Fig. 5(b). The PLS-DA predic- 
tion plot is shown in Fig. 6(c) and has a sensitivity of 89% and 
a specificity of 88% (Table  1). 
In order to determine if excessively bloody samples could be 
treated the same way as nonbloody samples in terms of data 
analysis, the Raman spectral data from the two groups (blood 
scale 0 and blood scale 2 and 3) were combined. Figure 7(a) 
shows the LV scores scatter plot, which highlights decreased 
discrimination between TN and HG cytology. However, the 
loadings shown in Fig. 7(b) remain similar to the loadings 
shown in Figs. 5(b) and 6(b) with Raman peaks at 482, 851, 
1129, 1184, 1251, 1338, 1449, and 1669 cm−1. The PLS-DA 
prediction plot is shown in Fig. 7(c) and has a sensitivity of 82% 
and a specificity of 87%  (Table  1). 
Interestingly, the loadings (482, 851, 936, 1149, 1338 and 
1669 cm−1) remain almost the same between all three datasets, 
blood scale 0, blood scale 2 and 3 and combined, confirming 
that glycogen, DNA, and proteins are the main discriminating 
features between negative cytology and HG cytology samples 
regardless  of  blood  contamination.  Similar  findings  have 
 
 
 
Fig. 5 (a) LV score scatter plot of Raman spectra acquired from 15 TN samples and 15 HG samples 
(blood scale index 0), (b) LV 1 loadings, and (c) PLS-DA prediction plot showing good discrimination 
between TN (blue) and HG (red) ThinPrep cytology samples. 
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Table 1 Sensitivity and specificity from PLS-DA classification of TN 
and HG cervical cytology samples with and without blood contamina- 
tion and combined. 
 
 
 
 
 
 
 
 
 
 
and 2 and 3)  
 
 
been reported previously.17,19 However, as mentioned earlier, 
some spectral features undergo minor changes following the 
blood removal method. As these features overlap with the dis- 
criminating features, this results in a reduction in classification 
efficiency when excessively bloody (blood scale index 2 and 3) 
samples and nonbloody samples (blood scale index 0) samples 
are combined for analysis. Comparing sensitivity and specificity 
of the test groups shows that blood scale 0 samples with no 
blood contamination performed best with a sensitivity of 92% 
and specificity of 93% when compared to excessively bloody 
blood scale 2 and 3 samples, which had a sensitivity of 89% and  
specificity  of  88%.  Combining  the  blood  scale  0  and 
blood scale 2 and 3 samples for analysis resulted in a sensitivity 
of 82% and specificity of 87%. The high specificity indicates  a 
good ability to accurately exclude negative samples (few false 
positives), however, the reduction in sensitivity indicates a 
reduced ability to accurately detect HG samples and an 
increased likelihood of false negatives. 
Despite the reduction in classification efficiency, the values 
are higher than previously reported for samples with blood con- 
tamination. Rubina et al.16 reported a classification efficiency of 
78% and 79% for normal and abnormal bloody samples treated 
with red blood cell lysis buffer. In addition, Kerr et al.20 con- 
cluded that excessively bloody samples were not suitable for 
diagnostics with Raman spectroscopy. 
 
4 Conclusion 
This study demonstrates for the first time that excessively 
bloody (blood scale 2 and 3) ThinPrep cervical smear samples 
can be used for diagnostics with Raman spectroscopy following 
a hydrogen peroxide treatment in the collection vial. However, 
the presence of excessive blood contamination (blood scale 
index 2 and 3) did result in reduced sensitivity and specificity 
for classification of negative and HG samples. A higher sensi- 
tivity and specificity could be achieved by keeping excessively 
bloody samples separate from nonbloody samples for analysis. 
Although this study has focused only on cervical cytology sam- 
ples, thyroid, urine, and serous fluid cytology samples may also 
 
 
 
Fig. 6 (a) LV score scatter plot of Raman spectra acquired from 15 TN and 15 HG samples (blood scale 
index 2 and 3), (b) LV1 loadings, (c) PLS-DA prediction plot showing some discrimination between TN 
(blue) and HG (red) ThinPrep cytology samples, blood scale 2 and 3 and treated with H2O2. 
 Sensitivity (%) Specificity (%) 
Negative versus HG 
(blood scale 0) 
92 93 
Negative versus HG 
(blood scale 2 and 3) 
89 88 
Combined (blood scale 0 82 87 
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Fig. 7 (a) LV score scatter plot of Raman spectra from TN and HG samples (combined blood scale 0 and 
blood scale 2 and 3), (b) LV1 loadings, and (c) PLS-DA prediction plot showing some discrimination 
between TN (blue) and HG (red) ThinPrep cytology samples, combined blood scale 0 and blood scale 
2 and 3 and treated with  H2O2. 
 
benefit from such an approach for Raman spectroscopic analy- 
sis. Serous fluids for cytological examination are often contami- 
nated with a high level of blood (pericardium, pleura, and 
peritoneum fluids) and often require additional treatment meth- 
ods, such a density gradient technique to remove red blood cells, 
which can result in a loss of diagnostic cellular material. The 
application of our blood treatment method would prevent this 
loss of material and allow Raman spectroscopy to be performed. 
While these results are promising for the development of 
Raman spectroscopy for cervical cancer screening, Raman 
spectroscopy in its current form does not have the ability to 
replace cytology for cervical cancer screening and its associated 
benefits (e.g., detection of Herpes Simplex virus or actinomyces 
like organisms). However, it could be used to supplement the 
pap  test or it  could have  potential as a  triage test  after  HPV 
testing. 
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1 |     INTRODUCTION  
 
Every year millions of cervical Pap tests are performed 
throughout the world in countries for purposes of cervical 
screening. Most Pap tests are performed through use of liq- 
uid based cytology (LBC) where cervical cells are collected 
before deposition into a volume of liquid preservative. As not 
all the material is required for cytological assessment, the 
surplus, which would ordinarily be discarded, can be stored    
within    tissue    biobanks    with    due    process of 
governance. Biobanks constitute a valuable source of mate- 
rial which may support a number of studies including those 
on the natural history of disease, evaluation of screening 
practices, vaccination effectiveness or the development of 
new technologies to support screening and disease manage- 
ment.[1–3] 
There were an estimated 527 600 new cervical cancer 
cases and 265 700 deaths from cervical cancer worldwide in 
2012.[4] This demonstrates the importance of both cervical 
screening   to   reduce   the   burden   of   disease   and   also 
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Patient samples are unique and often irreplaceable. This 
allows biobanks to be a valuable source of material. The aim 
of this study was to assess the ability of Raman spec- 
troscopy to screen for histologically confirmed cases of Cer- 
vical Intraepithelial neoplasia (CIN) using biobanked liquid 
based cytology (LBC) samples. Two temperatures for long 
term storage were assessed; 80oC and −25oC. The utility of 
Raman spectroscopy for the detection of CIN was compared 
for fresh LBC samples and biobanked LBC samples. Two 
groups of samples were used for the study with one group 
associated with disease (CIN 3) and the other associated with 
no disease (cytology negative). The data indicates that 
samples stored at −80oC are not suitable for assessment by 
Raman spectroscopy due to a lack of  cellular  material  and 
the presence of cellular debris. However, the technology can be applied to fresh 
LBC samples and those stored at −25oC and is, moreover, effective in the discrimi- 
nation of negative samples from those where CIN 3 has been confirmed. Pooled 
fresh and biobanked samples are also amenable to the technology and achieve a 
similar sensitivity and specificity for CIN 3. This study demonstrates that cervical 
cytology samples stored within biobanks at temperatures that preclude cell lysis can 
act as a useful resource for Raman spectroscopy and will facilitate research and 
translational studies in this area. 
 
  
biobank, cervical cancer, cervical pre-cancer, cytology, Raman spectroscopy, 
ThinPrep 
  
 
investment in research into new technologies that can 
improve the performance and “reach” of cervical screening 
Different collection media for liquid based cytology exist 
however one of the more common media is PreservCyt 
(Hologic). PreservCyt is a methanol based solution that pre- 
serves cell morphology via fixation. Fixation is routinely 
employed as it allows a “snapshot” of a cell's physical and 
biochemical state to be assessed. Methanol is an organic sol- 
vent that preserves cells through dehydration and precipita- 
tion of proteins
.
[5] Fixation is important given that sample 
collection and assessment is not performed concurrently. In 
addition to supporting routine screening, fixation of cells also 
supports longer term storage of residual material in biobanks. 
The advantage of the Pap test is that it is a widely 
accepted screening based test with a high specificity of 95% 
to 98% and a sensitivity of 74% to 96%.[6] The variability in 
the rates of sensitivity are due to sampling technique and the 
variability of the cytology based screening. This can result  in 
unnecessary gynaecological referral and patient recall. 
Persistent infection with high risk human papillomavirus 
(HPV), is accepted as the major cause of cervical pre-cancer 
and cancer.[7] HPV DNA testing has a higher sensitivity 
(>95%) but lower specificity (~84%) than the Pap test.[7] 
These tests are expensive, time-consuming and provide no 
information on cervical cytopathology. 
Current methods for detection of cervical cancer and pre- 
cancer (CIN) are limited and there is an unmet clinical need 
for new screening or diagnostic tests. Recently Raman spec- 
troscopy has shown potential as a tool for screening and 
diagnosis of cervical lesions and cancer.[8–10] Raman spec- 
troscopy is based on inelastic light scattering where a sample 
is illuminated by a monochromatic laser light and interac- 
tions between the incident photons and molecules in the 
sample result in the scattering of the light. The coupling of 
the light generates vibrations within the sample which are 
characteristic of the chemical structure. This means that the 
position, peaks and shape of the Raman bands carry infor- 
mation about the molecular makeup of the sample. The 
Raman spectrum of cells and tissues is made up of contribu- 
tions from many biochemical components including DNA, 
RNA, proteins, lipids and carbohydrates
.
[11] Raman spec- 
troscopy can offer a label free non-destructive method for 
cervical cancer screening. It is an objective method, less reli- 
ant on operator performance than cytology and potentially 
more specific than HPV testing. 
Due to confounding factors such as sample collection, 
blood contamination and sample variability, few studies have 
been performed using Raman spectroscopy on cervical 
cytology samples and none to our knowledge have investi- 
gated the potential of utilising biobanked LBC samples. The 
aim of this feasibility study was to assess the utility and per- 
formance of Raman spectroscopy for the detection of CIN 
using  biobanked  LBC  samples.  Samples  stored  at −80oC 
and −25oC were assessed and the ability of Raman spectra  to 
delineate disease from no disease was determined. Addi- 
tionally, Raman spectroscopy was assessed in un-banked 
LBC samples as a comparator. 
 
 
2 |    METHODS  
 
2.1   |   Sample  collection 
Two classes of samples were used for the study, classed as 
disease and no disease. Samples with no disease were defined 
as cytology negative and HPV negative whereas samples 
with disease were those associated with a histologi- cally 
confirmed CIN 3 with a HPV positivity according to HPV 
DNA and mRNA status. All samples were recruited from 
patients presenting at a colposcopy clinic for the first time, 
and had no prior history of disease. Samples were col- lected 
from each patient according to the standard operating 
procedure issued by Cervical Check Irelands national cervi- 
cal cancer screening programme and the NHS Scottish cervi- 
cal screening programme. Both procedures are similar and all 
samples were biobanked using the same methodology. 
One hundred thirty-three samples were used in total for 
this study  of  which  64  were  LBC  biobanked  samples;  32 
with no disease (cytology negative) and 32 with disease (CIN 
3). Biobanked samples were provided by the Scottish HPV 
Archive, a research tissue biobank set up to facilitate HPV 
associated research. 
Ethical approval for use of the samples was obtained from 
the East of Scotland Research Ethics Service—Tayside 
committee. Biobanked LBC samples used for this study had 
been sedimented  with the cellular pellet  transferred  into   a 
4.5 mL vial for long term storage in PreservCyt. After tran- 
sit, samples were re-constituted to a volume of 20 mL fresh 
PreservCyt solution to resemble the original LBC specimen 
from which the sample was derived. 
A  further  64  non  biobanked  “fresh”  LBC  samples,  32 
with no disease (cytology negative) and 32 with disease (CIN 
3), were collected in PreservCyt solution from the Coombe 
Women and Infants University Hospital (CWIUH), Dublin, 
Ireland, as part of routine cytological screening. Eth- ical 
approval for use of anonymised samples for the study was 
granted by the CWIUH Research Ethics  Committee (no. 28-
2014). A further 5 fresh LBC samples with disease (CIN 3) 
were collected and split into two separate vials. One vial from 
each sample underwent the standard biobanking process and 
was stored for 3 weeks, while the other was stored at room 
temperature. 
 
2.2 |   ThinPrep 
The samples were then prepared using the ThinPrep 2000 
processor (Hologic Inc., Marlborough, Massachusetts). The 
ThinPrep  process begins  with  the  patient's gynaecological 
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sample being collected by the clinician using either a cervi- 
cal broom or brush. The brush/broom is then rinsed in the 
specimen vial containing PreservCyt transport medium 
(ThinPrep Pap Test; Cytyc Corporation, Boxborough, Mas- 
sachusetts). The ThinPrep sample vial is then capped, 
labelled and sent to the lab to be processed. The ThinPrep 
processor homogenises the sample by spinning the filter, 
creating shear forces that breaks up any clumped material 
(blood, mucin and non-diagnostic material). The cells are 
then transferred onto a polycarbonate filter membrane of the 
TransCyt filter and transferred onto a glass slide to produce a 
circular monolayer of cells ~20 mm in diameter. The slide is 
then ejected into a fixative bath of 95% ethanol. 
 
2.3 |   Raman spectroscopy 
All Raman analysis was performed using a HORIBA Jobin 
Yvon XplorRA system (Villeneuve d'Ascq, France), which 
incorporates an Olympus microscope BX41 equipped with a 
×100 objective (MPlan, Olympus, Tokyo, Japan, NA = 0.9). 
A 532 nm diode laser source was used. Laser power was set 
to 100% resulting in 16 mW at the objective. The confocal 
hole coupled to a slit aperture of 100 μm, was set at 100 μm, 
for all the measurements. The system was pre-calibrated to the 
520.7 cm
−1 
spectral line for silicon. A 1200 lines per mm grat- 
ing was used. The backscattered light was measured using an 
air-cooled CCD detector (Andor, 1024 × 256 pixels). The 
spectrometer was controlled by Labspec V6.0 software. Two 
accumulations of 30 seconds were performed on each cell 
nucleus selected. Raman spectra were acquired from the nuclei 
of 20 randomly selected morphologically normal superficial 
and intermediate cells from each unstained Pap smear. 
 
2.4   |   Data pre-processing and analysis 
Data was normalised and analysed using Matlab software 
(Mathworks) and specific scripts developed and adapted for 
uploading of the spectra and their pre-processing, including 
smoothing (Savitzky-Golay K = 5, K = 13), baseline cor- 
rection (Rubberband) and vector normalisation. The spectra 
were also corrected for the glass background using a linear 
least-squares method with non-negative constraints (NNLS). 
The least-squares model was developed using spectra from 
the Thinprep glass slides and selected pure biochemicals (eg, 
actin, glycogen, RNA, DNA, etc.) that approximate the bio- 
chemical composition of cervical cells. The data was mean 
centred and subjected to partial least squares discriminant 
analysis (PLS-DA). PLS-DA involves the creation of latent 
variables to maximise the co variation between known data- 
sets and the response variable which they are regressed 
against. PLS-DA is a form of analysis that has the ability to 
distinguish between known classifications of samples and its 
aim is to find latent variables and directions to maximise 
separation in a multivariate space.[12] To validate the 
method,   leave   one    patient   out   cross   validation    was 
 
 
FIGURE 1 (A) LBC samples stored at −25oC present with intact cellular 
morphology. Note the presence of superficial and intermediate cells on the 
unstained slide which were selected for Raman spectral recording. (B) High 
quality spectra recorded from morphologically normal intermediate and 
superficial cells in the spectral range 400-1800 cm−1. (C) LBC samples stored 
at −80 oC. Note lack of cellular material and presence of cellular debris 
 
performed which involved data from one patient sample 
being removed from the model, with this process repeated 
until all patient samples were left out once. 
 
3 |    RESULTS  
 
3.1 |    −25oC vs −80oC biobanked LBC samples 
The samples stored at −25oC presented with intact cellular 
morphology  (Figure  1A)  and  allowed  for  high  quality 
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FIGURE 2    (A) mean spectra of fresh Negative (red) vs CIN 3 (blue). (B) is a latent variables (LV) scores scatter plot of LV1 and LV2, TN (yellow) vs CIN 
3 (blue). (C) LV1(blue) and LV2 (orange) loadings (D) PLS_DA prediction plot CIN 3 (blue), negative (yellow) 
spectra to be recorded (Figure 1B). The samples stored at 
−80oC presented with cell lysis, cellular debris and very little 
cellular material which prevented the recording of spectra 
(Figure 1C). One possible explanation for this, is the freeze 
thaw effect which is commonly used to lyse bacteria and 
mammalian cells. Storing cells at −80oC in PreservCyt with- 
out any Dimethyl Sulfoxide and bring up to room tempera- 
ture can cause the cells to contract during the thawing process 
resulting in cell lysis. As a result, only biobanked samples 
previously stored at −25oC were used for this study. 
 
3.2 |   Negative vs CIN 3 (fresh LBC samples) model 
In order to determine if biobanked LBC samples could be used 
to discriminate no disease (cytology negative) from disease 
(CIN 3) using Raman spectroscopy, fresh (non biobanked) 
LBC samples were first examined as a control. Figure 2A 
shows mean spectra of Negative vs CIN 3. Figure 2B is a 
latent variables (LV) scores scatter plot of LV1 and LV2, 
which shows good discrimination along LV1 and LV2. The 
loadings shown in Figure 2C, show that the discrimination is 
based around Raman peaks at 484 (glycogen), 575 (glycogen), 
881  (nucleic  acids),  1004  (proteins  Phenylalanine),  1139, 
1238 (proteins Amide III), 1487 (proteins), 1575 (nucleic 
acids), 1605 (proteins) and 1669 cm
−1 
(proteins Amide I). The 
LV2 loadings show discrimination is based around 1238 
(proteins), 1381 (glycogen), 1450 (proteins and lipids), 1642 
(proteins) and 1669 cm
−1 
(proteins) (see Table 1)
.
[13] The 
PLS-DA prediction plot shown in Figure 2D and has a sensi- 
tivity of 86% and a specificity of 90% for CIN 3. 
 
3.3 | Negative vs CIN 3 (Biobanked LBC samples) 
model 
In order to determine if the biobanked samples can be used in 
a similar fashion to the fresh samples, negative and CIN 
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TABLE 1    Tentative peak assignments for Raman spectra of cells and tissues[13] 
482 Glycogen 
577 Glycogen 
622 C   C twist Phe 
643 C   C twist Tyr 
727 CH2 def C  C head A 
752 Sym br. Trp 
781 U,C,T ring br 
826 Out of Plane ring br.Tyr PO2 a.str. 
851 Ring br. Tyr,C   C str. Pro 
852 Glycogen 
937 Glycogen 
985 C   C head 
1002 Sym. Ring br. Phe 
1033 C   H in plane Phe, C   C str. 
1044 Glycogen 
1060 C   N str. 
1082 C  N str. Chain C  C str. C   O str., Glycogen 
1096 Chain C  C str. C   C str. 
1106 Glycogen 
1123 C  N str. Chain C  C str. C   O str. 
1152 C   N str. 
1207 C   C6H5 str. Phe, Trp 
1238 C   N str., Amide III 
1261 Glycogen 
1334 Glycogen 
1338 Trp G 
1366 Sym. str. CH3 
1381 Glycogen 
1450 CH2 def CH2 def 
1458 Glycogen 
1487 CH2 def G,A 
1560 Tyr, Trp 
1575 A,G ring br 
1584 C   C str., C   C bend. Trp, Phe 
1605 C   C Phe, Tyr 
1642 C   O str., C   C sym. str. 
1669 C   O str. Amide I 
 
3 biobanked samples were compared. Figure 3A shows the 
mean spectra of biobanked Negative samples vs CIN 3. Fig- 
ure 3B is a latent variables (LV) scores scatter plot of LV1 
and LV2 which shows good discrimination along LV1 and 
LV2. The loadings from LV1 are shown in Figure 3C and 
show that discrimination is based around  Raman  peaks,  622 
(proteins), 640 (proteins),775 (proteins), 850 (proteins), 
1122 (proteins), 1152 (proteins), 1207 (proteins), 1450 (pro- 
teins), 1560 (proteins), 1605 (proteins), 1642 (proteins) and 
1669 cm
−1 
(proteins). LV2 loadings show discrimination is 
based on 1123 (proteins, lipids, carbohydrates), 1338 (pro- 
teins) and 1605 cm
−1 
(proteins) Raman peaks assigned to 
phenylalanine 1004 cm
−1 
show a slight shift between 1003 
and   1004 cm
−1   
which   is   most   likely   attributed   to the 
methanol based fixation method which suggests a change in 
the conformation of the phenylalanine protein.[14] The PLS- 
DA prediction plot shown in Figure 3D and has a sensitivity 
of 91% and a specificity of 92% for CIN 3. 
 
3.4 |   Biobanked vs non-Biobanked samples 
Five fresh CIN 3 patient samples were split into two separate 
vials. One vial from each sample was frozen as described 
earlier and the other stored at room temperature. Figure 4A 
shows the mean spectra for biobanked CIN 3 samples and the 
same samples kept at room temperature for 3 weeks after 
collection. The mean spectra appear identical. There  does not  
appear  to  be  a  difference  between  the  fresh  and 
Raman peak position [cm
−1
] Proteins Lipids Carbohydrates Nucleic acids 
  
 
 
FIGURE 3 (A) mean spectra of biobanked Negative (red) vs CIN 3 (blue). (B) latent variables (LV) scores scatter plot of LV1 and LV2, TN (yellow) vs 
CIN 3 (blue). (C) LV1 (blue) LV2 (orange). (D) PLS_DA prediction plot CIN 3 (blue), negative (yellow) 
 
biobanked samples. The latent variable scatter scores plot 
(Figure 4B) shows slight discrimination between the sample 
types, which is most likely due to internal sample variability 
[15] (LBC samples are variable by nature) and the low num- 
ber of spectra recorded (60 for room temperature/bio- 
banked). The PLS-DA prediction plot (Figure 4C) has a 
sensitivity of 29% and specificity of 88% for biobanked sam- 
ples indicating poor discrimination between the two groups. 
 
3.5 |    Mixed model 
In order to determine if we could mix fresh and biobanked 
samples together and still achieve a sensitivity and specific- 
ity similar to the fresh and biobanked models, 15 biobanked 
CIN 3 samples were mixed with 15 fresh CIN 3 samples and 
compared with 15 negative biobanked/ 15 fresh negative 
samples. Figure 5A shows the latent variable scatter scores 
plot of the model and we can see clear discrimination 
between the sample types across LV1 and LV2. The LV1 
loadings (Figure 5B) show that discrimination is based on 
482,  (glycogen),  1443  (proteins,  lipids)   1487  (proteins), 
1605 (proteins) 1669 cm
−1 
(proteins) while LV2 shows the 
discrimination is based around 486 (glycogen), 851 (pro- 
teins), 1152 (proteins), 1381 (glycogen), 1450 (proteins/li- 
pids), 1575 (nucleic acids) and 1669 cm
−1 
(proteins). The 
loadings show similarities to both the fresh and biobanked 
loadings, but overall show that glycogen and proteins are the 
main discriminating factor between negative and CIN 3 sam- 
ples. PLS-DA prediction plot has a sensitivity of 94% and a 
specificity of 95% for CIN 3 (Figure 5C). 
 
 
4 |    DISCUSSION  
 
From the results it is clear that samples biobanked at −80oC  are 
not suitable for screening using Raman spectroscopy due to a 
lack of cellular material and the presence of cellular debris. 
Spectral differences  between  fresh  negative  and  CIN 3 
samples were observed with regards to glycogen, nucleic 
acids and proteins. CIN 3 cells often contain little to no gly- 
cogen, hence the use of Lugol's solution to visualise abnor- 
mal cells in colposcopy
.
[16] The discrimination associated 
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FIGURE 4     (A) mean spectra of fresh CIN 3 (blue) vs biobanked CIN 
3 (red). (B) latent variables (LV) scores scatter plot of LV1 and LV2, fresh 
CIN 3 (yellow) vs biobanked CIN 3.(C) PLS-DA prediction plot biobanked 
CIN 3 (blue) vs fresh CIN 3 (yellow) 
 
 
with changes in proteins and DNA is consistent with the 
neoplastic changes that occur in CIN 3 supported by persis- 
tent HPV infection such as increased cell cycling with coin- 
cident increase in replication and levels of nucleic acids
.
[15] 
FIGURE 5 (A) latent variables (LV) scores scatter plot of LV1 and LV2, 
TN (yellow) vs CIN 3 (blue). (B) LV1 loadings (blue) and LV2 loadings 
(orange). (C) PLS-DA prediction plot CIN 3 (blue), negative (yellow) 
 
The PLS-DA prediction plot gives a sensitivity of 86% and a 
specificity of 90% for CIN 3. 
Negative vs CIN 3 biobanked sample results showed that 
discrimination was driven solely by proteins. Raman peaks 
associated  with  nucleic  acids/DNA  are  not  as  strongly 
  
 
present as they are in the non-biobanked samples. Long term 
storage of biobanked samples is likely to have led at least to 
an element of nucleic acids degradation which would explain 
why nucleic acid is not discriminatory between neg- ative and 
CIN 3 samples. However the PLS-DA prediction plot (Figure 
3D) does show slightly higher sensitivity (91%) and 
specificity (92%) rates when compared to fresh samples 
(86% sensitivity and 90% specificity) indicating that bio- 
banking at −20oC does not preclude discrimination of nega- 
tive and CIN 3 samples on Raman spectroscopy. 
The same patient samples that had been split in two with 
half biobanked and the other half stored at room temperature 
showed no discrimination between the samples. Hence, the  3 
weeks period of biobanking at −20oC had no detrimental 
effects on the physical or biochemical properties of the sam- 
ples. The mixed model showed that biobanked and fresh LBC 
samples could be combined with an improved sensitivity of 
94% and specificity of 95%. A limitation of this study is the 
inability to use biobanked LBC samples stored at −80oC for 
Raman spectroscopic analysis as most biobanks will have 
samples stored at -80 oC for long term storage[3] hence, the 
true potential of using biobanks as a source of patient samples 
could be lost. Further research in this area should involve the 
use of different biobank specimens (bronchial and thyroid fine 
needle aspirations) to investigate any detrimental effects the 
biobanking process may have on cytological specimens
17 18
. 
 
5    |    CONCLUSION  
 
Raman spectroscopy can effectively discriminate disease free 
cervical LBC samples from those with disease (CIN 3) and this is  
possible   using   biobank   cervical   LBC   samples   stored at 
−25oC.  Pooling  samples  stored  at  −25oC  with  fresh samples 
does not affect the sensitivity and specificity of Raman spectros- 
copy for the discrimination of disease. This study demonstrates 
that biobanks of cervical LBC samples are a useful resource for 
future Raman spectroscopy studies and will facilitate the further 
assessment of this technology which shows highly encouraging 
performance for the detection of cervical disease. 
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